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Summary of thesis 
Despite current improvement in newborn care, infection is still a common cause of neonatal 
morbidity and mortality. Innate immunity is the first line of defence against pathogens 
particularly in newborn infants. Quantitative and functional deficit in non-cellular 
(complement system) and cellular (neutrophils) arms of innate immune system is believed to 
contribute to neonatal susceptibility to infection.  
Neutrophil granule subsets contain a variety of proteases, including elastase, cathepsins, 
MMP-9 and proteinase 3 along with different granule markers and receptors. This thesis 
demonstrated that normal term neonatal neutrophils express more proteinase 3 and CD177 on 
their surface while no differences were found in expression of markers CD35, CD66b and 
CD63 (representing the secretory, secondary and primary granule subsets, respectively). Cord 
neutrophils contain more PR3 than adult cells but the proportion of PR3 released by cord and 
adult neutrophils was similar. In contrast, neonatal neutrophils contained only half of the 
cathepsin G and elastase functional activity of adult neutrophils. 
Bronchoalveolar lavage fluid studied from preterm infants ventilated for respiratory distress 
demonstrated higher proteinase 3 concentrations in lavage samples from infants who went on 
to develop chronic lung disease than in infants with resolved respiratory distress syndrome. 
Concentration of proteinase 3 in lavage samples was significantly higher than MMP-9 and 
elastase levels, suggesting that it may have an important role in disease pathogenesis. 
Complement is an equally important component of the innate immune system that plays a 
central role in recruiting and activating neutrophils, as well as being directly bactericidal 
through the terminal lytic pathway.  Analysis of neonatal complement system revealed that 
Complement function and terminal components levels particularly C9 are deficient (except 
C7) in healthy term newborn infants compared to normal adults. Bactericidal capacity of a 
selection of neonatal sera was tested along with adult sera against four serovars of 
Ureaplasma parvum, a potentially important perinatal pathogen. Results showed impaired 
bactericidal capacity of neonatal serum compared to adult serum especially against SV1. 
Ureaplasma SV3 was the most serum sensitive serovar whereas killing of the resistant 
serovars SV6 and 14 could not be induced by supplementation of the deficient components 
C6, C8 and C9. 
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1.1 Innate immunity. Overview  
 
 
The innate immune system is the first line of defence against pathogens and several 
mechanisms contribute to its function. The cellular components of innate immunity comprise 
a variety of cells that first recognize microbes by “foreign” pattern-recognition receptors 
(PRR) and then respond to them by launching defensive measures. Immediately after 
microbial invasion, these cells are recruited in increasing numbers to sites of infection. The 
innate immune system also informs and directs the response of the adaptive immune response 
through the release of bioactive peptides (complement fragments, chemokines, etc.) that leads 
to the evolution and maturation of a primary humoral and cellular immune response as well 
as the capacity for immune memory, for faster and more specific responses to repeat 
microbial exposure.  The adaptive response is also important for clearing microbes that evade 
or overcome the innate immune system. While the innate immune response is quick and can 
act without delay, the adaptive immune response takes days or weeks to develop (Kindt et al., 
2007; Murphy et al., 2008). 
 
Cells of the innate and adaptive immune systems are derived from common pluripotent 
haematopoetic progenitors called stem cells. These stem cells give rise to i) common 
lymphoid progenitors (CLP) which further differentiate into all cells of the lymphoid lineage, 
including T and B lymphocytes, and ii) common myeloid progenitors (CMP), that in turn 
give rise to granulocytes, monocytes, mast cells, and dendritic cells (DCs), all of which are 
involved in innate immune responses (Kindt et al., 2007; Murphy et al., 2008). However, 
serum proteins that make up the non-cellular components of the innate system are usually 
made by non-haemopoetic organs such as the liver (complement) or lung (surfactant proteins 
SP-A and SP-D). 
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Complement is a serum protein cascade integral to the innate immune response, and its role 
in combating invasive pathogens is more prominent in newborns owing to their immature 
adaptive immunity. Neutrophils represent the most abundant cellular component of the innate 
immune response. Infection remains a leading cause of neonatal morbidity and mortality and 
is linked to several quantitative and functional defects in complement as well as other 
humoral and cellular immune components especially neutrophils. 
 
In this introduction I aim to review the current literature about functional capacity of 
neutrophils and complement system in innate immunity of newborn infants with emphasis on 
neutrophil proteases in combating infection and their untoward effect implicated in 
pathogenesis of chronic lung disease. This review is also focused on serum levels and 
function of terminal complement components in full term newborn infants. 
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1.2 Neutrophils 
1.2.1 Neutrophil origin and structure 
Neutrophils are key components of innate immunity and the most effective killing phagocytes 
in the arsenal of cellular host defence. They were first described by Metchnikoff in 1892 who 
named them microphagocytes in comparison with macrophages. Neutrophils are the most 
abundant phagocyte in blood with 40-80 % of circulating leukocytes being neutrophils.  
There are 1.2 to 7.6 x10
9 
neutrophils per litre of blood in healthy person which can instantly 
accumulate in large numbers at the site of infection reaching over 20 x10
9
/L
 
within 24
 
hours 
in diseases such as pneumonia and septicaemia (Friedland et al., 1992; Braun et al., 1997)
. 
The neutrophil has a short life span in circulation 8-20 h compared with 1-4 days in tissue 
(Ogura, 1999). The transfer of neutrophils from blood to tissue is considered to be ‘one way 
only’ with fewer than 5% of the total number of neutrophils in the body normally present in 
the circulation (Dale and Liles 1998).   
 
They are large cells with a size of 9-16 μm in diameter and they have multi-lobed nuclei 
hence they are also known as polymonuclear neutrophils (PMNs), with number of lobes 
increased in more mature cells. Neutrophils are formed in bone marrow from a common 
progenitor cells to monocyte’s referred to as the granulocyte- macrophage colony forming 
unit (GM-CFU). The regulation of granulopoiesis is by a homeostatic balance between 
stimulatory and inhibitory humoral factors, in which colony stimulating factors play a major 
stimulatory role (Dale et al., 1995; Molineux, 2002). Neutrophils evolve from the myeloblast 
differentiating through the stages of premyelocyte, myelocyte, metamyelocyte, band cell and 
eventually mature neutrophil. Myelocytes do not proliferate and so there is no mitosis after 
this stage of neutrophil development (figure 1.1). 
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Figure1.1 Neutrophil myelopoiesis. Granulocytes and erythrocytes are derived from the 
Myeloid Stem Cell. Neutrophil cell line started from stem cells which differentiate into 
Myeloblasts, Promyelocytes, and then Myelocytes. These together form the Neutrophil 
Proliferative Pool (NPP) (A), Post-mitotic maturation then takes place, forming 
Metamyelocytes and Band cells which make the Neutrophil Storage Pool (NSP) (B) in bone 
marrow which can be released into the bloodstream before being fully mature. (C) Finally 
mature neutrophils are released into the circulation.Reproduced with permission from 
bpac
nz
. Available from: www.bpac.org.nz/resources/campaign/cbc/cbc_poem.asp.  
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1.2.2 Neutrophil granules 
 
Neutrophils contain four distinct types of granules: primary, also known as azurophilic 
granules, secondary or specific granules, tertiary or gelatinase-rich granules and secretory 
vesicles (Borregaard and Cowland 1997; Faurschou and Borregaard 2003) (Figure1.2). 
Proteomic studies have identified over 280 proteins which shed light on the complex 
structure of these organelles and the diverse functions of their contents. Granule proteins 
could be classified according to function into receptors and cytoskeletal membrane anchors, 
channels and transporters, cytoskeletal and actin binding proteins, luminal and host defense 
proteins, redox proteins, kinases and phosphatases membrane traffic and other proteins 
(Lominadze et al., 2005). The allocation of these proteins to the corresponding granule subset 
is determined by the timing of protein synthesis during neutrophil myelopoiesis in bone 
marrow and not by granule specific targeting (Borregaard et al., 2001). Subsequently, granule 
protein synthesised at a given stage of differentiation will be localized to the granule subset 
synthesised at the same time. However, overlap in the timing of protein synthesis may lead to 
localization in other granule types. It is estimated that approximately 50% of granule proteins 
are present in more than one granule subset (Lominadze et al., 2005).  
 
 
While the primary distinction between different granule types is the order in which they are 
synthesised during maturation, they can be distinguished by proteinase or membrane-
associated markers. Azurophilic granules contain all of the elastase and CD63, while 
secondary granules contain all the intracellular CD66b, and tertiary granules contain 75-80% 
of the MMP-9 (Kjeldsen et al., 1992).   
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Figure 1.2 Selected granule content. Bactericidal permeability increasing (BPI), Neutrophil 
gelatinase associated lipocalin (NGAL), = Human leukocyte elastase (HLE). Proteinase3, 
(PR3).   Myeloperoxidase (MPO) = Human cationic antimicrobial protein-18 (hCAP-18). 
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Azurophilic granules are formed in the promyelocytic stage followed by secondary granule 
formation in myelocytes. At the metamyelocyte stage tertiary granules are produced whereas 
secretory vesicles are believed to be formed by endocytosis in circulating neutrophils 
(Borregaard et al., 1987). Similarly, the stimulation required to mobilize these granules to the 
surface requires an increasing gradient: Secretory vesicles are easily mobilised upon 
neutrophil contact with endothelial cells while degranulation of tertiary granules coincides 
with transmigration of neutrophils. Secondary granule contents are subsequently released at 
the site of inflammation, while azurophilic granules are only released externally when 
inflammation or infection cannot be overcome by engulfing the organisms.  
 
Differential mobilization of neutrophil granules subsets helps to co-ordinate the multi-step 
inflammatory response components which include adhesion to activated endothelium that is 
followed by extravasation and migration of neutrophils towards the site of infection and 
culmination in elimination of the invading micro-organisms. All granule subsets have 
common structural features such as phospholipid bi-layer membranes and a matrix containing 
proteins for delivery into the phagosomes or for release outside the cell by exocytosis. 
 
1.2.2.1   Azurophilic (Primary) granules 
These are packed with acid hydrolases and antimicrobial proteins including myeloperoxidase, 
human neutrophil peptides 1-3 (HNP 1-3) and serine proteases: proteinase 3, cathepsin G and 
elastase. 
The three serine proteases found in azurophil granules have a major role in regulation of 
immune responses and in control of cell signalling through modulation of the cytokine 
network, processing of chemokines and activation of specific cell surface receptors. Together, 
they contribute to non-oxidative killing of pathogens inside the neutrophils. In addition, they 
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have bactericidal function on cell walls and they are involved in degradation of extracellular 
matrix in the process of inflammation (Korkmaz et al., 2008).  
 
Azurophilic granules are present in three forms large/spherical, nucleated and small granules. 
Myeloperoxidase, the defining protein of azurophil granules (Introne et al., 1999), reacts with 
hydrogen peroxide which is produced by nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase and this reaction results in formation of hypochlorus acid which is highly 
toxic for pathogens. Myeloperoxidase is released to the phagosome or to the exterior of the 
cell upon neutrophil activation (Gallin, 1985). Myeloperoxidase has a peripheral distribution 
in large azurophilic granules whereas its distribution in nucleated granules is uniform. Similar 
overall distribution was described for elastase, cathepsin G as well as for proteinase 3 which 
is additionally found in crystalloid structure in nucleated azurophilic granules. Bactericidal/ 
permeability increasing protein (BPI) which has bactericidal and bacteriostatic effect on 
Gram negative bacteria is localised to the membrane in all types of azurophilic granules 
(Eqesten et al., 1994).  
 
CD63, a member of the tetraspanin superfamily, is present only in azurophilic granules along 
with myeloperoxidase (MPO) and serine proteinases; therefore it has been described as a 
suitable marker for azurophilic granule fusion with the plasma membrane (Kuijpers et al., 
1991). It is expressed on the cell surface following neutrophil activation (Cham et al., 1994). 
Lopez et al. found that CD63 expression increased on synovial fluid neutrophils of 
rheumatoid arthritis patients (Lopez et al., 1995).  It has been hypothesized that CD63 may be 
associated with signal transduction although its role in leuckocyte function is not completely 
understood.  
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1.2.2.2   Secondary (Specific) granules  
Secondary granules are smaller and more numerous than azurophilic granules. They appear at 
a later stage in myelopoisis and are mobilised more readily than azurophilic granules upon 
stimulation. They are de-granulated in vitro by low concentrations of phorbol myristate 
acetate (PMA) or formyl Met-Leu-Phe (fMLP) (Cham et al., 1994). CD66b is an exclusive 
marker present in membrane of specific granules (Molinedo et al., 1999; Lominadze et al., 
2005). Lactoferrin is a member of transferrin family of iron binding protein which has a 
broad spectrum antimicrobial activity. Iron sequestration by lactoferrin deprives bacteria of 
essential iron for bacterial growth. It has also a direct bactericidal activity as a result of its 
irreversible binding to bacterial cell walls (Chapple et al., 1998; Farnaud and Evans 2003). 
Lysozyme is present in all granules types but secondary granules have the highest 
concentration (Lollike et al., 1995; Cowland and Boregaard 1999), and it is most noted for its 
intracellular role in the lysosome and phagolysosome. 
 
Secondary granules contain human cathelicidin antimicrobial pro-peptide (hCAP 18) which is 
converted to the active peptide LL-37. Cathelicidins are a group of antimicrobial and 
endotoxin binding proteins found in neutrophil granules of vertebrates (Zannetti et al., 1995) 
and hCAP is only found in humans (Cowland et al., 1995). Proteolytic processing of LL-37 
results in shorter peptides which have immune-stimulatory effect on certain cell types, for 
example, inducing production of interleukin-8 (IL-8) by keratinocytes (Braff et al., 2005). In 
addition to its antimicrobial action, LL-37 is thought to have a role in regulation of tissue 
neutrophil life span as it was demonstrated to induce neutrophil secondary necrosis in vitro 
(Zhang et al., 2008). 
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Secondary granules also contain a peptide known as neutrophil gelatinase –associated 
lipocalin (NGAL) which has antimicrobial properties. Most NGAL is not associated with 
gelatinase but found as monomer or homo-dimers in specific granules colocalising with 
lactoferrin (Kjeldsen et al., 1994). Its antibacterial action is thought to be by iron depletion 
through binding to bacterial ferric siderophores (Goetz et al., 2002).   
 
1.2.2.3   Gelatinase (tertiary) granules 
This subset of neutrophil granules contains 75 -80% of the cellular metalloproteases 
gelatinase (MMP-9) content and leukolysin (MMP-25) which are stored as proforms and 
activated only after exocytosis (Kjelsden et al., 1992; Pei, 1999; Kang et al., 2001). They are 
probably of central importance in the degradation of vascular basement membranes during 
neutrophil extravasation due to degradation of extracellular matrix components (Borregaard 
and Cowland 1997; Owen and Campbell 1999; Kang et al., 2001). 
 
1.2.2.4   Secretory vesicles   
This intracellular compartment formed by endocytosis represents an important store for 
membrane associated receptors which will be incorporated into the plasma membrane upon 
their release. This enables the neutrophil, not only to interact with endothelial cells, 
monocytes and dendritic cells, but also to receive inflammatory signals from the environment 
(Boregaard and Cowland 1997). These receptors include ß2 integrins, CR1 or complement 
receptor 1 (CD35), formyl peptide (such as fMLP) receptors, CD14 and CD16 (FcγRIII) that 
mediate the binding of immunoglobulin opsonized particles to neutrophils. Secretory vesicles 
in addition contain the metalloproteinase leukolysin as well as azurocidin, also known as 
heparin binding protein (HBP) (Sengeløv et al., 1993; Tapper et al., 2002). Azurocidin 
release facilitates extravasation of neutrophils by increasing vascular permeability and it 
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brings about enhancement of monocytes adhesions to endothelium (Gautam et al., 2001; Lee 
et al., 2003; Soehnlein et al., 2005).  
 
 1.2. 3   Serine Proteinases  
 
1.2.3.1   Neutrophil Elastase (NE) and Cathepsin G (Cat G) 
Neutrophil elastase and cathepsin G belong to the same subfamily of chymotrypsin-like 
serine proteinases. They are both synthesised as inactive zymogens in the promyelocytic and 
myelocytic neutrophils (Fouret et al., 1989) and processed post-translationally to mature 
active enzymes in azurophilic granules when they achieve a relatively high concentration of 
1-2 pg/cell (Wiedow et al., 1996). Both are very basic with isoelectric point (pI) of > 9 for 
elastase and approximately 12 for Cat G, which likely facilitates their anchorage to the 
heparin and chondroitin sulphate proteoglycan matrix of the granules, probably through 
arginine residues. Cat G has a chymotrypsin-like specificity and it comprises up to 18 % of 
azurophilc granule protein (Sun et al., 2004). Surface expression of elastase and cathepsin G 
on neutrophil has been reported following exposure to chemoattractants such as fMLP (Owen 
et al., 1995).  
 
Moreover, evidence from mouse model suggested that Cat G microbicidal activity could be 
redundant. Cat G knock-out mice have no obvious defect in neutrophil function and they 
probably use other proteases to compensate for Cat G absence (Maclover et al., 1999).  
While neutrophil morphology and function were essentially normal in Cat G deficient mice, 
recruitment to the site of injury was affected which suggests that it probably plays a role in 
inactivation of pro-inflammatory molecules (Maclvor et al., 1999). Anecdotal evidence for 
the importance of these proteinases comes from Chediak-Higashi syndrome patients, who are 
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believed to have an inhibitor of Cat G and elastase that contributes to the susceptibility of 
these patients to infection (Takeuchi and Swank 1989). Cat G is also required for activation 
of neutrophil collagenase (Capodici and Berg 1989; Capodici et al., 1989) and it has been 
suggested to have anticoagulant activity through inactivation of factor VIII. Nevertheless, this 
latter observation was disputed by another group that showed Cat G pro-coagulant effect by 
activation of factor VIII (Gale and Rozenshteyn 2008).  In addition, Cat G has been found to 
be a platelet agonist that binds to specific platelet receptors. Cat G induced platelet activation 
is further enhanced by elastase (Selak, 1992; Renesto and Chignard., 1993).  
 
At sites of inflammation, neutrophil degranulation results in release of elastase and Cat G 
primarily into the phagocytic vacuole and to lesser extent into the extracellular environment. 
The enzymes are either membrane-bound, incorporated in neutrophil extracellular traps 
(NETs) formation (Brinkmann et al., 2004) or freely released in the extracellular milieu 
(figure 1.3). 
Elastase is able to digest almost all components of the extracellular matrix including 
collagens I-IV, fibronectin, laminin and proteoglycans. In addition, neutrophil elastase is 
present in cystic fibrosis airways (Delacourt et al., 2002). It also induces excessive bronchial 
mucus production in chronic obstructive pulmonary disease (COPD) (Shapiro, 2002). 
 
1.2.3.2   Proteinase 3 (PR3) 
PR3 is a neutrophil serine proteinase, also called myeloblastin, found in the azurophilic 
granules. It is also present in secondary granules, secretory vesicles and, in a subset of 
neutrophils, on the plasma cell membrane (Csernok et al., 1990; Witiko-Sarsat et al., 1999). 
PR3 in azurophilic granules co-localises with MPO, elastase, and Cat G. Resting neutrophils 
have a bimodal distribution with two neutrophil subsets, one presenting very low levels of 
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PR3 (mPR3
low 
) and the other presenting high levels of PR3 (mPR3 
high
) (Halbwachs-
Mecarelli et al ., 1995). Despite the wide range of variation in the proportion of the high 
expression subset (0-100%), the proportion is stable in a given individual over long period of 
time suggesting genetic control of mPR3 expression (Abdgawad et al., 2010). This was 
supported by twin studies demonstrating that the proportion of mPR3 expressing neutrophils 
in monozygotic twins is highly concordant (Schreiber et al., 2003). Expression of PR3 on the 
membrane of neutrophils is upregulated by multiple proinflammatory mediators such as: 
TNF-α, PMA, LPS, IL-8, PAF, fMLP and GM-CSF (Campbell et al., 2000; Hellmich et al., 
2000; Brachemi et al., 2007). The binding of PR3 to the neutrophil cell membrane is still in 
debate, but widely suggested that the majority is bound hydrophobically to CD177, a 
glycosyl-phosphatidylinositol (GPI)-anchored surface receptor that is exclusive to 
neutrophils.  Cell confocal microscopy reveals that PR3 and CD177 colocalise on neutrophil 
membranes (Von Vietinghoff et al., 2007). However, CD177 negative individuals are still 
able to display mPR3 upon activation, (Hu et al., 2009) suggesting that alternative receptors 
other than CD177 can act as partners for membrane PR3 (mPR3). Other protein partner’s 
receptors for PR3 are CD11b/CD18, FcγRIIIb and phospholipase scramblase 1 found in lipid 
rafts (David et al., 2003; Fridlich et al., 2006; Kantari et al., 2007). Campbell et al showed 
that PR3 can be eluted from the membrane of neutrophils following cellular activation, and 
that ionic interactions are important in the binding of PR3 to the plasma membrane. PR3 can 
bind stably to anionic and neutral membranes, but binds strongly to negatively-charged 
bilayers.   
 
Proteinase 3 activity in elastin degradation is less than that of elastase at pH of 7.4 or 8.9, but 
it is slightly more active than elastase at the acidic pH of 6.5 (Kao et al., 1988). Other 
functions of PR3 include regulation of the inflammatory response via modulating cytokine 
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and chemokine signalling, cleaving pro-inflammatory cytokines such as TNFα, IL-1 and IL-8 
to their bioactive forms, activating platelets, and inducing IL-8 synthesis by endothelial cells 
(Renesto et al., 1994; Berger et al., 1996; Wiedow and Meyer-Hoffert 2005). Many of these 
proinflammatory activities are orchestrated with the action of the elastase and Cat G (figure 
1.3). Moreover, proteinase 3 cleaves the human cathalecidin hCAP-18 to produce the active 
antimicrobial peptide LL-37 after the cathelecidin release from specific granules (Sørensen et 
al., 2001). Many functions have been reported for mPR3 which can degrade fibronectin, 
elastin, laminin, collagen type IV and heparan sulfate proteoglycans in the subendothelial 
matrix.  
 
Activation of neutrophils by immune complexes (ICs) was reduced in mice lacking PR3 and 
elastase. ICs-mediated neutrophil infiltration was reduced in vivo in these mice. Similarly, 
impaired activation in response to ICs was demonstrated in neutrophils isolated from the 
combined PR3/elastase knock- out mice. Inflammation suppressing mediator progranulin 
(PGRN) is cleaved by PR3 and elastase and so its accumulation in these mice has an anti-
inflammatory effect (Kessenbrock et al., 2008). 
 
Experimental studies on hamsters showed that intra-tracheal proteinase 3 administration 
resulted in more dramatic bullous emphysema than combined intratracheal cathepsin G and 
elastase; therefore, the authors concluded that proteinase 3 may be implicated in the 
pathogenesis of emphysema in humans (Kao et al., 1988). PR3 specific anti neutrophil 
cytoplasmic autoantibodies are (ANCA) are important seromarkers found in a systemic 
autoimmune vasculitis known as Wegner’s granulomatosis. Its characteristic features include 
vasculitis, necrotizing inflammation of the respiratory tract and pauci-immune 
glomerulonephritis.  
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Figure 1.3 Neutrophil serine proteases (NSPs) and regulation of inflammation (a) Activated 
neutrophils (red) release NSPs by degranulation, or formation of NETs. Part of proteases is 
expressed on the neutrophil surface and remains in the pericellular environment. Serine proteases are 
controlled by protease inhibitors circulating in blood and interstitial fluids. (b) Extracellular PR3 
converts IL-8 released from neutrophils and endothelial cells by N-terminal truncation into a more 
bioactive chemokine. This may potently enhance the recruitment of further neutrophils to the site of 
inflammation. (c) PR3 converts the membrane bound precursor pro-TNFα to the potent inflammatory 
cytokine TNFα. (d) Neutrophils extravasating from the vasculature are initially controlled by anti-
inflammatory progranulin (PGRN). PR3 and elastase cooperatively enhance neutrophil activation by 
degrading inflammation suppressing PGRN which control neutrophil extravasation. (e) Cat G 
interacts with surface integrins during neutrophil adhesion to immobilised ICs, where it promotes 
integrin clustering, cytoskeletal rearrangements, and chemokine release. Reproduced with permission 
from Kessenbrock et al., 2011. 
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1.2.3.3    CD177 
 
Human CD177, neutrophil membrane PR3 receptor, is a GPI linked 58-64 KDa membrane 
protein that belongs to the Leukocyte Antigen 6 (Ly- 6) gene family as its gene is located on 
chromosome 19q13.2. Ly-6 genes encode proteins implicated in proliferation, differentiation 
and homing of haemopoietic cells and lymphocytes since these proteins are overexpressed in 
rapidly proliferating and malignant cells such as in polycythaemia vera (Katz et al., 1994; 
Eshel et al., 1995). 
CD177 neutrophil-specific glycoprotein is found on the plasma membrane and secondary 
granules of neutrophils.  It is expressed by neutrophils and their precursors but not on other 
blood cells (Goldschmeding et al., 1992). CD177 heterogenous expression is uniquely found 
on a subpopulation of neutrophils.  In the same individual, two subsets of neutrophils in terms 
of expression, CD177negative as well as CD177 positive could be observed. The reason for 
this phenomenon is not completely understood but a genetic polymorphism is thought to 
cause CD177 non expression in a neutrophil subset (Wolff et al., 2003).  
CD177 overexpression was reported in neutrophils from patients with polycythaemia vera.  
The commonest allele of CD 177 gene is PRV-1 (Polycythaemia rubra vera-1) (Caruccio et 
al., 2006). Other studies found that CD177 expression was up-regulated on positive cells 
when neutrophils were stimulated with granulocyte-colony stimulating factor (G-CSF), but 
the fraction of CD177 negative neutrophils did not increase after G-CSF stimulation 
(Temerinac et al., 2000; Wolff et al., 2003). Also the expression of CD177 antigen increases 
during pregnancy which suggests that the variability of CD177 expression among individuals 
may be caused by differences in gene regulation or in post-translational protein modification 
(Caruccio et al., 2003). Absence of CD177 was described in approximately 3% of 
Caucasians, 5% of African American and 11% of Japanese who have CD177 deficient 
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neutrophils (Matsuo et al., 2000; Stroncek et al., 2004). One cause of this deficiency is 
mRNA splicing defect (Kiessel et al., 2002). The role of CD177 in the immune system 
remains to be defined but it is believed to be involved in adhesion of neutrophil to endothelial 
cells and in transendothelial migration (Goldschmeding et al., 1992; Sachs et al., 2007). 
 
1.2.3.4   Protease inhibitors 
To avoid digestion of healthy tissue neutrophil elastase and Cat G levels are tightly controlled 
by physiological inhibitors (Table-1).  These plasma- derived inhibitors are synthesized in the 
liver and they belong to the family of serpins (serine proteinase inhibitors), which are highly 
abundant extracellular proteins (Shapiro, 2002). Elastase and Cat G are inhibited by α1-
antitrypsin (AAT) and α1-antichymotrypsin (ACT), respectively (Beatty et al., 1980). They 
can inhibit free, but not membrane-bound elastase and Cat G (Owen et al., 1995). Hereditary 
deficiency in AAT causes destruction of alveolar walls eventually leading to development of 
pulmonary emphysema (Gadek et al., 1981; Eriksson and Elzouki 1998; DeMeo and 
Silverman 2004). Similarly, deficiency of ACT predisposes patients to chronic lung disease 
(Faber et al., 1993). 
  
Cat G binds heparin and this binding protects it from inhibition by ACT and AAT.  Cat G 
affinity to bind heparin is identical to that of elastase but heparin binding has little effect on 
inhibition of elastase with AAT (Ermolieff et al., 1994). In addition, DNA binding has 
similar effect on these enzymes making Cat G resistant to inhibition by AAT and ACT 
whereas it only marginally affects the rate of elastase inhibition by AAT.  Other studies have 
demonstrated that DNA binding to elastase impairs the inhibitory action of AAT and 
Secretory Leukoprotease Inhibitor (SLPI) (Belorgy and Bieth 1995; Belorgey and Bieth 
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1998). PR3 inhibition by AAT was not affected by nucleotide binding (Duranton et al., 
2000). 
 
PR3 is inhibited by serpins, mainly, AAT. Membrane PR3 is active and quite resistant to 
inhibition by proteinase inhibitors including AAT, possibly due to steric interference of the 
membrane-embedded protease. However, when exposed to exogenous AAT, activated 
neutrophils mPR3 was completely inhibited (Hu et al., 2009). AAT binds covalently to PR3 
associated with CD177, resulting in a conformational change that promotes PR3 dissociation 
from CD177 forming a soluble neutralised complex with AAT (Korkmaz et al., 2008).  
 
Serpin B1 also known as monocyte neutrophil elastase inhibitor (MNEI) primarily inhibits 
neutrophil elastase, cathepsin G and proteinase 3. SerpinB1 has been identified in a number 
of other tissues such as the bone marrow, spleen, pancreas, glandular epithelial cells and 
conducting airways of the lung (Yasumatsu et al., 2006).  The cytoplasmic location of Serpin 
B1 suggests that its role would be the prevention of the intracellular damage by serine 
proteases.   
 
Secretory Leukoprotease Inhibitor (SLPI) is present at the highest concentration in the upper 
airways where it plays a more important role (Vogelmeier et al., 1991) although 
immunohistochemistry staining showed that it is present also in contact with elastin fibres in 
lower airways which might suggest that it has physiological role in lung (Kramps et al., 1989; 
Korkmaz et al., 2010). It is produced by mucosal epithelial cells and bronchiolar goblet cells 
in human airways.  Some of the chemical properties of SLPI enhance its anti-elastase activity, 
as it is acid resistant and resistant to oxidation and cleavage by most other proteinases ; all of 
which are important in the inflammatory setting (Wright  et al., 1999 ). In addition it binds to 
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similar tissue sites to those of proteases and since it is a small molecule, it is able to penetrate 
the microenvironment around the neutrophil where other proteinases are unable to act (Owen 
et al., 1995). Of note, cells of mucosal surfaces produce SLPI, a barrier protein protecting 
cells from the destructive action of elastase and cathepsin G, but SLPI has minimal or no 
effect on proteinase 3 which was shown to degrade this inhibitor protein (Rao et al., 1993). 
 
Table-1: Inhibitors of serine proteases 
Protease inhibitors Target Proteases Source 
I-Serpins   
AAT Elastase, PR3, CatG Plasma, neutrophils 
Antichymotrypsin Chymotrypsin Plasma 
Serpin B1 Cat G, Elastase, PR3 Neutrophils, Macrophages 
II-Chelonianin   
SLPI Elastase, Cat G Epithelial cells, plasma , 
neutrophils 
Elafin Elastase, PR3 Bronchial secretion, skin 
III- α Macroglobulins Elastase, PR3, Cat G Plasma 
IV- TIMPs 
TIMP-1 
TIMP2 
Matrix metalloproteinases           
MMP-2 /MMP-9 
MMP-1/ MMP-8 
 
TIMP: Tissue Inhibitors of Matrix Metalloproteases 
 
1.2.4   NADPH oxidase system 
This system is crucial for generation of reactive oxygen species (ROS) that mediate oxidative 
killing of pathogens. Electrons are transferred from cytoplasmic NADPH to oxygen outside 
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the cell or on the phagosomal side of the membrane generating superoxide along with several 
other ROS including hydrogen peroxide, hydroxyl radical, hypochlorous acid, nitric oxide, 
peroxide nitrite and chloramines (Hampton et al., 1998). The NADPH oxidase is a 
multicomponent enzyme which is inactive in resting cells with its multiple components kept 
separately in several membrane-bound and cytosolic subunits. The membrane-bound subunits 
form the cytochrome b588 which are incorporated into the membranes of secondary and 
secretory granules. The NADPH oxidase activity produces superoxide which is converted to 
hydrogen peroxide by superoxide dismutase. Hydrogen peroxide reacts to form other ROS 
such as hydroxyl radical which can kill bacteria. Moreover, myeloperoxidase oxidizes halides 
in presence of hydrogen peroxide to form bactericidal acids, especially HOCl. Hydrogen ion 
influx into the phagosome increases initially to compensate for influx of negatively charged 
electrons.  
 
1.2.5 Neutrophil adhesion and migration 
Neutrophils reversibly adhere to the activated endothelial cells at site of infection or 
inflammation. A group of sugar binding cell surface glycoprotein known as selectins plays a 
significant role in this process. L-selectin is constitutively expressed on the surface of 
neutrophils and shed after cellular activation (Smith et al., 1991). Endothelial, E- selectin is 
expressed on activated endothelial cells whereas platelet P-selectin is expressed on platelets 
as well as endothelium (Gahmberg et al., 1992; Carlos and Harlan 1994). The main leukocyte 
glycoprotein ligand is P-selectin glycoprotein which serves as a ligand for the other two 
selectins (L and E). Additionally, E-selectin recognizes a specific ligand on a leukocyte 
which is known as E-selectin ligand-1. The activation of neutrophils by these chemokines 
triggers surface upregulation of integrins. Thereafter, the integrin CD11b/CD18 mediates 
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firm adhesion to the endothelial cells and the density of these integrin complexes on the cell 
surface increases as a result of translocation from secretory vesicles, specific and gelatinase 
granules and also by de novo synthesis. CD11b/CD18 binds to its endothelial ligand, 
intercellular adhesion molecule-1 (ICAM-1) and ICAM-2 (Bailly et al., 1995; Xie et al., 
1995; Henzen et al., 2000). 
Neutrophil firm adhesion to the endothelium is followed by extension of neutrophil 
pseudopods between endothelial cells and penetration of the intercellular junctions, before 
moving into the interstitium (Carlos and Harlan 1994). 
 
1.2.6 Chemotaxis 
Leukocyte chemotaxis is regulated by a number of chemoattractants including bacterial by-
product fMLP, complement proteolytic fragment C5a and chemokines. Neutrophils migrate 
along a chemokine concentration gradient across the wall of blood vessels and within the 
tissues.  The migration is determined by chemokines like IL-8 and other related chemokines 
and also by expression of adhesion molecules (Roitt and Male 2001). Actin polymerization 
and de-polymerization within the neutrophils, upon interaction with chemokines, results in 
rearrangement of cell shape and upregulation of receptors before emigration (Springer, 1994). 
 
1.2.7 Neutrophils phagocytosis and degranulation  
Movement of granules and discharge of their contents is known as degranulation and 
different types of granules are released independently because their release is controlled by 
different control mechanisms. Granules fuse with phagocytic vesicles, phagosomes where 
they discharge their content to kill the ingested microbes, as a result of the high concentration 
of proteins in the granules; protein concentration in the phagolysosome is raised to 30-40%. 
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During phagocytosis, the plasma membrane of neutrophil tightly surrounds the microbe to 
limit the amount of extracellular fluid inside the phagosome vacuole. Eventually, the osmotic 
pressure of the protein inside the phagosome will withdraw water and the resulting influx will 
decrease the protein concentration. NADPH oxidase complex also assembles at the 
phagosomal membrane and produces oxygen radical antibacterial mediators: HOCl is 
probably the dominant mediator of oxidative bacterial killing inside the phagosomes 
(Hampton et al., 1998). Neutrophils rolling along the endothelial cells are exposed to 
chemokines released from the endothelium including platelet activating factor (PAF), 
complement fragments, leukotriene B4 and IL-8 and this will lead to upregulation of integrins 
on the surface of these leukocytes. 
 
Subsequently, neutrophils are firmly adhered to the endothelium mainly by the integrin 
CD11b/CD18 which are expressed at relatively low levels on the surface of resting 
neutrophils. Neutrophil activation also results in the altered conformation (activation) of 
CD11b/CD18 as characterized by formation of new epitopes, which correspond to increased 
affinity for CD11b/CD18 to bind to ligands. It is also characterized by increased density of 
CD11b/CD18 on neutrophils and mobilization of these receptor from specific and gelatinase 
granules, as well as secretory vesicles, to cell surface (Borregaard and Cowland 1997). 
 
1.2.8 Neutrophil Extracellular Traps (NET) 
This is an additional pathogen combat strategy used by neutrophils in the extracellular killing 
of bacteria, fungi and parasites. Recent work revealed that uncondensed chromatin DNA and 
histone proteins are released from neutrophils to an extracellular structure or a lattice which is 
supplemented by proteins released from azurophilic, specific and tertiary granules and bound 
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to this structure. The resulting lattice is known as a neutrophil extracellular trap (NET). 
Immunoflourescence studies revealed that NET contains elastase, Cat G and MPO from 
azurophilic as well as lactoferrin from specific and gelatinase from tertiary granules. Histone 
proteins from the nucleus are an important component of NETs which also exert 
antimicrobial action at surprisingly low concentration (Brinkmann et al., 2004). 
NETs also represent a physical barrier capable of trapping Gram positive and Gram negative 
bacteria. Moreover, high concentrations of several antimicrobial proteins and enzymes 
attained in the NET ensure efficient killing of the sequestered microbes. Neutrophil elastase 
present in NETs was shown to target specifically bacterial virulence factors (Belaaouaj et al., 
2000; Weinrauch et al., 2002). In addition, containment of microbicidal granule contents 
minimizes their harmful effect on the surrounding tissues (Xu et al., 2009; Brinkmann et al., 
2010).   
Some bacteria can resist bactericidal action of NETs. DNase enzyme from group A 
Streptococcus, a known virulence factor, is thought to mediate increased virulence through 
the ability to destroy NETs (Buchanan et al., 2006). 
Reactive oxygen species (ROS) are of pivotal importance in NET formation.  The evidence 
for this conclusion comes from the demonstration of defective NET formation in patients 
with chronic granulomatous disease, who have a defect NADPH oxidase pathway leading to 
impaired ROS generation (Nishinaka et al., 2011) 
Recalcitrant Aspergillus infection of chronic granulomatous disease patients was cleared and 
NET formation ability was restored in another study as a result of gene therapy, supporting 
this hypothesis (Bianchi et al., 2009). The role of ROS in NET formation is believed to act as 
a component of the signaling pathway (Papayannopoulos and Zychlinsky 2009). 
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 More recently, neutrophil elastase was demonstrated to play an essential role in NET 
formation with synergestic activity of myeloperoxidase. ROS production triggers selective 
intracellular release of neutrophil elastase followed by myeloperoxidase from primary 
granules. Once translocated to nucleus, elastase digests nucleosomal histones and promotes 
extensive chromatin decondensation and subsequently myeloperoxidase binds chromatin and 
enhances further decondensation. Elastase knock-out mice failed to form NET which could 
contribute to their immune deficiency (Papayannopoulos et al., 2010). Moreover, histone 
hypercitrullination catalyzed by peptidylarginine deiminase 4 (PAD4) is involved in 
neutrophil chromatin decondensation hence in NET formation. Evidence came from inability 
of PAD4 knock- out mice to form NET leading to increased susceptibility to bacterial 
infection (Li et al., 2010). 
 
The factors that direct the microbicidal strategy selection by a particular subset of neutrophils 
remain largely unknown. The individual neutrophils may respond differently within the 
population. In contrast, the length of time required for various neutrophil strategies may 
determine the order of putting them into operation: phagocytosis followed by degranulation 
and eventually NET formation before neutrophil death (Papayannopoulos and Zychlinsky 
2009).           
 
1.2.9 Neutrophils in neonates 
Infection is a major cause of morbidity and mortality in newborn infants, particularly preterm 
neonates, and the innate immune system is of prime importance in this age group. Limitation 
in cellular and humoral components of this system is believed to contribute to newborn 
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susceptibility to microbial invasion. Interest in this concept is obviously reflected in the 
number of studies which compare aspects of innate immunity in adults and newborns seeking 
answers that could be utilized to provide novel therapeutic strategies against neonatal 
infections.  
Neutrophil chemotaxis has been shown to be impaired in neonates (Abughali et al., 1994; 
Tan and Davidson 1995). Reduced responsiveness to chemoattractant in newborn neutrophils 
is due to impaired chemoattractant induced signaling (Weinberger et al., 2001).  
Similarly, the leukocyte aggregation pattern in response to chemotactic peptide, N-formyl-L-
methinoyl L-leucyl L-phenylalanine (fMLP) was different in newborns compared to adult 
neutrophils. The newborn neutrophil aggregation curve showed slow aggregation with no de-
aggregation whereas adult neutrophils had faster initial aggregation and was followed by 
slow de-aggregation. Examination under an electron microscope revealed that adult 
neutrophils were loosely bound with no cell membrane projections in contrast to newborn 
neutrophil which were irreversibly aggregated due to the close proximity of the cytoplasmic 
membrane projections (Olson et al., 1983). 
 
Neutrophil CD11b expression and transmigration ability (spontaneous and IL-8 induced) 
were higher in neutrophils from neonates whose birth was assisted than in neutrophil taken 
from neonates who were born by normal vaginal delivery, suggesting differential activation 
between these types of delivery. Transmigration and CD11b expression were least in 
neutrophils taken from neonates born by elective Caesarean section before the onset of 
labour, which likely reflect the minimum activation signaling for neutrophils (Yekataei-
Karrin et al., 2007). 
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In addition, levels of several antimicrobial peptides were found to be low in newborn infants. 
Plasma bactericidal permeability increasing (BPI) protein level increased in newborn infants 
after infection.  In spite of higher plasma BPI levels in septicaemic newborn than in healthy 
neonates and adults, the ability of newborn neutrophils to release BPI after stimulation with 
PMA was less in term newborn than in adults, and less in preterm than in term newborns 
(Nupponen et al ., 2002). Levy and coworkers (1999) in keeping with this study found that 
newborn neutrophils are relatively deficient in BPI. In another study, they demonstrated that 
adding a supplement of recombinant BPI to cord blood neutrophils enhanced their 
bactericidal ability and inhibited TNF release in response to different Gram negative 
pathogens (Levy et al., 2000). This report is promising in the management of Gram negative 
infection in newborns, but further studies are needed before its potential application in 
clinical neonatology.  Moreover, plasma levels of hCAP 18 and NGAL in neonates and adults 
do not show significant differences, but their levels in newborn neutrophils were significantly 
lower than in adults.  LL-37 has been found in skin of healthy neonates and detected along 
with lysozyme in proteins derived from Vernix caseosa, which is a cream like substance 
present on the skin of newly born infants (Marchine et al., 2002).  
 
Bactericidal activity against 11 strains of Enterococcus was identical in adult and neonatal 
neutrophils isolated from term newborn infants. Neutrophil killing of Enterococcus was 
mediated mainly by complement and supplemented by immunoglobulin which played a 
potentially important, yet not indispensable role in elimination of this bacteria (Harvey et al., 
1992) 
 
Neutrophil functions were studied in 13 preterm (PT) neonates (mean birth weight 1,506 g) in 
comparison with adult and term newborn neutrophils as controls. Adherence, chemotaxis and 
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phagocytosis of Candida albicans were reduced in neutrophils from PT infants in comparison 
to adult neutrophils. Chemiluminesence and degranulation of elastase and lactoferrin in 
response to zymosan were also impaired in PT neutrophils (Bektas et al., 1999). 
While some studies reported that O2 is produced equally in adult and PT neutrophils in 
response to PMA stimulation (Bektas et al., 1990), other studies found that generation of 
oxygen radicals is less effective in PT and full term infants than in adults particularly in 
stressed newborns (Driscoll et al., 1990; Usmani et al., 1991).  
Comparative studies of adult and cord neutrophils have also addressed the recently described 
NET formation and the results were in agreement with the view of functional immaturity in 
newborn innate immune system. Initially, newborn neutrophils could not form NETs when 
observed for one hour after activation compared with adult neutrophils, which were able to 
form NETs within 15 to 30 minutes (Yost et al., 2009 a ). Further research revealed that 
newborn neutrophil could eventually produce NET formation after 2-3 hours (Marcos et al., 
2009). The delayed NET formation in newborn neutrophils was demonstrated when they 
were stimulated with live bacteria or with natural or synthetic agonists of TLR2 or TLR4 but 
no delay was found upon stimulation of TLR5, TLR8 or TLR 9 stimulation (Marcos et al., 
2009). However, delayed NET formation for 2-3 hours could provide adequate time for 
invading bacteria to multiply to sufficient degree to escape containment and elimination by 
neutrophils (Yost et al., 2009 b). Delayed NET formation is probably due to delay in 
maturation of regulatory mechanisms and it was more marked in preterm newborn as 
neutrophils from preterm newborns never formed NETs (Yost et al., 2009 b).      
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1.3 Chronic Lung Disease of Prematurity (CLD) 
Chronic lung disease (CLD) of prematurity is the most important complication seen in 
premature newborns who required mechanical ventilator support for neonatal respiratory 
distress syndrome (RDS).  The incidence of CLD has been rising over the past decade despite 
improvement in management of RDS including antenatal steroid administration and 
surfactant treatment (Fraser et al., 2004). However, the rising trend seen recently seems to 
represent a different pathological entity since it is observed in extremely premature neonates 
(less than 28weeks) and believed to be mediated by inflammation and altered lung 
development (Manktelow et al., 2001; Viscardi, 2012). 
 
The definition of CLD has varied in recent years. Initially it was defined as being the need for 
supplemental oxygen beyond 28 days of age with associated radiographic changes. Recently 
CLD is applied to infants who need supplemental oxygen at 36 weeks corrected gestational 
age and who have characteristic chest x-ray changes (Kotecha, 1999; Bancalari et al., 2003) 
(Table 2). 
 
The pathogenesis of CLD is linked to a number of risk factors involved in initiation or 
continuation of inflammatory process in preterm lung. Historically, the neutrophil appears to 
be the key player in this unresolved inflammatory process. 
 
Merritt et al 1983 examined the tracheal aspirate fluid (TAF) of 26 neonates and found that 
significantly higher granulocyte counts were present in preterm infants with respiratory 
distress syndrome (RDS) than in fluid aspirated from term infants ventilated for non- 
respiratory reasons. Granulocyte counts were particularly high in those preterm infants who 
later went on to develop CLD. By the third day of life, infants who later developed CLD had 
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neutrophil counts a hundred times higher than that of preterm infants who had resolved RDS. 
They also reported that the total cell count started to fall after three days in those infants in 
whom RDS resolved, whilst the cell count stayed high much longer in those preterm infants 
who went on to develop CLD (Merritt et al., 1983). 
 
Table-2 Diagnostic criteria for CLD 
 
 
Table 1.2 Diagnostic criteria for CLD as set out by National Institute of Child Health and 
Human Development NICHD/ National Heart, Lung and Blood Institute NHLBI workshop 
(Jobe, Bancalari 2001). Definition of abbreviation: CLD chronic lung disease of 
prematurity; NCPAP = nasal continuous positive airway pressure; cGA corrected 
gestational age; PPV = positive-pressure ventilation. 
Age at birth,     
weeks GA 
Mild  CLD Moderate CLD Severe CLD 
<32 weeks Breathing room air at 36  weeks 
cGA  or discharge, whichever 
comes first 
 
Need for < 30% oxygen at 36 
weeks cGA or discharge. 
whichever comes first 
 
 
Need for  ≥ 30% oxygen 
and/or positive pressure, (PPV 
or NCPAP) at 36 weeks cGA  
or discharge, whichever comes 
first 
 
≥32weeks Breathing room air by 56 day 
postnatal age or discharge, 
whichever comes first 
 
Need for < 30% oxygen  at 56 
day postnatal age or discharge, 
whichever comes first 
 
  
Need for ≥ 30% oxygen and/or 
positive pressure (PPV or 
NCPAP) at 56 day postnatal 
age or discharge, whichever 
comes first 
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1.3.1 Risk factors for CLD 
The pathogenesis of CLD is complex and multiple risk factors have been identified. CLD is 
more common in extremely premature infants as well as in male, non- black infants. 
Hyperoxia and high pressure and volume ventilation are linked with the development of 
CLD. Other risk factors include the presence of a patent ductus arteriosus (PDA), neonatal 
sepsis and the presence of maternal chorioamnionitis, figure 1.4.  
 
1.3.1.1   Oxygen  
Hyperoxia has a harmful effect on developing lung. Animal models demonstrated that 
exposure of newborns to high concentrations of oxygen can lead to tissue injury similar to 
that seen in classical CLD with thickening of interstitium , parenchymal and peripheral 
fibrosis associated with a significant influx of inflammatory cells (Pappas, 1983).  
ROS interfere with surfactant production and impair lung growth and repair. Preterm lungs 
are particularly vulnerable to oxygen related lung damage, partly due to immaturity of the 
lungs antioxidant defenses (Saugstad, 2003).  Hyperoxia enhances the proteolytic action of 
elastase whereas it decreases the inhibition by AAT which is shown to be cleaved or oxidized 
when exposed to a fraction of oxygen in inspired air ( FiO2 ) more than 0.6 (Merritt et al., 
1983; Bruce et al., 1992).  
 
1.3.1.2   Barotrauma/ Volutrauma 
Mechanical ventilation causes barotrauma and volutrauma particularly with high peak 
inspiratory pressures (> 35cm water) (Taghizadeh and Reynolds1979). Despite advances in 
ventilatory techniques, including the development of high frequency oscillatory ventilation, 
barotrauma and volutrauma continue to contribute to lung injury.  
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Figure1.4. Diagram shows the mechanism by which multiple risk factors lead to development 
of CLD. 
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Ventilation-induced lung injury results from excessive tidal volume (volutrauma) rather than 
the barotrauma of high inspiratory pressure (Speer, 2009). Positive airway pressure results in 
over distension of the airways and alteration of the alveolar capillary membrane permeability 
causing pulmonary oedema. Neutrophil recruitment and release of inflammatory mediators 
such as IL-6, IL-8 and other cytokines may also increase lung permeability contributing to 
lung injury (Vlahakis et al., 1999; Yoder et al., 2000). ‘Priming’ of the foetal lung by LPS 
triggers inflammation and mechanical ventilation may represent a ‘second strike’ that 
augments the inflammatory response (Speer, 2009). Moreover, the combined action of 
barotrauma and oxygen toxicity interfere with normal mechanisms for clearance of airways 
and the low humidity and temperature of inspired gas reduce the mucociliary surface which 
can predispose to nosocomial infection (Goodwin et al., 1985; Sherman et al., 1988). 
 
1.3.1.3   Infection 
Intrauterine and postnatal infections have been implicated in the development of CLD. 
Antenatal infection is a known risk factor for preterm labour with 60 -80 % of preterm labour 
showing evidence of infection, with pathogens being isolated from placentas or amniotic 
fluids (Goldenberg and Rouse 1998). Preterm delivery is a risk factor for development of 
CLD. The most common organisms involved are Ureaplasma urealyticum, Mycoplasma 
hominis, Gardnerella vaginalis and Bacteroides, all of which are vaginal commensals 
(Goldenberg et al., 2000). Bacterial sepsis and viral infections (adenovirus and 
cytomegalovirus (CMV) are examples of post natal infection implicated as independent risk 
factors for the development of CLD (Sawyer et al., 1987; Cordero et al., 1997; Couroucli et 
al., 2000; Liljedahl, 2004). 
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Attention is focused on the role of Ureaplasma in the development of CLD since it is present 
in the lower genital tract of 40-80% of pregnant women (Van waarde, 1997). Moreover, 22% 
of women with preterm labour or premature rupture of membranes (PROM) were shown to 
have evidence of Ureaplasma in their amnioitic fluid (Kirchner et al., 2007). In addition, 
intraamniotic and maternal inflammatory responses were shown to be more intense in 
intraamniotic infection with genital mycoplasma than in infection with other microorganisms 
(Oh et al., 2010).  
 
Animal models in which Ureaplasma urealyticum is injected into the amniotic fluid of 
pregnant baboons have demonstrated the ability of organism to provoke an inflammatory 
response in the lungs of the preterm animal once delivered (Yoder et al., 2003 )  which may 
go on to develop CLD. Similarly, intraamniotic inoculation of clinical isolates of genital 
Mycoplasma and U Parvum SV1 in rhesus Macaque monkeys resulted in release of 
proinflammatory cytokines and induced uterine contraction. The proinflammatory response in 
rhesus monkeys contributed to preterm labour and foetal lung injury (Novy et al., 2009). 
Thus many of the risk factors implicated in the development of CLD have inflammation of 
the lung as the mechanism through which injury occurs.  
 
In the Alabama preterm study, Ureaplasma and Mycoplasma were detected in cord blood of 
23% of extremely premature infants and these neonates were more likely to have systemic 
inflammatory response and CLD (Goldenberg et al., 2008). A meta-analysis of 17 clinical 
studies included 1479 neonates and supported a significant association between Ureaplasma 
respiratory tract colonization and CLD development (Wang et al., 1995). A more recent 
meta-analysis analysed 36 cohort studies until 2004 involving approximately 3000 preterm 
infants showed a significant association between Ureaplasma respiratory colonisation and 
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CLD development (P<0.001). However, the greatest effect was seen in small studies and this 
increased effect could be due to reporting bias towards positive association (Schelonka et al., 
2005). 
Despite the accumulating evidence from epidemiological studies and the experimental studies 
using animal models to study Ureaplasma and development of CLD, no consensus was 
reached in this matter and the role of Ureaplasma remains controversial (Speer, 2009).  
 
1.3.2   The changing pattern of CLD  
Classical CLD affects neonates born at 32-36 weeks of gestation who need mechanical 
ventilation and oxygen supplement for treatment of respiratory distress syndrome (RDS). 
Characteristic histopathology includes variable areas of atelectasis and hyperinflation, smooth 
muscle hyperplasia and extensive fibroproliferation (Northway et al., 1967). In preterm 
infants with RDS, CLD appears to proceed as a continuous process from acute lung injury in 
the first few days through proliferative and reparative phases lasting for approximately 2 
weeks and characterised by regeneration of alveolar epithelium by alveolar type II 
pneumocytes, granulocytic infiltration in the alveoli and increasing numbers of 
myofibroblasts in the interstitial tissue before development of the chronic phase of CLD 
(Cherukupalli et al. 1996; Toti et al., 1997).  
 
Interstitial and alveolar protein-rich oedema in early stages progressed to persistent airway 
inflammation with significant alveolar septal and peribronchial fibrosis and bronchiolar and 
pulmonary vascular smooth muscle hypertrophy, which can lead to right heart failure 
(Stocker, 1986; Hislop and Haworth 1990). Chest radiographs showed severe over-inflation 
with a mixture of cystic emphysema and areas of fibrosis with volume loss and 
extrapulmonary air leak (Jobe and Ikegami 1998; Bancalari et al., 2003). 
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The more recent pattern that is seen in extremely preterm infants (23-26 weeks) is quite 
different, with a decreased number of large, over simplified alveoli and significantly less 
fibrosis than seen in classical CLD (Figure 1.5).  
 
 
 
 
Figure1.5 Histology of developing lung: (A) Late canalicular/early saccular stage of lung 
development (GA 24 weeks, died 2 hours after birth) showing large simple air spaces with 
early secondary crest formation. (B) Ventilated premature lung (GA 23 weeks, lived for 7 
days), shows cellular infiltration of the widened septa with focal haemorrhages within 
airspaces. (C) Late saccular/early alveolar lung (full term) showing well developed gas 
exchange parenchyma; compare it with (A), with thin septa and abundant secondary crest 
formation. (D) CLD in ventilated preterm infant (GA 27 weeks, lived for 12 weeks) showing 
simple, large-sized air spaces with hypercellular and thickened septa. (De Paepe et al., 
2006). Reprinted with permission of the American Thoracic Society. Copyright © 2013 
American Thoracic Society. 
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Therefore, it is felt that there has been a change in CLD that we see now from the 
consequence of a destructive process to represent an aberration of normal lung development, 
so called new CLD. New CLD has less fibrosis which is more diffuse, more uniform lung 
inflation; fewer and larger alveoli increased elastic tissue and decreased pulmonary 
microvascular development. 
 
Clinical observation showed that extremely premature neonates (GA 23-27 weeks), which 
coincide with saccular stage of lung development, are at highest risk for CLD whereas the 
risk of CLD development for infants born at GA >32 weeks (late saccular-alveolar stage) is 
much lower (Jobe, 2011). New CLD described in this era of surfactant therapy and prenatal 
corticosteroid has different pathophysiology characterized by growth arrest of lung tissue and 
pulmonary vessels rather than by fibrosis and less fulminant pulmonary inflammation (Jobe, 
2011). 
 
Imbalance in proinflammatory and anti-inflammatory mediators leads to activation of the 
cellular death pathways in the lung, which is followed by resolution of normal lung 
architecture (healing) or disorganised repair (Bhandari and Bhandari., 2003) characterized by 
impaired alveolarization and dysregulated angiogenesis, which lead to fewer, larger 
simplified alveoli and a dysmorphic pulmonary vasculature: the pathologic hallmarks of CLD 
(Baraldi   and Filippone 2007).  
 
Inflammation-mediated injury during a critical window of vulnerability alters the 
development program of the foetal or newborn lung leading to abnormal alveolar 
development (Jobe, 1999; Viscardi, 2012). A similar pattern of abnormal alveolar formation 
has been observed in animal models of CLD, with preterm lambs treated with surfactant and  
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minimal oxygen supplementation and ventilator support developing fewer and larger alveoli 
than control animals (Albertin et al.,  1999). 
1.3.3   Proteases in CLD 
A potential role has been attributed to proteases in the pathogenesis of CLD in preterm 
infants. An imbalance between proteases and anti-protease inhibitors has been implicated in 
the pathogeneses of CLD. In the pre-surfactant era increased elastase and decreased elastase 
inhibitory activity was detected in the majority of lung lavage samples from infants who 
developed CLD (Merritt et al., 1983; Watterberg et al., 1994). However, more recently, a 
number of studies have found elastase in only a minority of samples from the lung of 
premature infants and questioned the relationship of elastase to the development of CLD 
(Speer et al., 1993; Sveger et al., 2002). On the other hand, elastase is capable of digesting 
elastin. Elastin seems to have a key role in alveolar-genesis, the process by which septae form 
across the terminal air sacs to form alveoli. The process requires alveolar fibroblasts to form 
at the tips of the developing septae and synthesise elastin. Studies using elastin knockout 
mice (Wendel et al., 2000) demonstrate that absence of elastin leads to dilated distal air sacs 
with abnormally large cavities, consistent with an arrest in terminal airway development 
which is similar to that observed in new CLD. Thus loss of elastin through disruption of 
elastase regulation in the lung may impact on lung development.  
 
Matrix metalloproteinases (MMP) are proteases which are important in normal lung 
development (Greenlee et al., 2007) when appropriately controlled by specific protease 
inhibitors but their unregulated activity, particularly MMP-8 and MMP-9, may be associated 
with the development of CLD (Cederqvist et al., 2001; Ekekezie et al., 2004; Sweet et al., 
2004). 
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1.4    Complement system overview  
The complement system in humans was discovered in the 1890's as the heat-labile anti-
bacterial component of serum and its name is derived from the capacity to enhance 
antibacterial activity of antibodies. Antibody activation of the complement cascade is known 
as the classical pathway (CP). Over fifty years later, the alternative pathway (AP), used to 
describe antibody-independent activation of complement was first postulated in the 1950’s by 
Louis Pillemer (although he referred to it as the properdin pathway). The AP was not 
accepted by the scientific community until substantiated by Mayer (Mayer, 1984) almost 30 
years later and the dispute of its existence is thought to have contributed to Pillemer’s suicide 
in the late 1950’s. The lectin pathway, as characterised by activation through carbohydrate 
recognition by MBL, was first described in the 1990’s however complement activation 
through carbohydrate recognition by ficolins is still not fully understood. The complement 
system consists of approximately 35 proteins in plasma and an array of receptors and 
regulators on cell surfaces (Volankkis and Frank 1998; Walport 2001a; Walport 2001b). 
 
  Liver is the principal site of production of most complement components (Hobart et al., 
1977). One of the notable exceptions is C7, where less than 50% is of hepatic origin 
(Würzner et al., 1994). While baseline constitutive synthesis provides a normal range of 
circulating protein levels, almost all components are acute phase reactants and synthesis can 
be induced locally in fibroblasts, endothelia, astrocytes and other cell types by the primary 
acute cytokines (e.g. IL-6, IL-1 and TNF). For example, pregnancy upregulates all 
complement components in the maternal circulation except for C8. Hepatic synthesis is 
thought to account for 90% of complement production. 
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Well established non-hepatic complement synthesis includes secretion of C3 from activated 
neutrophils (Botto et al., 1992). C6 and C7 are produced by neutrophils precursors in bone 
marrow as well, but not in mature neutrophils. However, large stores of pre-synthesised C6 
and C7 are found in mature cells that can be released on stimulation (Høgåsen et al., 1995). 
In addition, early components of the classical pathway C1, C2, C3 and C4 are also 
synthesised by macrophages (Johnson and Hetland, 1988; Morgan and Gasque, 1997). 
 
 Prevalence of total or partial deficiency of individual complement components have been 
described and certain deficiencies are reported to have a high incidence in certain ethnic 
groups (Halle et al., 2001; Barroso et al., 2004; Kang et al., 2005). Deficiency of components 
are associated with increased frequency of pyogenic infection (C3, C1, C4 and C2), while 
deficiencies of the terminal pathway (C5, C6, C7, C8 and C9), properdin and MBL are 
associated particularly with fulminant or recurrent Neisseria infection (Loirat et al., 1980;  
Sjöholm et al., 2006; Garcia-Laorden et al., 2008 ). Autoimmunity has also been found to be 
linked to deficiency of classical components C1 or C1q (90%), C4 (75%) and C2 (25%) 
including dermatomyositis and SLE-like disease (Figueroa and Densen 1991; Pickering et al., 
2000; Winkelstein et al., 2003). 
 
1.4.1    Pathways of Complement activation 
 The complement system is activated through three essential pathways: classical, alternative 
and lectin pathways (Volanakis and Frank 1998; Walport 2001a; Walport 2001b), figure 1.6. 
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Figure 1.6 Summary of the three pathways of complement activation showing initiation via 
either the classical mode which is activated by an antigen/ antibody complex, or by the lectin 
or alternative mode, which are antibody-independent. All pathways converge at the 
conversion of C3 into C3a and it is active form C3b which participates in the formation of C5 
convertase (C5b). All the three pathways converge to form the membrane attack complex. 
The complement system is tightly regulated by a number of regulators (blue lettering).  
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Complement has also been reported to be activated through incidental cleavage by non-
complement system proteases, also known as extrinisic activation (Markiwski and Lambris 
2007). Notably, the activity of cleavage of C3 into active C3a and C3b has also been 
described for human elastase released following neutrophil activation (Vogt et al., 1986). 
 
1.4.1.1   The Classical pathways 
The classical pathway is initiated by the interaction of C1 with Fc region of IgG or IgM 
antibodies bound to an activating surface (Walport, 2001a). C1 in serum is macromolecular 
complex consisting of 6 molecules of C1q and two molecules each of C1r and C1s held 
together in a complex C1q6r2s2 stabilized by Ca
+2
 ions . Each C1q molecule is composed of 3 
polypeptide chains, which combine to form six collagen-like triple helical arms with globular 
heads. The C1q globular head is the binding site for C1 complex, which binds to Fc region of 
aggregated or immune complex bound IgG (IgG1 or IgG3) or IgM antibodies found on a 
target surface. C1q can bind to the antibodies only when at least two IgG molecules are 
attached close enough to each other on the target to engage 2 separate C1q molecules 
(achieved by approximately 10
6
 molecules per cell); therefore relatively high surface density 
of IgG is needed for the classical pathway activation. In contrast, only one target bound IgM 
molecule can activate the complement cascade because it has 5 C1q binding sites per 
molecule. In the absence of antibodies, C1q can bind to bacterial lipopolysaccharides (LPS) 
nucleic acids, immune complexes and some viruses (Loos et al., 1978; Loss et al., 1986; 
Spiller and Morgan, 1998). 
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Binding of C1q to Fc binding sites induces a conformational change in C1r that stimulates 
autocatalysis of C1r to an active serine protease enzyme which in turn cleaves C1s to an 
active serine protease enzyme. C1s has two substrates: C4 and C2. C4 is activated when C1s 
hydrolyzes a small fragment C4a, which acts as a weak anaphylatoxin (Gorski et al., 1979) 
from the amino terminus of the α chain, inducing a conformational change that exposes the 
thioester binding site on the larger fragment C4b. The C4b fragment covalently attaches to 
the target surface in the vicinity of C1, and the C2 proenzyme then associates with the 
conformationally altered C4b in the presence of Mg
+2
 ions, where the C2 is then cleaved by 
the C1s into C2a, an enzymatically active 70kDa carboxy-terminal fragment and a small 
fragment C2b, a 30kDa amino-terminal fragment which diffuses away (Nagasawa and Stroud 
1977). The resulting C4b2a complex is called the classical C3 convertase (Xu et al., 2001), 
although it is identical to the convertase created by the lectin pathway. 
 
C3 is an essential component of all complement pathways and the most abundant 
complement component in plasma. It is a large protein cleaved by C2a leading to hydrolysis 
of a small chemotactic fragment of C3a from its amino-terminus, and exposing an internal 
thioester group in the large fragment, C3b (Kindt et al., 2007). A single C3 convertase 
molecule can generate over 200 molecules of C3b, resulting in tremendous amplification at 
this step of the sequences, some of C3b binds to C4b2a to form a trimolecular complex, 
C4b2a3b (the classical/lectin C5 convertase), which in turn binds to C5 and causes 
conformational changes that enables C4b2a component to cleave C5 into C5a (a potent 
anaphylotoxin and chemotaxin) which is liberated leaving C5b associated to C3b on the 
activation surface. C5b has a greatly increased affinity for C6 binding and initiates formation 
of membrane attack complex (MAC) (Pettigrew et al., 2009). 
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1.4.1.2   The alternative pathway 
The initiation of this pathway differs significantly from the classical and lectin pathways. It 
does not rely on antigen-antibody complexes. The alternative pathway activation involves 
four serum proteins C3, factor B, factor D and properdin. It is triggered by native C3, which 
contains an unstable internal thioester bond prone to slow spontaneous hydrolysis (called 
“tick over”) to a C3b-like molecule, C3H2O. The C3H2O binds to factor B, a single chain 
plasma glycoprotein structurally related to C2, in the presence of Mg
+2
.  Binding to the C3b-
like molecule exposes a site on factor B that serves as the substrate for factor D which 
subsequently cleaves factor B into a small fragment (Ba) that diffuses away and a larger 
fragment, Bb that remains complexed with and forms C3H2O Bb, a soluble short lived C3 
convertase which cleaves native C3 into C3b that covalently binds to hydroxyl or amino 
groups on bystander surfaces and remains active for longer time (Friec and Kemper 2009).  
Target bound C3b also binds factor B in the presence of Mg
2+
, which when cleaved by factor 
D forms the alternative C3 convertase (C3bBb). C3 convertase activity of C3bBb has a short 
half-life but its binding to properdin greatly extends the half- life and stabilises the complex. 
Properdin can recognize and bind to the surface of certain pathogens such as E. Coli, 
Neisseria and yeast and facilitates complement activation. The complex properdin/C3b 
thereafter, binds factor B and cleaves it into Bb and Ba, and forms C3bBbP which acts as C3 
convertase (Hourcade, 2006; Spitzer et al., 2007; Kemper et al., 2008; Friec and Kemper 
2009).  
 
Active surface-bound C3b which is required to initiate the alternative pathway cascade, can 
also originate from classical pathway activation, providing an amplification feed-back loop 
mechanism linking the two pathways. Alternatively, the “tick over” phenomenon occurs 
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spontaneously at rate of ≈1% of total C3 per hour. It is important to note that surface bound 
C3b on host cells is rapidly enzymatically inactivated by factor I to iC3b, which no longer 
binds factor B.  Serum factor I cleavage is accelerated through C3b binding to cofactors 
CD46 (membrane co-factor protein), which is expressed on all human cells except 
erythrocytes, or serum factor H which is recruited to host surfaces by sialic acid (commonly 
added to surface glycoproteins on eukaryotic, but not prokaryotic, cells). Therefore, the 
alternative pathway on its own is only really effective for surfaces that lack the ability to 
regulate C3b.  The C3 convertase activity of C3bBb generates the C3bBb3b complex, or the 
alternative C5 convertase (equivalent to the C4b2a3b complex in classical pathway), which 
then cleaves C5 and initiates the common terminal lytic pathway.  
 
1.4.1.3    Lectin pathway 
The lectin pathway is activated by soluble pattern recognition molecules (PRM), most 
notably mannan binding lectin (MBL) and the ficolins M, L and H. Both MBL and ficolins 
rely on the C1r/C1s homologue MBL-associated serine protease -2 (MASP-2) to activate 
complement system (Thiel , 2007): upon binding of MBL/MASP-2 complex to microbial 
surface through recognition of prokaryotic carbohydrate motifs, MASP cleaves C4 and C2 
generating the C4bC2a, C3 convertase which finally leads to opsonization (deposition of 
C3b) and enhancement of phagocytosis, cell recruitment through chemotaxin release (C3a 
and C5a) and lysis of pathogens (Turner, 1996; Sorensen et al., 2005 ). 
 1.4.1.4 Terminal pathway  
The common outcome of all three complement activation pathways is initiation of the 
terminal pathway. The terminal pathway differs from the activation pathways in that only C5 
is cleaved by the C5 convertases for activation and the resulting complex has increased 
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affinity for the binding of the sequential components: C6, C7, C8 and C9. Complement 
component C6, C7, C8 and C9 are structurally homologous to each other. The C5b 
component is extremely labile and is rapidly inactivated unless stabilized by binding to C6. 
All complement reactions take place on the amphipathic surfaces of membranes or on 
immune complexes in fluid phase. The complex C5b6 binds to C7 and undergoes 
conformational change forming a C5b67-complex. If the reaction occurs on a target cell 
membrane, the hydrophobic binding sites enable C5b67 complex to insert into the 
phospholipid bilayer (Kindt et al., 2007; Murphy et al., 2007). There is some evidence that 
potential cytolytic effect is caused by deposition of C5b67 complexes on the membrane of 
nearby host cells (Podack et al., 1979). The C5b678 complex has also been referred to as a 
“leaky patch” and in sufficient numbers can induce lysis of red blood cells (but not nucleated 
cells) in the absence of C9 ( Kindt el al., 2007). The final step in the formation of the MAC is 
the binding of multiple units of C9. As many as 10-18 molecules of C9 can be bound and 
polymerized by a single C5b678complex. The completed MAC consists of a C5b678 
complex surrounded by a poly-C9 complex, although only 1 or 2 C9 molecules are sufficient 
for effective cytolysis of nucleated cells. The MAC, once inserted, kills the cells by osmotic 
lysis; therefore, many pores are required to overcome the active ion pumps on eukaryotic 
cells which will attempt to maintain osmotic balance. 
 
1.4.2    Complement regulation 
Complement system activation is kept under tight control to avoid the potential harmful 
effect on host cells. The system can attack bystander host cells as well as foreign cells, 
infected cells and invading microorganisms (Kindt., et al 2007). Inappropriate complement 
activation has been linked to pathogenesis of some diseases and ischemia-reperfusion injury. 
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Complement regulation occurs mainly at two steps within the cascades, at the level of 
convertases, both in their assembly and in their enzymatic activity, and during assembly of 
MAC. The regulatory proteins are soluble (C4bBP, factor H, factor I and C1 inhibitor) or 
membrane bound (DAF, MCP, CR1 and CD59).  
1.4.2.1   Membrane bound regulators 
The majority of regulatory proteins have similar structure and are encoded within the 
Regulators of Complement Activation (RCA) gene cluster on the long arm of chromosome 1 
(Hourcade et al., 1989). Decay accelerating factor (DAF, CD55), complement receptor 1 
(CR1, CD35), CD59 and membrane cofactor protein (MCP, CD46) are membrane bound 
regulatory proteins that belong to the RCA (Rey-Campos et al., 1988). 
1.4.2.1.1 Decay Accelerating Factor (DAF) is a glycol-phosphoinositol (GPI) lipid-
anchored protein widely expressed on various tissues and cells and a soluble form is found in 
different body fluids (Nicholson-Weller et al., 1983; Medof et al., 1987; Rooney et al 1992). 
It accelerates the dissociation of both alternative (C3bBb) and classical (C4b2a) pathway C3 
and C5 convertases.  It displaces C2a from C4b and Bb from C3b, which abrogates further 
C3 cleavage and as a result limits their ability to participate in further complement activation 
(Fujita et al., 1987). Many pathogens use DAF as a receptor such as some viruses (e.g 
Coxsackie virus and echovirus) and uropathogenic E Coli (Lindahl et al., 2000). 
1.4.2.1.2   Membrane Cofactor Protein (MCP) is classical type I transmembrane protein 
with two alternate cytoplasmic domains. It is present in a vast variety of tissues and 
circulating cells (Seya and Atkinson 1989; Johnstone et al., 1993).  It serves as a cofactor for 
factor I mediated cleavage of C3b and C4b (with lesser affinity) deposited on host cell 
surfaces leading to the formation of iC3b, C4c and C4d cleavage products (Seya et al 1986; 
Seya and Atkinson 1989). Some microbes like measles virus, HHV-6, Neisseria gonorrhoeae 
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and N meningitides use MCP as a receptor to facilitate entry to nucleated cells and adherence 
to epithelial cells (Lindahl et al., 2000). Of importance, CD46 has also emerged as a key 
signalling molecule on the surface of T-cells that modulate adaptive immune responses 
(Kemper et al., 2001). 
1.4.2.1.3   Complement Receptor 1(CR1; CD35) is expressed on the surface of 
erythrocytes, neutrophils, monocytes and podocytes in glomeruli (Fearon, 1980). CR1 
mediates phagocytosis of particles opsonized with C3b and act as cofactor for factor I 
mediated breakdown of C3b and C4b and also cleavage of iC3b to C3c and C3d. CR1 on 
erythrocytes play an interesting role in the transport and clearance of immunocomplexes from 
the circulation to the reticuloendothelial system (Medof et al., 1982), which is hypothesised 
to underpin development of autoimmunity when CR1 is absent or present as certain isoforms. 
Moreover, CR1 acts as a receptor for C1q and their interaction further augment clearance of 
immunocomplexes (Klickstein et al., 1997).  
   1.4.2.1.4    CD59, initially called membrane inhibitor of reactive lysis (MIRL) is the most 
abundant cell surface regulator of complement, expressed by all blood cells, endothelial and 
epithelial cells (Davies et al., 1989; Meri et al., 1991). It blocks formation of MAC by 
binding to C5b-8 and preventing binding of C9 to the complex (Meri et al., 1990; Rollins and 
Sims 1990). 
1.4.2.2   Fluid phase regulators   
1.4.2.2.1   Factor I -is a serine protease which prevents the formation of active convertases 
through catabolism of C3b and C4b into inactive fragments, such as C4d, iC3b, C3c and 
C3dg (Sim et al 1993; Sim and Laich 2000). Factor I cleaves C3b in presence of cofactors 
MCP, CR1 and factor H. The inactivation of C4b by factor I take place in presence of C4 
binding protein (C4BP), CR1 or MCP as cofactors (Nagasawa and Stroud 1977).  
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1.4.2.2.2   Factor H (FH) is soluble protein similar to C4BP; it is a fluid phase inhibitor 
which plays an important role in self-recognition and protection from the alternative pathway 
complement. It acts as a dominant cofactor for factor I in cleavage of C3b preventing 
formation of functional C3 convertases (Weiler et al., 1976; Whaley and Ruddy 1976; 
Pangburn et al., 1977). It also binds to C3b preventing initial factor B binding or it 
accelerates the dissociation of Bb from the convertase. The importance of factor H is 
underpinned by factor H deficiency association to diseases like atypical haemolytic uremic 
syndrome (aHUS), membranoproliferative glomerulonephrits and age-related macular 
degeneration (Atkinson and Goodship, 2007).  
1.4.2.2.3   C4BP is able to bind C4b in the classical and lectin pathway convertases C (4b2a) 
can compete with C2 for binding to C4b, but its dominant mode of action is the cleavage of 
C4b to inactive fragments by acting as a factor I cofactor (Seya et al., 1995). This not only 
prevents formation of the convertase, but also accelerates its decay and blocks the convertase 
reformation (Gigli et al., 1979).  
 1.4.2.2.4   C1 inhibitor (C1INH) is a soluble regulatory protein that inhibits C1 by binding 
to the activated C1r and C1s, similar to the mechanism for AAT control of elastase (suicide 
inhibitor) and removing them from C1 complex (Ziccardi and Cooper, 1979). It also prevents 
autoactivation of C1 that could occur in the absence of activating antibodies (Ziccardi, 1982). 
Deficiency of C1INH causes hereditary angioedema (HAE) (Carugati et al., 2001). 
 
1.4.3   Complement system in neonates 
Complement activation is of prime importance in neonatal defence against infections, 
particularly in presence of low antibody levels and poorly developed specific immunity. 
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Moreover, newborn infants, especially those born prematurely, are at higher risk of 
developing infection. All complement components appear in foetal serum by 18 weeks of 
gestation and increase gradually afterwards (Adinolfi and Beck 1975). Previous studies have 
shown that neonates have a low concentration of most complement factors as well as low 
haemolytic activity compared to adults (Fireman et al., 1969; Ferriani et al., 1990; Wolach et 
al., 1997). The exceptions to this trend are factor D and C7 which are reportedly identical or 
higher in newborns than in adults (Johson et al., 1983; Wolach et al., 1994; Stonntag et al., 
1998 b). Johnson et al found factor D concentration is higher in cord than in maternal blood.  
 
The level of complement components is lower in preterm infants than in term neonates (Drew 
and Arroyave 1980). Similar or lower levels are noted when classical and alternative pathway 
components from preterm were compared to term newborns (Kohler, 1973; Stunk et al., 
1979; Johnston et al., 1979). A significant correlation has been reported between complement 
components level and gestational age (Fireman et al., 1969; Drew and Arroyave 1980; 
Shapiro et al., 1981; Notarangelo et al., 1984). Gestational age probably had a greater 
influence than birth weight on complement development. Furthermore, intra-uterine growth 
retardation (IUGR) does not seem to affect the development of complement (Drew and 
Arroyave 1980; Shapiro et al., 1981; Kitajima et al., 1990). 
Complement hypoactivity in neonates is believed to be a predisposing factor to 
microorganism invasion (Sonntag et al., 1998 a). On the other hand, activation of the 
complement system has been linked to the pathogenesis of meconium aspiration (Mollnes et 
al., 2008) ischemia-reperfusion injury associated with pre- or perinatal asphyxia as well as in 
preterm infants that underwent cardiopulmonary bypass to aid in oxygenation when their 
lungs were very  underdeveloped ( Enskog et al., 1996; Sonntag et al.,1998a). Regardless, the 
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mechanisms of activation in general appear to be intact in term infants, even if they are 
diminished (Zilow et al., 1993; Wagner et al., 1996) and in some cases it may be difficult to 
distinguish between low complement levels due to underproduction relative to those where 
complement is being consumed due to some underlying pathology associated with the 
precipitation of premature birth. On the other hand, serum concentrations of the soluble 
regulator proteins also appear to be low in neonates and preterm neonates, which may allow 
lower effector component concentrations to function prior to inhibition. 
 
1.4.3.1   Complement Component of Classical and Lectin Pathways in Neonates 
Many studies found that the functional activity and the components levels of classical and 
lectin pathways are low in cord blood compared to adult levels (Fireman et al., 1969; 
Adinolfi and Beck, 1975; Feinstein and Kaplan 1975; Strunk et al., 1979). 
Fireman and his colleagues found that the level of C1, C2 and C4 were only about 50% of 
maternal level (Fireman et al., 1969).  C1 level was found in term and preterm to be between 
53-79% and 27-65% respectively. In term newborns, C2 and C4 level ranged between 62-
85% and 42-73% (Miyano et al., 1996; Sonntag et al., 1998b). The level of C2 and C4 were 
found to reach adult values at 1 to 6 months respectively whereas C1q level was lower than 
adult levels even by 6 months of age (Davis et al., 1979).  
Newborn infants are able to synthesise MBL and maternal MBL is not transferred to the 
foetus (Kilpatrick et al., 1996; Van der zwet et al., 2007). In addition, Aittoniemi et al 1996 
demonstrated a correlation between gestational age and MBL levels in newborns. Their 
results were in keeping with other studies which demonstrated that MBL is detectable in cord 
blood and the level of MBL increased with the duration of gestation (Molhortra et al., 1994; 
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Lau et al., 1995; Maruyama et al., 2003). In contrast, other studies found no correlation 
between MBL level in cord blood and gestational age (Kilpatrick et al., 1996; Swierzko et 
al., 2009). Moreover, mothers with high MBL level during pregnancy were more likely to 
have premature infants (Van de Gijn et al., 2008). MBL can modulate cytokine production in 
vitro and in vivo and this may influence the response of neonates to even minor infections 
(Jack et al., 2001). Synthesis of circulating MBL concentration is determined by variations in 
the structural and promoter region of MBL-2 gene (Turner et al., 1993). On the other hand, 
variants of MBL gene resulting in low level of MBL in neonatal blood were also associated 
with CLD complicating RDS in preterm infant (Hilgendorff et al., 2007). This was in 
agreement with the findings of Frakking et al., 2007 who reported a 15-fold higher risk of 
early onset sepsis in neonates with variant MBL-2 genotype that gives low MBL levels 
compared with neonates with wild type MBL-2 genotype. 
 Low MBL levels in premature neonates reflect insufficient production due to physiological 
immaturity of the liver as noted for other complement and liver proteins (Polberger et al., 
1990; Kanakoudi et al., 1995).  De Benedetti et al 2007 also found that low MBL levels were 
associated with sepsis in newborns. MBL’s protective role against neonatal sepsis was 
demonstrated and the low MBL levels at birth were associated with an increased risk of 
hospital-acquired sepsis in infants admitted to the neonatal intensive care unit (NICU). 
Similar results were reported by Frakking et al., 2007 who demonstrated high susceptibility 
to infection in premature and term NICU patient with low MBL level.  
 MBL serum concentrations in cord blood samples were significantly lower in preterm infants 
compared to term newborn. The lowest levels of MBL as well as SP-D were seen in infants 
less than 28 weeks of gestational age especially in those with lower Apgar scores. This may 
be a predisposing factor to pulmonary and systemic infections (Hilgendorff et al., 2005). 
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MBL levels in term neonates increased in the first five days of life (Terari and Kobayashi, 
1993) and tripled in the first 3 month of life (Thiel et al., 1995; Van dez zwet et al., 2007). 
1.4.3.2   Alternative pathway 
The complement components and the activity of this pathway exhibit similar trends to those 
of the other pathways with significantly lower levels in infants compared to adults. Factor B 
level was shown to be less in neonates compared to adult level (P<0.001) with level between 
27-64% in term (wolach et al., 1997; Sonntag et al.,1998b) and 31-53% in preterm compared 
to adult values (Feinstein and Kaplan 1975; Miyano et al., 1996; Wolach et al., 1997). 
Moreover, properdin ranges in term and preterm infants compared to adults were 33-72 and 
13-41% respectively (Strunk et al., 1979; Drew and Arroyave 1980; Johnson et al., 1983; 
Wolach et al., 1994). Properdin levels correlated with birth weight (Adamkin et al., 1978). 
Davis et al reported that the level of factor B reached adult level by 6 months of age while 
properdin levels were still lower than adult levels even at 6 months and only reached adult 
levels at 16-24 months after birth (Davis et al., 1979).  
1.4.3.3 Complement functional activity  
The functional activity of alternative and classical pathways in term infants was decreased by 
50% relative to the adult level (Adinolfi and Beck 1975; Johnston et al., 1979; Anderson et 
al., 1983; Notrangelo et al., 1984; Wolach et al., 1994). Total haemolytic complement 
(CH50) was found to be between 52-73% and 32-78% in term and preterm infants, 
respectively. However, several studies indicated that alternative pathway function (AP50) in 
term or close to term infants is around 60-70% of adult levels (Wagner et al., 1996; Wolach 
et al., 1997; Sonntag et al., 1998 b). Low haemolytic activity of the neonatal complement 
system was attributed to the inability of these sera either to generate adequate number of 
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target sites or to stabilize sufficiently the enzymatic sites on the target cell membrane 
(Edwards, 1986). Furthermore, Drew and Arroyave (1980)  reported that nearly absent levels 
of C3 and factor B split products in the sera of a majority of their normal study infants 
suggest that the low CH50 activity and low concentrations were developmental and not due 
to consumption of components.  
CH50 was also studied in preterm newborns where adult/cord CH50 ratio was 32-78% 
(Adamkin et al., 1978; Strunk et al., 1979; Drew and Arroyave 1980; Miyano et al., 1987; 
Wolach et al., 1997; Høgåsen et al., 2000). Wolach et al studied cord/ adult CH50 ratio in 
term neonates and in 2 groups of preterm neonates with a gestational age of 34-36 weeks and 
28-34 weeks respectively. They found the highest ratio (78%) in 28-34 weeks preterm 
followed by 34-36 weeks preterm newborns (75%) and the lowest level was in term group 
(69%) but the difference was not statistically significant (Wolach et al., 1997). In a similar 
study, Petrova et al., 2003 compared CH50 of cord blood and CH50 at 3
rd
 or 4
th
 postnatal day 
with maternal CH50 in 2 groups of preterm infants. Group I were gestational age (GA) of 28-
32 weeks, whereas group II GA was 33-36 weeks. Group I showed significantly lower 
cord/maternal ratio (34.4%) than neonatal/maternal ratio (54.5%) whereas group II 
percentages were 62.9% and 56.4% respectively and the difference between these 2 ratios 
was statistically insignificant. Significant correlation between CH50 and gestational age was 
found in many studies (Ueda et al., 1980; Notarangelo et al., 1984; Miyano et al., 1987; 
Kitajema et al., 1990; Petrova et al., 2003). 
Ferriani et al. (1990) studied CH50 in three groups of neonates; healthy infants aged 1 to 24 
months and healthy adults. They found that neonates have the lowest values among groups 
studied. Surprisingly, they demonstrated that serum lytic activity among children aged 7-24 
months was higher than normal adults. This finding disagreed with data reported by Norman 
et al. (1975) who did not find a difference in CH50 results of newborns and children up to 14 
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years old (Norman et al., 1975). Another study reported CH50 was proportional to gestational 
age and reached adult levels at 3-6 months of age (Fireman et al., 1969). Similarly, Pedraz et 
al. (1980) demonstrated that CH50 levels reached maternal level at six months of age. 
 
Strunk et al., 1979 found that CH50 and AP50 were significantly correlated with birth 
weight. Moreover, they found that alternative and classical pathway functional activities were 
equally deficient in newborns as suggested by unchanged CH50/ AP50 ratio in cord and adult 
serum. In contrast, Drew and Arroyave 1980 did not find any correlation between 
concentrations of alternative pathway components (factor B and properdin) and gestation age 
and they believed that components of alternative pathway have steady rate of production 
during foetal life unlike classical pathway. Stossel et al have suggested that low levels of 
alternative pathway components may be more important in predisposing infants to infection 
than defects of classical pathway (Stossel et al., 1973)   
On the other hand, Ferriani and co-workers (1990) reported that classical pathway activity 
matures at earlier age than the alternate pathway (1-3 months and 13-18 months respectively). 
Inter individual variation was demonstrated by Johnston et al when they measured the rate of 
haemolysis in 27 babies. Only 14 had CH50 lower than 2SD below the mean compared with 
21 normal adult sera and so not every term baby had abnormal complement activity, at least 
of the classical pathway (Johnston et al., 1979). 
Drew and Arroyave, 1980 studied effect of gestational age and birth weight on CH50. They 
demonstrated that preterms have lower CH50 than full term neonates and found statistically 
significant correlation between gestational age and serum concentrations of complement and 
CH50 activity. They suggested that intrauterine growth retardation has no effect on 
haemolytic activity and Shapiro et al. in agreement with them had shown equal CH50 levels 
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in small for gestational age and newborn with appropriate weight for age (Shapiro et al., 
1981). Drew and Arroyave also compared haemolytic activity and components levels in 
normal and infected newborn and suggested that relative absence of C3 and factor B split 
products in the sera of the majority of normal infants is indicative of developmental aetiology 
(low production) for the low complement component levels and CH50 activity rather than 
due to consumption, secondary to activation of the complement system by either the classical 
or alternative pathways.  
 
 1.4.3.4   Complement component C3 
 C3 is central complement component which has a major role in bacterial opsonisation by all 
pathways. The synthesis of this component starts from 9
th
 week of foetal life and increases 
with foetal development (Adinolfi, 1970). The level of C3 has been found to be lower in term 
and preterm infants compared to adults and also in term compared to preterm.  Mean C3 
concentration in small for gestational age group was significantly lower than in the 
appropriate weight for gestational age group P<0.02 (Shapiro et al., 1981). Johnson et al. 
found the level of C3 in newborn serum 88% of adult level using electroimmunoassay 
(Johnson et al., 1983). Lower values were reported by Miyano and co-workers using a 
different method. They found that level of C3 was only 45-47% of adults using radial 
immunodiffusion. Measurement of C3 in 32-42 gestational week neonates by ELISA was 
shown to be 56% of adults. The median level in full term neonates was 0.67g/l compared to 
0.8-1.2 g/l in adults, rising to adult levels by 3-6 months of age (Fireman et al., 1969; 
Norman et al., 1975). Quantitative maturation of complement components C2, C4, C5, C6 
and factor B occurred in an age related fashion, so their levels were not significantly different 
from adult level by six month age (Davis et al., 1979). 
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There are several reports of increased formation of complement activation products such as 
Ba, C3a, C3d and SC5b-9 in infants with neonatal infections compared with healthy 
newborns, indicating that activation fragments are valid indexes of infection and underscore 
normal complement activation in neonates (Drew Arroyave 1980; Peakman et al., 1992; 
Zilow et al., 1993; Zilow et al., 1997).  
1.4.3.5   Terminal pathway in neonates 
Activation of C5-C9 in the terminal pathway occurs as a result of C3 convertase activation 
irrespective of which pathway cleaves C3 and ultimately results in formation of MAC 
responsible for pathogen killing. Levels of terminal complement components were lower in 
term and preterm infants compared to adults except for C7 which was equal to or higher than 
adult level (Johnson et al., 1983; Wolach et al., 1994; Wolach et al., 1997; Sonntag et al., 
1998b). The exception to these studies is Adinolfi and Beck who showed that C7 
concentration in neonates was only about 70% of adult levels (Adinolfi and Beck, 1975). 
Fireman and his colleagues found that the level of C6 to be about 50% of maternal level 
(Fireman et al., 1969) but comparison with maternal level may underestimate complement 
level in newborns because complement components (except C8) are acute phase reactants and 
pregnancy induces higher levels than in non-pregnant females. 
Wolach and co-workers studied complement levels in two groups of preterm and a group of 
term infants. They found a significant correlation between levels of complement and 
gestational age and the most significant surge in levels occurred later in pregnancy (Wolach 
et al., 1997). 
C9 concentration varies considerably, possibly due to different methodology. Ballow et al in 
1974 found that the level of C8 and C9 are in range of 10-25% of adult level whereas Zilow 
et al in 1994 reported that the level of C9 was as low as 1% of adult value. Lassiter used 
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radial immunodiffusion to measure C9 concentration and found that C9 level was 17% of the 
mean serum concentration from their mothers. He also found that reconstituting C9 levels 
corrected the limited E coli bactericidal capacity of neonatal sera with low C9 concentration 
(Lassiter et al., 1992). Høgåsen et al studied C9 using ELISA which is more quantitative and 
found that 15% of neonates in their study had C9 levels less than 2% of adult values 
(Høgåsen et al., 2000). Levels of C9 were also found to correlate with the gestational age.  
 
1.4.3.6   Anaphylatoxins 
The anaphylatoxin C3a, C5a, C5a-desArg are pro-inflammatory polypeptides generated after 
proteolytic cleavage of C3 and C5 in response to complement activation. C3a and C5a 
regulate vasodilation, increase the permeability of small blood vessels and induce the 
contraction of smooth muscles and may impair cardiac function (Ember et al., 1998; Klos et 
al., 2009). The anaphylatoxins in humans are rapidly inactivated by carboxypeptidase B 
which cleaves off the C-terminal arginine (hence the designation des-Arg) residue from the 
anaphylatoxins. Degradation products C3a desArg and C5a desArg molecules have much 
reduced anaphylatoxin activities. They increase vascular permeability and trigger smooth 
muscle contraction and release histamine from mast cells and basophils (Hugli, 1984). C3a 
and C3adesArg are eliminated by the kidney, while C5a is internalized and degraded by 
neutrophils. They only appear in plasma when the binding capacity of the neutrophils is 
exceeded. There is a correlation between C3a and MAC, while no correlation was found 
between C3a and C5a. C5a and C5adesArg activate neutrophils and macrophages, while both 
C3a and C5a induce the release of proteases and cytokines from leukocytes (Enskog et al., 
1996). C5a has potent chemotactic activity and plays an active role in pulmonary 
inflammation (Struck et al., 1988) Sonntag et al and Enskog et al found that anaphylatoxin 
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concentrations were higher in term neonates than in healthy adults. The reason for the higher 
plasma concentration in newborns may be due to the limited capacity of leukocytes to bind 
anaphylatoxins (Enskog et al., 1996; Sonntag et al., 1998b). In contrast, Zilow et al used a 
capture sandwich ELISA to measure C3a-desArg and found that the level was similar in 
healthy term and adult. 
It was found that premature babies who had birth complications tend to have high plasma 
anaphylatoxin concentrations and C5a was high in fluid aspirated from tracheobronchial fluid 
in preterm infants who were at risk of lung disease (Groneck et al., 1993; Enskog et al., 
1996). The levels of C3a were found to be increased in asphyxiated neonates as well as those 
with septic shock (Hack et al., 1989; Schrod et al., 1992). 
 Miyano et al reported that the level of C3, C4 and C3d as well as CH50 and factor B were 
lower in infants with RDS compared to infants with other lung diseases such as pneumonia  
or normal lung function (Miyano et al., 1991), while C1q and other serum component 
concentrations were similar between infants with and without RDS.  
1.4.3.7   Regulatory proteins 
The lack of some regulatory proteins, such as factor H, factor I and properdin are associated 
with greater susceptibility to infections and may represent a life-threatening condition. There 
are several studies investigating the concentration of regulatory proteins in neonates 
compared to adults. De Paula et al (2003) found significantly lower levels of factor H, factor 
I, C4BP, properdin and vitronectin in healthy neonates when compared to adults. Schwartz 
and co-workers have reported that free protein S levels in cord blood (gestational age 29-34 
weeks) was 74% of that of adult plasma, and total protein S (which is usually bound as a 
component of C4BP) only 23% of adult mean. This is because of higher levels of C4BP in 
the term infants relative to adults (Schwartz et al., 1988). Other studies on preterm and term 
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infants have also showed low levels of C4BP had a marked correlation with gestational age; 
(Malm et al., 1988 Melissari et al., 1988), while the levels of protein S were found to reach 
adult levels by 4 months of age (Sthoeger et al., 1989). 
Melissari et al (1988) found that C4BP was lower in term (18%) and preterm (6%) cord 
blood when compared to adult plasma (P<0.001) while neonates were reported to have 35-
78% factor H and 25-75% of adult  factor I concentrations (Davis et al., 1979). Reduced 
levels and function of C1INH was reported in neonates compared to adults: term levels of 
C1-INH were about 62% of adult and 77% of maternal level (Cat et al., 1993). 
1.4.3.8 Complement activation and pathogenesis of some newborn diseases 
Uncontrolled complement activation was implicated in pathogenesis of organ damage 
induced by premature rupture of membrane (PROM). Complements levels were normal in 
maternal and cord blood of preterm neonates born after premature rupture of membranes of 
more than 24 hours, but C5a levels increased significantly in the third postnatal day (Petrova 
and Mehta 2007).
 
Amnionitis stimulated production and triggered activation of complement 
component in preterm infants (Kitajima et al., 1990). The level of C3, C4, C3d, CH50 and 
factor B were demonstrated to be high in infants born with associated chorioamnionitis 
whereas C5, C1q, C2 and C9 levels showed insignificant change compared to control 
(Kitajima et al., 1990; Miyano et al., 1996) 
The level of C9 in CSF obtained from 16 infants with hypoxic injury encephalopathy (HIE) 
has been reported to be reduced  compared to CSF from 7 control infants due to the activation 
of complement to form MAC and consumption of C9 during complement activation in the 
CNS following resuscitation (Schultz et al.,  2005). C9 was deposited on cerebral neurons, 
and they also found the concentration of MAC in cerebrospinal fluid (CSF) of newborns with 
HIE to be greater than in infants without hypoxia.  
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Evidence that the classical pathway contributes to
 
the hypoxic-ischemic brain injury has 
come from animal studies. A study on neonatal rats showed that complement activation 
contributes to hypoxic–ischaemic injury in the brain; however, depletion of complement 
activity by cobra venom factor (CVF) did not eliminate complement deposition within 
injured brain. This may indicate a role for local complement component synthesis in the CNS 
contributing to pathology (Cowell et al., 2003). 
Meconium aspiration syndrome (MAS) is infrequent and severe disease of newborns 
characterised by respiratory distress, pulmonary inflammation, hypoxia and persistent 
pulmonary hypertension. The pathophysiology of MAS is complex with activation of 
different immune pathways and pro-inflammatory mediators (Van Ierland and de Beaufort 
2009). Complement activation probably contributes to the pathogenesis of MAS (Castelheim 
et al., 2004; Mollnes et al., 2008). It is also responsible for neutrophil inflammatory 
responses mediated by C5a (Castellheim et al., 2005). These findings are substantiated by a 
neonatal pig model.  Intrapulmonary instillation of meconium in piglets resulted in massive 
elevation of membrane attack complex followed by similarly substantial increase in cytokine 
levels. MAC and cytokine levels correlated with the degree of lung dysfunction and were 
higher in animals that died than in surviving animals (Lindenskov et al., 2004). Additionally, 
a recent study had demonstrated that meconium can activate the lectin pathway as well as 
alternative pathway in human serum (Salvesen et al., 2009).   
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1.5   UREAPLASMA 
Ureaplasma spp is a member of the Mollicutes class together with mycoplasma. They were 
initially named T- Mycoplasma due to their tiny colonies compared to other Mycoplasma 
colonies but later renamed as Ureaplasma to reflect their ability to utilize urea as energy 
source. The species Ureaplasma urealyticum was later sub-divided into 2 biovars. Biovar 1 
included serovars (SV) 1, 3, 6 and 14 whereas biovar 2 included SV2, 4, 5, 7, 8, 9, 10, 11, 12 
and 13. The classification was reviewed in 2002 and the biovars 1 and 2 were reclassified in 
to 2 species (based on 16S rRNA homology): Ureaplasma parvum SV1, 3, 6 & 14) and 
Ureaplasma urealyticum (remaining SV), respectively (Robertson et al., 2002). Both of these 
species have been detected in clinical samples particularly U. parvum (Abele-Horn et al., 
1997; Kong et al., 1999). The common features of these species are lack of cell wall, small 
genome size, and utilization of urea as primary energy source. Despite being recognized as a 
commensal in the female genital tract of low virulence, it is increasingly linked with various 
obstetric and gynaecological problems including infertility, foetal loss, chorionamnionitis and 
preterm labour (Waites et al., 2005). 
1.5.1   Ureaplasma in neonates  
Ureaplasma urealyticum is known to cause non-gonococcal urethritis (Horner et al., 2001). It 
was also reported as a causative agent for meninigitis in an immunocompromised adult after 
renal transplant (Geissdörfe et al., 2008). Ureaplasma is believed to be a major cause of 
chorioamnionitis and thereby linked to preterm labour, spontaneous abortion and chronic 
lung disease in neonates (Cassell et al., 1986; Yoon et al., 1998). It is also known to cause 
meningitis in term and premature neonates (Waites et al., 2005). 
Neonatal Ureaplasma colonisation has been associated with development of CLD in preterm 
infants (Yada et al., 2010). Moreover, a cohort of 1,988 pregnant women had cervical culture 
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for Ureaplasma at the initial antenatal visit and followed up during pregnancy. Abnormal 
vaginal flora were detected in 22.7% of which 53.6% had Ureaplasma spp. In all intrauterine 
models, Ureaplasma infection was persistent which highlights the limited capacity of 
newborns to clear these bacteria (Viscardi, 2012). Ureaplasma colonisation in preterm 
newborn that subsequently developed CLD could be persistent or transient (Castro-Alcaraz et 
al., 2002). Using logistic regression to analyze the outcome with other risk factors of PT 
labour taken into consideration. PT labour was significantly correlated (p= 0.02) with 
positive Ureaplasma culture with an odds ratio (OR) of 1.64 and 95% confidence interval 
1.08-2.48 (Breugelmans et al., 2010).   
In contrast, a recent study investigated the prevalence of Ureaplasma species in amniotic 
fluid obtained trans-abdominally at 16-20 weeks of pregnancy from 121 asymptomatic 
pregnant women. Ureaplasma were not isolated by culture in any of the studied amniotic 
fluid samples but 4 cases were identified on multiplex PCR (2 U. parvum and 2 U. 
urealyticum). All the 4 cases had normal labour and gave birth to normal weight babies. Four 
other cases of PT delivery in the series were from Ureaplasma negative mothers. Their 
prematurity is not associated with Ureaplasma infection. (Rodríguez et al., 2011). This was 
in agreement with another study which did not demonstrate association between preterm with 
Mycoplasma hominis, U. urealyticum or U.parvum colonization and labour outcome 
(Govender et al., 2009). 
One animal model study suggested a role for Ureaplasma urealyticum in the development of 
chronic lung injury of some immature infants, but the critical finding is the differential 
response to U. urealyticum among an apparently homogeneous group of antenatal exposed, 
immature, nonhuman primate infants (Yoder et al., 2003). The same study revealed that 
approximately 50% of immature baboon infants (GA 125 days;  full term is 185 days) could 
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clear Ureaplasma from their pulmonary system within the first week after delivery and those 
who failed to clear the bacteria where at higher risk of pulmonary complications (Yoder et 
al., 2003).  
Moreover, epidemiological human studies suggest that Ureaplasma infection is associated 
with pathogenesis of CLD. The Alabama preterm birth study was undertaken to evaluate the 
prevalence of Ureaplasma and Mycoplasma spp infection in neonates born at gestational age 
of 23-32 weeks and its association with adverse outcomes. The study included 351 mothers 
and their newborn babies and it demonstrated that Ureaplasma spp and Mycoplasma hominis 
infections were significantly more common in spontaneous PT labour. Positive cultures were 
found in 23% of the women and associated with systemic inflammatory response in 
newborns and probably with CLD (Goldenberg et al., 2008). Another prospective study on 
very low birth weight  (<1501 gram birth weight; VLBW) preterm neonates agreed with 
Alabama study results and suggested that invasive Ureaplasma infection probably increases 
the risk of severe intraventricular haemorrhage in VLBW infants (Viscardi et al., 2008). 
Another experimental study in Rhesus monkeys showed that intraamniotic inoculation of M. 
hominis or U. parvum as a sole pathogen elicits a remarkable pro-inflammatory response that 
contribute to PT labour and foetal lung injury. Chorioamnionitis and pneumonitis also worsen 
with duration of in utero infection (Novy et al., 2009). 
In addition, VLBW newborns colonized with Ureaplasma were twice more likely to develop 
pneumonia than non-colonised VLBW neonates (Pacifico et al., 1997). All the past studies 
were reviewed by Viscardi and Hasday (2009) who concluded that the balance of reports 
showed that Ureaplasma infection definitely contributes to the pathogenesis of CLD and is 
augmented by the barotrauma of the ventilatory support and adverse effect of oxygen therapy. 
These factors collectively lead to dysregulated inflammatory response in the immature lung 
that impairs alveolarization and stimulates collagen and elastin deposition secondary to 
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fibroblast proliferation and activation (Viscardi and Hasday 2009). More convincing 
evidence of the significant association between Ureaplasma infection and subsequent 
development of CLD comes from a meta-analysis of 23 cohort studies that recruited VLBW 
infants colonized or infected with Ureaplasma. More than 200 newborn were included in the 
analysed studies published between 1988 and 2004 (Schelonka et al., 2005).  
A recent case report also presented autopsy results of a newborn that died, concluding the 
cause of death to be U. parvum congenital pneumonia which was confirmed by PCR 
(Morioka et al., 2010). 
 
Recent interest in collectins, in particular surfactant protein A (SP-A) have resulted in a 
report where SP-A played an important role in clearance of Ureaplasma infection. Evidence 
came from in vitro study showing enhancement of macrophage cell line (RAW 264.7) ability 
to phagocytose and kill Ureaplasma spp when SP-A was added in a concentration of 10-50 
µl/ ml (Okogbule-Wonodi et al., 2011). Moreover, SP-A deficient mice when infected with 
Ureaplasma were less efficient in clearing the infection and also exhibited an exaggerated 
inflammatory response compared to wild type mice. Simultaneous administration of SP-A 
and Ureaplasma to the deficient mice did not improve the rate of bacterial clearance but on 
the other hand, reduced the inflammation which denotes the importance of this collectin in 
regulation of pulmonary inflammatory response to infection (Famuyide et al., 2009). 
Expression of secretory leukoprotease inhibitor and anti-neutrophil elastase activity were also 
reduced in bronchoalveolar fluid from SP-A deficient mice, suggesting anti-inflammatory 
action of SP-A is in part due to its ability to inhibit cleavage of secretory leukoprotease 
inhibitor by matrix metalloproteases (Ramadas et al., 2009). 
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1.6 Hypothesis and Aims 
Hypothesis: Neonatal neutrophils are deficient in proteases relative to adult levels and 
newborn cord serum is also relatively deficient in terminal complement components (C6-C9) 
which impairs complement function and capacity of cord serum to kill pathogens.   
Aims 
The objectives of this research were: 
 
 To compare the total and releasable concentration of cathepsin G and proteinase 3 
between normal adults and normal caesarean-delivered term neonates, including the 
expression and surface binding of proteinase 3 and its high affinity neutrophil surface 
receptor CD177. 
 To examine surface proteinase 3 expression on the surface of neutrophils lacking 
CD177 (both in deficient individuals and normally occurring CD177-negative 
subsets) in adults and neonates. 
 To measure proteinase 3 concentrations in bronchoalveolar lavage samples (BAL) 
from ventilated premature neonates, correlated to clinical outcome (resolved 
respiratory distress versus chronic lung disease) and to assess its relationship with 
other neutrophil proteases, elastase and MMP-9.  
 To examine developmental insufficiency of complement in term neonates (relative to 
normal adults) by developing ELISAs for C6, C7, C8 and C9 and establishing 
accurate reference ranges for these components and relating the deficiencies to 
decreased complement function as measured by lysis of sensitized sheep erythrocytes 
(CH50 assay) and bacteriocidal activity against the important neonatal pathogen, 
Ureaplasma parvum.  
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2.1  Enzyme-Linked Immunosorbent Assay (ELISA) 
 
  ELISA is a biomedical technique used to detect antigens (Ag) in biological samples. It is 
based on the direct interaction of the Ag with an antibody (Ab) which is labeled with an 
enzyme. The antibody bound to the antigen is detected by the addition of the enzyme’s 
colourless substrate (chromogen). The coloured reaction product indicates the presence of 
Ag. The coloured change can be measured and quantitated by reading the Absorbance in a 
spectrophotometer (Murphy et al., 2008).  
 
Optimised sandwich ELISAs were created for measuring C6, C7, C8 and C9, choosing the 
most sensitive monoclonal antibody from commercial and non-commercial sources. Where 
necessary, sensitivity and range of assay were enhanced by immobilising monoclonal 
antibodies with rat anti-mouse IgG1 monoclonal antibody. Amino acid hydrolysis (performed 
by the supplying company, Quidel Corporation), was used to accurately quantify affinity 
purified C6, C7, C8 and C9. Confidence intervals for complement concentration were 
determined in 20 normal adults and 20 cord sera from uncomplicated caesarean-delivered 
term newborns. Study was approved by Research Ethics Committee (REC) and written 
informed consent was obtained from mothers prior to section and from volunteers.  Serum 
preparation is described in section 2.3.4.  
 2.1.1 Complement C9 ELISA 
2.1.1.1 Antibodies 
The suitability of different monoclonal antibodies (mAb) as capture Abs for purified C9. 
ELISA was tested in order to choose the most sensitive antibody. Monoclonal antibodies 
tested against human C9 were supplied by Quidel, anti-C9 (cat.A223), and from Hycult 
Biotechnology (clone WU13-15, X179 and aE11). Non-commercial monoclonal anti-C9 
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antibody (B7) was kindly provided by Professor Paul Morgan. In addition to testing this 
antibody’s ability to capture purified Quidel C9, they were also tested for their ability to 
capture C9 in C5b-C9 complex as well as native C9 in diluted serum samples. Only Quidel 
goat anti-C9 polyclonal antiserum was tested as a detecting antibody, which was visualised 
by Jackson Laboratories’ HRPO-conjugated minimum cross-reactivity Donkey anti-goat 
antibody and OPD (measured at 490 nm). 
 
2.1.1.2 Varying the concentration of mAbs to coat C9 ELISA plate 
In order to optimise C9 ELISA, The effect of different concentrations of B7, X179 and aE11 
mAbs, were tested to detect the most suitable working concentration of these antibodies to act 
as capture mAb for C9 ELISA. Tested mAbs concentrations started from 1 µg/ml to 4 µg/ml. 
Where nessary, sensitivity and range of assay were enhanced by immobilising monoclonal 
antibodies on plates coated with rat anti-mouse IgG1 monoclonal antibody at final 
concentration of  4 µg/ml (Stock concentration 1mg/ml, Lifespan Bioscience). 
 
2.1.1.3 C9 ELISA antibody selection 
The capture anti-C9 monoclonal antibodies (mAbs) were diluted in coating buffer 
(NaHCO3/Na2CO3, pH 9.6) at a final concentration of 2-4 µg/ml and used to coat  ELISA 
plates (96-well flat bottom, Nunc-Immuno Maxisorb, Thermo Fisher Scientific, Denmark) by 
adding 100 µl of diluted antibody into each well. The plates were then sealed with an 
adhesive strip and incubated at 37°C for one hour, followed by complete removal of liquid by 
inverting and tapping the plates against clean paper towel. Non-specific binding sites were 
then blocked by filling the wells with 115 µl blocking buffer [5% bovine serum albumin 
(BSA) in phosphate buffered saline (PBS), containing 0.05% Tween 20 (PBST)]. The plates 
were incubated for one hour at 37°C, before being washed once with PBST. The purified C9 
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standard (Quidel C9) serial dilutions ranging from 0.78 to 200 ng /ml of C9 were prepared in 
blocking diluent buffer and used for the preparation of the standard curve.  Similar steps were 
performed to obtain C5b-C9 standard curves. Standard curves were run in duplicates for each 
ELISA, 100 µl of the standard was dispensed into designated wells and the plates were 
incubated for 1 hour at room temperature (RT).  
 
The detecting Ab (polyclonal goat anti- human C9 Ab) was diluted to a final concentration of 
1:1000 in blocking buffer and added to each individual well. The plates were sealed and 
incubated at room temperature for one hour.  Plates were washed three times with PBST and 
incubated at room temperature with 1:1000 of Horseradish peroxidase(HRPO) anti- goat 
antibody (Jackson Laboratories), diluted in blocking buffer, for one hour. Plates were washed 
three times with PBST then once with PBS. The plates were developed with a substrate 
solution made up by adding two tablets of Ortho-Phenylenediamine, (OPD-EASY) (each 
contains 3.5 mg of 1,2-phenylendiamine dihydrochloride) (Fisher Scientific), to 6.4ml of 
sterilised water mixed with 2.5 µl of hydrogen peroxide (Aldrich, Steinheim, Germany). One 
hundred µl of substrate solution was added to each well and incubated for about 10-20 
minutes, depending on the rate of colour change of the standard curve wells. The reaction 
was stopped by adding 100 µl of 2N sulphuric acid (H2 SO4) (Sigma-Aldrich) and read on a 
plate reader (Dynex technologies, Chantilly, VA) at 490nm. 
 
2.1.1.4 C9 ELISA in cord and adult sera 
The most sensitive capture antibody, locally available anti-C9 (B7) was coated onto 96-well 
Nunc-Maxisorb plates at a concentration of 2µg/ml. The standard curve ranged from 0.78 to 
200 ng /ml, cord and adult serum samples were assayed at 1:1000 and 1:2000 dilution as 
detailed above in section 2.1.1.3. 
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Table 2.1 List of monoclonal antibodies used in ELISA 
Antibody specificity Clone Isotype Concentration Source 
Monoclonal antibody 
to human C9 
    A223 IgG2bk >1 mg/ml Quidel,san, Diego USA 
Monoclonal antibody 
to human C9 
WU 13-15 Mouse IgG1 100 µg/ml Hycult-Biotechnology 
Monoclonal antibody 
to human C9 
X197 Mouse IgG1 100 µg/ml Hycult-Biotechnology 
Monoclonal antibody 
to human C9 
aE11 Mouse IgG1 100 µg/ml Hycult-Biotechnology 
Monoclonal antibody 
to human C9 
Non-
commercial B7 
Unknown 0.6mg/ml Paul Morgan Lab-
Cardiff university 
Monclonal to human 
C6 
WU6-4  MouseIgG1k 100 µg/ml Hycult-Biotechnology 
Monclonal to human 
C6 
A219  Mouse IgG1 1 mg/ml Quidel,san, Diego USA 
Monclonal to human 
C7 
WU 4-15 MouseIgG1k 100 µg/ml Hycult-Biotechnology 
Monclonal to human 
C7 
A221 MouseIgG1K 1mg/ml Quidel,sanDiego USA 
Monoclonal to human 
C9 
A249 Mouse IgG1 1mg/ml Quidel, San Diego USA 
Monoclonal to human 
C8 
Clone αC8 E2 BPM 0.411 mg/ml Non-commercial 
Morgan Lab 
 
72 
 
2.1.2  Complement C6 ELISA 
 
2.1.2.1 Optimising C6 ELISA 
 
Different monoclonal antibodies(mAbs) were tested for their ability to capture purified C6 
listed in table 2.1 as well as human serum. In addition, working concentration of the most 
sensitive antibody was optimised by testing serial different concentration ranging from 1 to 4 
µg/ml as illustrated above in C9 ELISA section 2.1.1.3. Quidel goat anti-C6 polyclonal 
antiserum was tested as a detecting antibody, which was visualised by Jackson Laboratories’ 
HRPO-conjugated minimum cross-reactivity Donkey anti-goat antibody and OPD (measured 
at 490 nm). 
 
 
2.1.2.2 Cord and adult C6 ELISA 
 
C6 levels in cord and adult sera were measured using an ELISA assay. A 96-well plate which 
was coated with the selected Hycult anti-human C6 (clone WU 6-4), diluted in carbonate 
coating buffer at final concentration of 4 µg /ml stock concentration 0.88mg/ml, Hycult-
biotech). Standard C6 (Quidel) along with cord and adult sera were diluted using blocking 
buffer as mentioned above. The standard C6 range was 500 to 1.23 ng /ml, and samples were 
assayed at 1:500 and 1:1000 dilution, all done in duplicate at 100 µl /well. After 1 hour 
incubation at RT, the plate was washed three times with PBST then  100 µl /well of 
polyclonal anti-C6 (Quidel), diluted to 1:1000 in blocking buffer were added. The detection 
goat antibody was detected as detailed above, section 2.1.1.3. 
 
73 
 
2.1.3 C7 ELISA 
2.1.3.1 Optimising C7 ELISA 
Different monoclonal antibodies were tested to capture purified C7 as listed in table 2.1 
Titration of the most sensitive one was done to reach the best working concentration. In 
addition, rat anti-mouse IgG1 antibody was used to enhance the binding of capture antibody 
and allow using it at lower concentrations. Only one detecting antibody (Quidel polyclonal 
anti-C7) was used and the reaction was visualised using (HRPO) anti-goat antibody. 
 
2.1.3.2 C7 ELISA in cord and adult sera 
Rat anti-mouse IgG1 antibody was pre-coated into 96-well microtiter plate by incubation 
(100µl/well) of a 4µg/ml dilution in ELISA coating buffer at 37°C for one hour. Plates were 
blocked with (0.5% BSA in PBS containing 0.05% Tween 20), 115µl/well at 37°C for 45 
minutes. Rat anti-mouse IgG1 coated plates were used to immobilise the best mAb, murine 
anti-human C7 (Ouidel, stock concentration 1.16mg/ml) at a concentration of 2µg/ml. The 
plate was washed once with PBST, before adding standard ranging from 1.23 ng/ml to 500 
ng/ml (Quidel). Serum samples (100µl/well) were tested at 1:500 and 1:1000 dilutions in 
blocking buffer. After incubation for one hour at room temperature, the plate was washed 
three times with PBST, before addition of goat polyclonal anti –sera to human C7 (Quidel) at 
1:1000 dilution in blocking buffer, 100 µl/well. The detection antibody was measured as 
detailed above in section 2.1.1.3.  
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2.1.4 C8 ELISA 
2.1.4.1 Optimising C8 ELISA 
96 well Maxisorb microtiter plates were coated with three different monoclonal antibodies 
specific for C8 (Ouidel, Hycult, and non- commercial BPM antibody) listed in table 2.1.  
Different concentrations of these antibodies were used to capture purified C8. The 
empirically-determined most sensitive antibody (BPM) was titrated for its optimal working 
concentration as described for C9 mAbs. Only Quidel goat anti-C8 polyclonal antiserum was 
tested as a detecting antibody, which was visualised by Jackson Laboratories’ HRPO-
conjugated minimum cross reactivity Donkey anti-goat antibody and OPD (measured at 490 
nm). 
 
2.1.4.2 C8 ELISA in cord and adult sera 
96 well Maxisorb microtiter plates were coated with the selected best mAb, BPM anti-C8 
(clone αC8E2, stock concentration 0.411 mg/ml) at 2µg/ml diluted in coating buffer, 
100µl/well and incubated at 37°C for one hour. Plate was incubated for further one hour with 
blocking buffer (0.5% BSA in PBS with 0.05% Tween 20) and washed once with PBST. The 
standard was diluted in blocking buffer ranging from 1.953ng/ml to500 ng/ml. Cord and adult 
serum samples were diluted 1:500 and 1:1000 and aliquots of 100 µl were measured. The 
plates were incubated for one hour at room temperature before being washed three times with 
PBST.  Polyclonal goat anti-sera to human C8 diluted 1:1000 in blocking buffer was used as 
detection antibody and was measured as above for other assays, section 2.1.1.3. 
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2.2 Complement Haemolytic activity (CH50) assay 
The CH50 assay was used to assess the ability of cord sera to haemolyse sensitised sheep 
RBCs (complement-mediated haemolysis). Sheep erythrocytes (SRBCs) were gently 
resuspended in the stock bottle by tapping the side of the bottle and by gentle inversion and 
pipetting (TCS serological products, UK). Six mls of sterile SRBCs were aseptically 
transferred to a 15 ml conical tube using a biological safety cabinet. Tube was topped up with 
fresh PBS and mixed by gentle inversion, then centrifuged at 1000xg for 4 minutes. 
Supernatant was removed and the pellet was gently re-suspended twice in 10 ml PBS. The 
tube was centrifuged at 1200xg for 4 minutes and the supernatant was removed. Five ml of 
PBS was added to two lots of universal containers, one of which received 20 µl of 
amboceptor antibody (rabbit α-sheep erythrocyte antibody) while the other received 400 µl of 
washed sheep erythrocyte pellet. These two lots were pooled together. The resulting 
suspension of erythrocytes was incubated in water bath, 37° C for 30 minutes and mixed 
gently every 10 minutes. Following sensitisation the tube was gently mixed and centrifuged 
at 1500 xg for 4 minutes.  The pellet was washed with 20 ml PBS and centrifuged at 1500 xg 
for 4 minutes and then subsequently washed in 10 ml of veronal buffer saline (VBS) followed 
by centrifugation for 4 minutes before being resuspended in 20 ml of VBS as the working 
stock (sensitised erythrocytes diluted to 1% in VBS). Cord and adult serum samples were 
then diluted to 1:20 in VBS in preparation for the assay. A flat bottom 96-well plate was 
prepared for each assay: Row (A) contained 50 µl of extran (1 ml of H2O in 50 µl of Tween 
20) was added to all wells in row A. 50 µl of the 1:20 serum (internal control) was added to 
row B wells. C-H received 50 µl VBS. Wells in row C received an additional 100 µl of the 
1:20 serum dilution (final dilution 1:30) from both cord and adult sera.   
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Where indicated serum samples were supplemented with 50 micrograms/ml C9 and 
compared to matched unsupplemented samples in parallel.  All samples were run in triplicate. 
Serial 2:3 dilutions (100 µl) were made down the plate from well C to well G after which the 
remaining 100 µl was discarded. Row H wells were left as a serum-free VBS negative lysis 
control. The 4% erythrocyte solution was diluted 1:1 to give a working 2% solution of which 
50 µl was added to each well. The plate was then incubated at 37° C for 30 minutes with 
absorbance reading being taken every 3 minutes in a plate reader at wavelength of 690 nm.  
 
2.3 Ureaplasma killing assay 
2.3.1 Ureaplasma Strains used 
All experiments were conducted using prototypic Ureaplasma parvum strains of serovar 
(SV1) (DKF-1; obtained from health protection agency (HPA); Colindale, London, UK), SV3 
(HPA5), SV6 (HPA2) and SV14 (HPA32). All strains were maintained in Ureaplasma 
specific medium (USM; purchased from Mycoplasma Experience, Surrey, UK). 
 
2.3.2 Ureaplasma selective culture medium and culture conditions 
Ureaplasma serovars were grown in Ureaplasma selective medium (USM) purchased from 
Mycoplasma Experience Ltd. (Surry, UK). USM consisted of a simple broth base medium 
supplemented with yeast extract, 7 mM urea, 10% heat-inactivated porcine serum, with 
phenol red as the pH indicator (starting pH, 6.65) and with 2.5 µg/ml amphotericin B and 
0.25 mg/ml ampicillin. Cultures were performed in flat-bottom  96-well plates covered with 
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adhesive strip (Elkay, Basingstoke) or in 5 ml bijoux containers (Elkay, Basingstoke) and 
incubated in a humidified tissue culture incubator set at ambient CO2 concentration at 37 °C. 
 
2.3.3 Quantification of Ureaplasma parvum growth 
 Ureaplasma growth was expressed as colour changing units (CCU). To determine the 
number of CCU within a sample or culture a series of 1:10 dilutions are made as follows. 180 
µl of USM was added to a single column (8 wells) of a 96 well flat plate. 20 µl of sample was 
incubated into the first well to give an initial 1:10 dilution. From this well the process is 
repeated down the plate to 7
th
 well give a dilution gradient to 10
-7
. The final well remained 
un-inoculated to serve as a negative colour, to rule out false positives. Plates were then 
incubated for 48 hours at which time colour change had ceased. The final well in which 
colour change occurred was denoted as 1 CCU. By knowing the dilution of the well giving 1 
CCU, the number of CCU in the initial sample could be calculated. 
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Figure 2.1 Diagram of complement killing assay, a 96 well plate setup for four Ureaplasma  
Parvum isolates (A-D) under two conditions. 50% heat inactivated normal human serum (HI-
NHS) and 50% normal human serum (NHS). Following complement attack Ureaplasma were 
titrated out as set out in the plate above, initially 1:10 dilutions followed by 1:1 dilutions, to 
determine the fold reduction of colour changing units between HI-NHS and NHS. (Yellow 
wells indicate no growth while pink colour indicates positive growth). 
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2.3.4 Preparation of human serum 
Stored serum was collected from 20 healthy adult volunteers and 20 full term umbilical cord 
samples of unknown Ureaplasma colonisation status. Blood samples were originally obtained 
by our laboratory from the adult volunteers and from placentas of consented Caesarean 
section mothers. Blood was collected in 20 ml glass universal bottles and allowed to clot at 
room temperature for one hour. The clot was dislodged from the wall of the bottle and 
incubated for an additional hour on ice to allow the clot to contract further. Samples were 
centrifuged at 3600 xg for 10 minutes. Supernatant (serum) was then dispensed into 1.5 ml 
tubes and centrifuged again at 16000 xg for 1 minute to remove remaining coagulated debris. 
Aliquots of 250 µl of normal human serum (NHS) were dispensed into 0.5 ml (Eppendorf) 
tubes and stored at -80° C until required.  Heat inactivation of serum was done by incubation 
at 56°C for 30 minutes to eliminate heat labile complement components. Heat inactivated 
normal human serum (HI-NHS) lacks functional C2 (required for the classical and lectin 
pathways) and factor B (required for the alternative pathway).  A mixture of 50% NHS and 
50% HI-NHS was prepared by mixing equal volumes of them with veronal buffered saline 
(VBS or Complement Fixation Buffer; Oxoid, Basingstoke).  
 
2.3.5 Complement killing assay in cord and adult sera 
A volume of 200 µl of each Ureaplasma parvum serovar culture was dispensed in duplicate 
in a point-bottomed 96 well plate. Plates were sealed and centrifuged at 3600 xg for 10 
minutes at room temperature followed by careful aspiration of the supernatant to avoid 
disrupting the pellet. Pellets were re-suspended in 200 µl of 50% NHS diluted in VBS in 
parallel with a matched 50% HI-NHS control to compare the degree of killing. Plates were 
sealed and incubated at 37° C for 1 hour then centrifuged at 3600 xg for 10 minutes. 
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Supernatant was discarded and pellets were re-suspended in 200 µl USM and transferred to 
the first column in another 96 well flat bottom plate. Matched serum and heat-inactivated 
control were titrated in adjacent wells to ensure accurate calculation of killing in the assay.  
In each row, serum exposed Ureaplasma were diluted 1:10 for three consecutive wells 
followed by serial dilution 1:1 in the remaining 8 wells in the same row giving a dilution 
gradient to 2.56 x10
-5
. Plates were sealed and incubated for 48 hours until colour change had 
ceased. Degree of killing was determined by calculating the fold decrease in CCU from HI-
NHS relative to the NHS for each serovar and each serum (figure 2.1). 
  
2.3.6 Killing assay in cord sera supplemented with terminal complement complex (C6-
C9). 
Complement killing assay in cord sera was performed as described in section 2.3.5. Killing 
assays were also performed in parallel where purified C6, C8 and C9 (Quidel Corporation, 
San Diego, CA) were added to give an excess of 50 μg/ml concentration for each (to correct 
the ELISA determined deficiency of these components) in each cord serum for comparison of 
ureaplasmacidal activity. Degree of killing was determined by comparing fold decrease of 
Ureaplasma survival following incubation with heat inactivated versus normal sera. 
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2.4 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE)  
2.4.1 Western Blot for anti-Ureaplasma antibodies in cord sera 
Western blotting, also known as immunoblotting, is a well-established technique to detect a 
specific protein within a sample (Burnette, 1981). Proteins were separated by mass using gel 
electrophoresis and then probed using specific antibodies to a given protein of interest. It is a 
technique that has been used previously on bacteria and human serum.  
 
Prior to the experiments, Ureaplasma parvum samples were prepared for Western blot by 
culturing 5ml from each Ureaplasma parvum serovar overnight in a bijoux tube. An aliquot 
of 1.25 ml from each culture were transferred to a universal container (1.5ml  Eppendorf 
tube) and centrifuged at 13000 x g for 10 minutes at RT. After discarding the supernatant, the 
pellet was resuspended in another 1.25 ml of the same culture to accrue a cumulative pellet 
for the entire 5 ml in a single eppendorf tube. Pellets were then washed three times by 
suspension in 1 ml PBS followed by re-centrifugation. Pellets were then re-suspended in 25 
µl PBS along with 25 µl LDS gel loading buffer (Invitrogen, Paisley). Samples were boiled 
for 2 minutes then cooled prior to loading for separation. SDS-PAGE gel was set up as 
follows: Gel casting apparatus was set up as directed by manufacture (BIORAD, 
Hertfordshire, UK) and resolving gel were made up by using the volumes indicated in the 
table 2.2 and the mixture was poured between gel plates and allowed to set leaving 1.5-2 cm 
space at the top, 400 µl of butanol was immediately overlaid to remove unwanted air bubbles 
and to level out the top of the resolving gel which was washed off with de-ionised water after 
the gel had polymerised. The stacking gel was prepared as shown in table 2.2 and then 
layered on top of the set resolving gel between the gel plates, with the addition of a gel comb 
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which was removed after the gel had polymerised. All gels were poured at 1.5 mm thickness 
with a 15-well comb. Plates containing set gels were set up in the running tank with the 
central reservoir filled with running buffer composed of 25 mM Tris, 192mM glycine and 
0.1% SDS at pH 8.3 (Biorad, Munich, Germany). Five µl of  molecular mass standard 
containing a mixture of  equal volumes of EZ Run TM pre-stained recombinant protein 
ladder (Fisher Scientific, UK,  Ltd) and Magic Mark
TM
 XP Western protein standard 
(Invitrogen, Paisley) was loaded a long side with 7 µl of  each solubilised Ureaplasma 
serovar into adjacent wells of the gel with elongated pipette tips. Gels were electrophoresed 
at 150 Volt (V) and approximately 120mA for 1 hour (until the dye front reached the bottom 
of the gel). 
 
2.4.2 Western blotting 
 The proteins were electrophoretically transferred from gels to 0.22 µm nitrocellulose 
membranes (Anachem) using a BioRad Mini-Protean 3 system as indicated by manufacturer 
instructions. Transfer was carried out in a transfer tank with the transfer cassette, using 
transfer buffer (14.4 g/l Glycine, 3.03 g/l Tris base, 20% methanol), an ice pack to keep the 
transfer buffer cool and a magnetic stir bar to circulate buffer. Transfers were run at 100 V 
for 1 hour. Nitrocellulose membranes containing transferred proteins were placed within a 50 
ml falcon tube (Elkay, Basingstoke) and blocked with 10 ml of  blocking buffer using 5% 
w/v skimmed milk  (Marvel, Premier International Foods, Spalding, UK),  in 50 ml  PBS 
with  0.05% Tween 20 detergent (Fisher Scientific) (PBST) on a roller for one hour. 
Membranes were probed with 1:200 of cord serum, diluted in blocking buffer and incubated 
overnight in cold room (4°C). Probing was followed by washing three times with 15ml of 
PBST each for 10 minutes on a roller. Five microliters of a goat anti-human IgG (FC 
specific) peroxidase-conjugated secondary antibody (Sigma, UK), diluted 1:1000 in blocking 
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buffer, was incubated on a roller for one hour. Membranes were washed three times in PBST 
as described above followed by one wash in PBS. Blots were developed by using a mixture 
of 1.5 ml of peroxide solution and 1.5 ml of luminol enhancer solution (Pierce® ECL 
(Thermo scientific, Loughborough) poured on the nitrocellulose membrane. In a 
photographic dark room the nitrocellulose membrane was exposed to x-ray film in a light-
proof cassette for varying lengths of time before being developed. The length of exposure 
time was determined empirically by the intensity of signal once developed, but was usually 
about two to five minutes. 
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Table 2.2 Composition of Western blot stacking and resolving gel 
 
Stacking gel  Resolving gel  
Reagent 4% Reagent 7.5% 
40% Bisacrylamide 
37.5:1 
1.1012 ml 40% Bisacrylamide 
37.5:1 
1.93 ml 
dH2O 6.4 ml dH2O 5.47 ml 
Upper buffer pH6.8 2.4 ml Lower buffer pH8.8 2.5 ml 
10% APS w/v 100 µl 10% APS w/v 100 µl 
TEMED 40 µl TEMED 10 µl 
 
APS= Ammonium persulphate. TEMED= Tetramethylethylenediamine.  
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2.5 Adult and Cord neutrophil study  
2.5.1 Blood samples collection  
Blood was taken by venepuncture from consented healthy adult volunteers. Cord blood was 
collected from the umbilical veins of term infants delivered by elective Caesarean section 
after normal pregnancy with no history of premature rupture of membrane or known risk of 
infection. Ten pairs of cord and adult samples were used for these experiments; study was 
approved by REC and written informed consent was obtained from mothers prior to section 
and from volunteers.  
 
 2.5.2 Isolation of peripheral blood neutrophils 
Percoll method was used to isolate neutrophils and blood was obtained by venepuncture from 
the placental end of umbilical cord by midwife immediately after delivery. Umbilical cord 
blood was used as it is normally discarded following delivery of the infant and the volumes of 
up to 40 ml can be obtained relatively easily in most samples. After collection of each cord 
sample, a similar volume of blood from a healthy adult volunteer was obtained and 
simultaneously prepared in identical steps to cord blood sample. All samples were collected 
in 50 ml syringe which contains citrate 1/10 volume 3.8 % sodium citrate (Sigma, Life 
Science) to prevent coagulation. Citrated anti-coagulated blood was gently transferred to a 50 
ml conical tube and mixed by gently inversion of the tube then centrifuged for 20 minutes at 
450xg at room temperature. The supernatant (platelet rich plasma) was carefully removed and 
transferred to a clean tube then centrifuged at 1300 xg for 20 minutes at room temperature to 
remove any remaining red blood cells and platelets. This platelet poor plasma (PPP) was 
saved in clean 15 ml conical tubes and used to make up the plasma percoll gradient later.  
86 
 
The bottom layer (leukocytes and erythrocytes) were differentially sedimented by adding       
3 ml of 6% warm sterile Dextran (Sigma Life science ) per 20 ml blood and then made up to 
the original blood volume with warm 0.9% sterile saline. This mixture was left to settle for 45 
minutes in 37° C water bath loosely covered with the lid on until a clear line of demarcation 
could be observed between the lower layer containing red cells and the upper layer containing 
the white blood cells.  Leucocyte rich supernatant was carefully removed from the tube and 
centrifuged at 200 xg for 6 minutes at room temperature. The supernatant was discarded and 
the cell pellet gently re-suspended in 2 ml of PPP.  
Percoll (Sigma-Aldrich, Dorset, UK) is suitable for density gradient experiments due to its 
low viscosity and low osmolarity. Percoll consists of polyvinylpyarrolidone (PVP) - coated 
colloidal silica particles which are 15-30 nm in diameter (23% W/W in water). The PVP 
coating renders the percoll non-toxic to cells. In a bijoux tube, 1.02ml of 90% percoll and 
0.98ml of PPP were mixed (51% gradient layer). In a separate bijoux tube, a 42% gradient 
layer was made consisting of 0.84 ml of 90% percoll and 1.16 ml of PPP. The 51% gradient 
mixture was put carefully in a 15 ml conical tube. The 42% mixture was very carefully 
layered over the 51% gradient layer in the 15ml tube to avoid mixing of the layers. The 
leukocyte fraction was then carefully layered on the top of the appropriate adult or cord 
plasma percoll gradient once again to avoid mixing of the layers. 
The gradients were centrifuged at 350 xg for 13 minutes at room temperature without 
braking. This allows the formation of 3 layers of cells in each tube (figure 2.2). The upper 
layer consists of mononuclear cells whereas the middle layer contains neutrophils and the cell 
pellet in the bottom of the tube contains any remaining red blood cells. 
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Figure 2.2 Separation of neutrophils following purification by Percoll density gradient 
centrifugation. 
 
         Plasma  
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The neutrophil layer was carefully aspirated from the gradient and placed into a clean tube 
and re-suspended in flow cytometry medium (FACS buffer) (PBS containing 0.1% bovine 
serum albumin, 15 mM EDTA, 30 mM sodium azide, pH7.35) (Oxoid, Basingstoke, UK), 
before being centrifuged at 1000 xg for 2 minutes at 4°C. The neutrophils were then washed 
once in 10 ml of warmed Hanks buffered salt solution (HBSS) without calcium and 
magnesium and twice more in HBSS with calcium and magnesium to remove the trace of 
EDTA, before being counted on a haemocytometer and re-suspended at a density of ~10
6
 
cells/ml in HBSS  buffer for FACS staining and analysis. Cell used for intracellular staining 
were not washed in HBSS. 
2.5.3 Neutrophil stimulation 
The neutrophil suspension was divided into seven aliquots of one million cells in one ml as 
below: 
1) Unstimulated cells: no additional stimulant added 
2) A final concentration of 1 M formyl-met –leu-phe (fMLP) (Sigma-Aldrich). 
3) A final concentration of 5 g/ml cytochalasin B (Sigma –Aldrich). 
4) A combination of 1 M of fMLP and 5 g of cytochalasin B (final concentrations). 
5) A final concentration of 10 g/ml of lipopolysaccharide (LPS). 
6) A final concentration of 100 ng /ml IL-8. 
7) A final concentration of 1g /ml PMA. 
LPS is a bacterial membrane polysaccharide, whilst fMLP is a synthetically derived peptide, 
representative of bacterial peptides that stimulate the fMLP receptor on neutrophils. 
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 IL-8 is a chemotactic cytokine signalling through the CXCR2 receptor. All of these are 
capable of mildly stimulating neutrophils. Cytochalasin B is a cell permeable mycotoxin, 
isolated from fungus that acts by chelating actin filaments within the cell. When cytochalasin 
B is combined with fMLP their combined action is significantly augmented as a powerful 
stimulant of neutrophil degranulation (Saeki et al., 2001).  All seven tubes were mixed using 
a vortex and incubated in a water bath at 37°C for 15 minutes. The tubes were vortexed again 
and part of the sample removed (400l) and prepared for flow cytometry analysis. Of the 
remaining 600 l of cell suspension, 500 l were put into an Eppendorf tube and centrifuged 
at 1300 rpm for 3 minutes to separate released extracellular proteases from those retained 
within the cells. The supernatant, containing any released proteases was then removed and 
100 l of the supernatant was placed in a clean Eppendorf tube containing 10 l of 
Phenylmethanesulphonyl fluoride PMSF (Sigma Aldrich) which is a serine protease inhibitor. 
The remaining supernatant was placed in a clean Eppendorf tube without any inhibitor. The 
cell pellet was dissolved by adding 250 l of lysis buffer (distilled water containing 10 nM 
Tris and 0.5% triton X100, pH 7.4). All samples were stored at -20° C until used for ELISA 
and functional activity assay. 
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Table 2.3 List of antibodies used in neutrophil flow cytometry  
Antibody 
specificity 
Clone Isotype Conjugated Source Volume used 
Proteinase 3 1B10 IgG2a Phycoerythrin-
(PE) 
HyTest Ltd 0.5l/100l 
CD177 MEM-166 IgG1 Allophycocyanin Caltag Medsystems 0.5l /100l 
CD66b 80H3 IgG1 Allophycocyanin SeroTec.UK 0.5l/100l 
CD63 MEM-259 Mouse IgG1 Phycoerythrin BioLegend 5 l/100l 
CD43 L-10  MouseIgG1 Phycoerythrin Invitrogen 5 l/100l 
CD35 7E9 Rat IgG2a Allophycocyanin Invitrogen 1l/100l 
Control  Mouse-IgG1 Phycoerythrin Caltag Medsystems 2l/100l 
Control  Mouse- IgM Allophycocyanin Caltag Medsystems 2l/100l 
Control  Mouse-IgG2b FITC Caltag Laboratories, 
CA, USA 
2l/100l 
serpinB1  IgG1 FITC Prof. Remold-
O’Donell, Harvard 
University 
5l/100l 
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2.5.4 Flow cytometry analysis 
Flow cytometry is an invaluable technology that allows for quantitative analysis of single 
cells present in a complex mixture. Cell antigens (surface or intracellular) can be detected 
using fluorescent conjugated Abs. The most common fluorescent molecules used include: 
fluorescein isothiocyanate (FITC), which emits at 530 nm, and R- phycoerythrin (RPE), 
which emits at 578 nm, after excitation with the 488 nm Argon laser. In contrast to RPE, 
FITC produces significant amount of orange and yellow light that overlaps into the RPE 
channel, and this spurious signal needs to be compensated during two colour flow cytometry 
(Brown and Wittwer, 2000). 
  In the present study, flow cytometry was used to analyse neutrophil surface and intracellular 
expression of the CD177, PR3, CD35, CD43, CD66b, CD63, C3aR, C5aR and SerpinB1. 
 
2.5.4.1 Extracellular preparation for flow cytometry 
Using a round bottomed 96 well plate, 100 l /well of flow buffer was dispensed, followed 
by 100 l /well of stimulated or unstimulated cell suspension (105 cells) added to each well. 
The plates for cord and adult samples were centrifuged for 2 minutes at 1000 xg at 4°C, 
before the supernatant was discarded. The antibodies listed in table 2.3 were prepared in flow 
buffer according to their concentration. The pellets were then re-suspended with the 
appropriate antibody and each antibody was tested for all six conditions in duplicate. The 
plates were incubated for 25 minutes at 4°C before adding 150 l of FACS buffer to all wells. 
The plates were centrifuged again at 1000 xg for 2 minutes, followed by two washes with 200 
l/well of FACS buffer in repeated sequence of centrifugation and re-suspension. Thereafter, 
92 
 
cells were re-suspended in 200 l/well of FACS buffer before being transferred to test tubes 
ready for immediate FACS analysis. 
2.5.4.2 Intracellular Staining 
The following flow cytometry preparation on the neutrophils was performed by Dr Brad 
Spiller using a fixation and permeability kit from An Der Grub Bio Research GmbH 
(Kaumberg, Austria).  However I have assisted and analysed the data collected. 
For intracellular staining, isolated neutrophils were suspended only in cold FACS buffer 
without exposure to HBSS.  In a 96 well round bottomed plate, 100 l of cell suspension 
were dispensed in each well mixed with 100 l of cold FACS buffer. The plates were 
centrifuged at 1000 xg for 2 minutes at 4°C followed by cell pellet re-suspension in 100 l of 
flow cytometry buffer and 100l of fixation buffer and incubated for 15 minutes at RT. The 
wells were topped with 150 l of flow buffer and the plate centrifuged. The cells were 
washed in 200 l of flow buffer and centrifuged once more at 1000 xg for 2 minutes. Pellets 
were then re-suspended in 100 l of saponin-containing permeability medium which 
contained 1:10 diluted antibodies listed in table 2.3. This was incubated at RT for 15 minutes. 
The plate was then centrifuged and the pellet re-suspended in 200 l of flow cytometry buffer 
before centrifuged again at 1000 xg for 2 minutes. Finally, pellets were re-suspended in 200 
l of flow cytometry buffer and transferred to test tubes for analysis. 
Flow cytometry analysis was performed using a Becton-Dickinson FACSCalibre. The data 
was analysed using the associated Cell Quest software. All experiments were performed in 
duplicate. 
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2.5.5 Cathepsin G (Cat G) activity assay 
Cat G kinetic activity assay was performed on supernatants taken from cord and adult blood 
neutrophils as well as on solubilised cell pellets for all conditions including unstimulated 
cells as well as conditions described above in section 2.5.3. Integral Dynex Revelation 
software in the spectrophotometer calculated the rate of chromogenic conversion of the 
colourless SUC-Ala-Ala Pro-Phe-pNA substrate to yellow product by comparing the rate of 
conversion with a standard curve of purified Cat G (purchased from Athens Research and 
Technology, Athens, Georgia). Stocks of standard human neutrophil Cat G (Athens Research 
and Technology, Georgia, US) were prepared by reconstituting 100g of lyophilized 
cathepsin G powder in a 200 l solution of 50 mM sodium acetate, pH 5.5, 150 mM sodium 
chloride. The 16.9 M enzyme solution was then divided into 20 l aliquots and stored at -
20°C. To make up a standard curve,  5 l  aliquot of Cat G  stock was thawed and diluted 
using “activity buffer” (0.1M tris, Fisher Scientific, Loughborough, UK;  0.5M sodium 
chloride, pH 7.4, 0.05% triton X-100). Standard concentrations of Cat G ranged from 170 nM 
to 0.3 nM.  These standard dilutions were then added in duplicate in a volume of 100l per 
well in flat-bottomed 96 well plates. Supernatants and cell lysate samples were thawed and 
100l from each sample dilution was added to plate wells, again in duplicate. A stock 
solution of neutrophil Cat G specific chromogenic substrate was thawed and diluted to 1:100 
concentration using activity buffer. Each well of the 96 well plate containing sample or 
standard concentrations of neutrophil Cat G was topped up with 100 l of substrate solution. 
The kinetic assay was read on a plate reader (Dynex Magellan Industries, Chelmsford, UK) 
warmed to 37°C while shaking the plate with readings recorded over 1 hour at 1 min intervals 
and wave length of 405nm using Integral Dynex Revelation software to calculate 
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concentration of Cat G by comparing the rate of substrate conversion in the samples against 
the standard curve of purified Cat G. 
 
 2.5.6 Proteinase 3 ELISA 
 
Microtiter 96 well plates (Nunc-maxisorb) were pre-coated with monoclonal rat anti-mouse 
IgG1 antibody at 4g/ml dilutions in carbonate binding buffer (NaHCO3/Na2CO3, pH 9.6). 
Aliquots of 100 l/well were dispensed and plate sealed and incubated at 37°C for one hour 
then fluid was discarded. The plate was blocked with 115 l/well of blocking buffer (5% 
BSA in PBS containing 0.05% tween 20) for 45 minutes at 37°C to block additional protein 
binding sites.  The plate was washed once with PBST (200 l/well) followed by coating with 
monoclonal antibody (MoAb) Mouse anti-human PR3-G2 at a concentration of 2 g/ml 
diluted in blocking buffer  (Hycult, stock concentration 0. 94mg/ml). After that, the plate was 
incubated for 30 minutes at 37°C and washed three times with PBST. Stocks of standard 
human neutrophil PR3 (1mg/ml, Athens Research and Technology, Georgia, US) were 
prepared by adding 5 l from stock solution to 45 l PBS. Standard solutions were further 
diluted in blocking buffer which contains (PMSF) (Sigma, Aldrich; stock concentration-50 
mg/ml) at 25 l/ml (1/40) to a final concentrations ranging from 0.976 ng/ml to 250 ng/ml. A 
total of 100 l /well were incubated along with samples described in section 2.5.3 at RT for 1 
hour. Freshly thawed cell lysate diluted at 1:200 and supernatant samples, diluted at 1:10 in 
blocking buffer containing 1/40 PMSF, were incubated along with the standard as described. 
Plates were washed three times with PBST. To detect bound PR3, rabbit anti-human PR3 
polyclonal antibody (Euro Diagnostic) was added at 1:1000 dilutions in blocking buffer and 
incubated for one hour at RT.  After being washed three times with PBST, 100l /well of 
95 
 
Horseradish peroxidase (HRPO) anti-rabbit antibody (Jackson Laboratories) diluted at 1:1000 
in blocking buffer was incubated at RT for one hour. Plates were washed three times with 
PBST and once with PBS then developed with OPD-EASY (Sigma-Aldrich), and the reaction 
stopped with 2N H2SO4 before reading at 490nm.  
 
2.6 PR3 in BAL samples 
2.6.1 Sample information  
Bronchoalveolar lavage samples were used from an ongoing study and collected by Dr 
Davies. All samples were collected after ethical approval and written informed consent from 
parents of patients located on the Neonatal intensive care or high dependency units at the 
University Hospital of Wales, Cardiff, U.K. The study included three groups of mechanically 
ventilated infants. Infants included in the first group were premature infants (<32 weeks 
gestation) who developed CLD whereas preterm infants who developed and recovered from 
neonatal respiratory distress syndrome (RDS) were in the second group. A control group 
including full term infants who were ventilated for non-respiratory reasons were also 
examined. 
2.6.2 BAL PR3 ELISA 
PR3 levels were measured using the method outlined above in section 2.5.6. One hundred 
microliter of standard or lavage supernatant samples diluted in (blocking buffer with 
stabilisers) at 1:10 and 1:50 was added to designated wells. This was then sealed and 
incubated at RT for one hour and bound PR3 detected as outlined in the previous section. 
Any samples with PR3 levels above the upper end of the standard curve were diluted further 
and re-assayed. 
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2.7 Statistical analysis 
Statistical analysis for this thesis was performed using Microsoft Excel and Graphpad Prism 
software version 5.01 (Graphpad Software Inc). In general cord and adult data results were 
normally distributed and as such data was expressed as mean and standard error of the mean 
(SEM). Significance was taken as a P value <0.05.  For lavage data was non-parametric in 
nature and comparisons between data sets were made using Mann Whitney U tests, while 
correlations between groups were performed using spearman correlation co-efficient. Data of 
lavages is expressed as median values. 
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Chapter Three 
 
 
Proteases and other neutrophil markers              
in cord and adult blood 
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3.1     Introduction 
 
Newborn infants are at higher risk of infection which is a major cause of morbidity and 
mortality. Neonates’ susceptibility to infection is believed to result from quantitative and 
functional deficit in humoral and cellular arm of innate immune system (Wilson et al., 1986; 
Fleer et al., 1988). Cord blood neutrophils are relatively deficits in adherence, chemotaxis, 
phagocytosis, oxidative metabolism and bactericidal permeability-increasing (BPI) protein 
level (Levy et al., 1999; Kim et al., 2003). Neutrophil proteases are part of bactericidal 
arsenal. Another factor for susceptibility of neonates to infection could be that infant’s 
neutrophils contain or release less proteolytic enzymes, required for bactericidal activity, than 
adults. Nevertheless, their untoward effects are believed to have an important role in the 
pathogenesis of inflammatory lung diseases. Studies of neonatal neutrophil elastase 
demonstrated that newborn neutrophil have lower elastase activity compared to adult (Davis 
et al., submitted). However, thus far no study on proteinase 3 and cathepsin G in neonate’s 
neutrophils has been published. 
 In this chapter, (A) I have examined neutrophil proteinase content and the ability of 
newborn neutrophils to release these enzymes compared to adult cells. In particular, I 
have examined cathepsin G functional activity and PR3 intra and cell-surface 
expression as well as measuring PR3 release following stimulation with a variety of 
pharmacological agonists. 
 (B)  I have sought to examine the levels of different neutrophil markers on the 
neutrophil surface and intracellular levels of theses markers, which are representative 
markers expressed by different granules (CD15, CD16, CD35, CD63, and CD66b). 
 (C) I have examined the neutrophil intracellular and surface membrane expression of 
CD177 which is believed to be a surface receptor of PR3. 
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3.2     Results  
 
3.2.1     Neutrophil surface expression of high affinity PR3 receptor, CD177 
CD177 is a neutrophil specific protein reported to be found in the plasma membrane and 
secondary granules of neutrophils. It has been proposed as mPR3 receptor on the neutrophil 
surface (Goldschmeding et al., 1992; Stroncek et al., 1994; Bauer et al., 2007). 
CD177 has a variable distribution on the surface of unstimulated neutrophils, ranging from 
completely absent to uniformly high, but usually is observed as a bimodal mixture of 
expression (Bauer et al., 2007). These will be referred to as the bright and dim sub-
populations of cells in this chapter. Neutrophils taken from adult and cord blood were 
incubated with APC-conjugated (IgG1) isotype control and APC anti-CD177, then the 
samples were analysed by flow cytometry to determine the expression of CD177-bright and if 
the CD177-dim were different from the isotype control (i.e. to differentiate between CD177-
low and CD177-negative) 
 The histogram for isolated adult and cord  neutrophils  showed a clear bimodal distribution 
of CD177 in the absence of stimulation (unstimulated cells) compared with the unimodal low 
expression of background (isotype control). The dim subset represents low or possibly 
negative CD177 expression, whereas the brighter subset expresses a substantial amount of 
CD177. Of note, negative expression of CD177 was detected in two cord sample as shown in 
figure 3.1. 
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Figure 3.2 shows that the mean cellular fluorescence (MCF) of CD177
bright
 cells on 
unstimulated cord neutrophils was remarkably higher than that of adults (p = 0.002). This 
was a consistent observation for each paired set of neutrophils analysed, with the exception of 
the two CD177-negative cord samples. Moreover, the mean percentage of CD177- expressing 
unstimulated cells was also significantly higher in cord neutrophils (mean ± SEM, 79 % ±2.2) 
compared with adults (49 % ±5.9, p = 0.0005). 
 
The mean fluorescence intensity (MFI) for CD177
dim
 expression subset on unstimulated cord 
neutrophils was significantly greater than that of isotype matched control staining (24.8 units 
and 2.5 units respectively, p= 0.0006). Similarly, surface CD177 expression on the dim 
subpopulation of adult neutrophils was 14.26 units, which was significantly higher than 
background staining by the isotype control (p = 0.019), suggesting that the CD177
dim
 subset 
are not completely deficient in CD177 expression. However, mean cellular fluorescence 
comparison of the CD177
dim
 subpopulations between adult and cord neutrophils were not 
statistically different (figure 3.2). CD177 expression on the two negative cord samples could 
not be increased above background staining even after stimulation, confirming a lack of 
intracellular CD177 stores for these samples. Absence of CD177 from these two cord sample 
was also confirmed by intracellular FACS staining: background MFI =2.42 compared to 
negative CD177 cord MFI =3.15. 
 
 
 
 
 
 
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure3.1 Overlay histogram of mean cellular fluorescence showing the expression of CD177 
on unstimulated cord and adult cells (blue) compared to the isotype control (green). Bimodal 
distribution of CD177 is observed in all cord and adult neutrophils except for the last two 
cord samples (*) which were CD177 negative. (10 pairs of cord and adult neutrophil samples 
were studied). 
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Figure 3.2 Surface expression of CD177 on unstimulated cord and adult neutrophils. (A) 
Percentage of CD177
bright
 among adult and cord neutrophil samples. (B) Mean cellular 
fluorescence (MCF) of CD177
bright
 expression on unstimulated neutrophils. (C) MCF of 
CD177
dim
 cells for unstimulated cord and adult neutrophils compared to isotype control 
(background). (D) MCF of  CD177 expression on the two CD177 negative cord samples in 
unstimulated cells  compared to isotype control (background).Data expressed as mean, error 
bars demonstrate SEM, *= p< 0.05; **=p<0.01; ***=p<0.001 (n=10). 
A
du
lt
C
or
d
0
20
40
60
80
100
A

P
e
rc
e
n
ta
g
e
 o
f 
C
D
1
7
7
b
ri
g
h
t
A
du
lt
C
or
d
0
500
1000
1500
2000
B

M
C
F
 o
f 
C
D
1
7
7
b
ri
g
h
t
di
m
A
du
lt 
C
D
17
7
A
du
lt 
B
kg
d dim
co
rd
 C
D
17
7
C
or
d 
B
kg
d
0
10
20
30
40
C


M
C
F
 o
f 
C
D
1
7
7
d
im
C
or
d 
6 
B
kg
d
C
or
d 
6 
C
D
17
7n
eg
C
or
d 
8 
B
kg
d
C
or
d 
8 
C
D
17
7n
eg
0
1
2
3
4
5
D
M
e
a
n
 c
e
ll
u
la
r 
fl
u
o
re
c
e
n
c
e
103 
 
3.2.1.1 No change in the percentage of CD177
bright
 neutrophils following 
stimulation 
Alterations in neutrophils CD177 expression was analysed in response to LPS, fMLP, cytoB, 
PMA and IL-8. These pharmacological agonists are potent inducers of neutrophils 
degranulation and stimulation. Cells were treated with these stimulants for 15 min before 
staining with APC-conjugated anti-CD177. The percentage of CD177 expressing neutrophils 
was higher (77-79%) in unstimulated cord neutrophils compared to adult (45%-49 %, p = 
0.001); and stimulation did not increase the percentage of CD177
bright
 cells. No alteration was 
seen in CD177 expression in the two negative cords following stimulation (leading edge of 
histogram only 1.6%-4.2% greater than the isotype control histogram), except when 
incubated with the phorbol ester (PMA). However, the isotype control histogram also 
increased following PMA treatment for the CD177-negative cord neutrophils (figure 3.3). 
 
 Alteration to the mean cellular fluorescence for the CD177
bright
 subpopulation following 
neutrophil stimulation was also measured. While the percentage of CD177
bright
 neutrophils 
did not change after stimulation, the amount of CD177 expressed increased in this subset.  
All agonists caused a significant right shift in the histogram of CD177 expression and 
increased mean cellular fluorescence compared with unstimulated cells (p ≤0.01). Cord blood 
neutrophil showed the same response to all of the stimulants. However, cord neutrophils, both 
unstimulated and in response to all stimulants, expressed significantly more CD177 on the 
surface of CD177
bright
 cells compared to adult cells p ≥0.01, figure 3.4. 
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Figure 3.3. (A) Percentage of CD177 expressing neutrophils (CD177
bright
 neutrophils) in 
cord and adult samples, data for unstimulated (un) as well as following stimulation with LPS, 
fMLP, cytoB, fMLP with cytoB, PMA and Il-8 are shown separately.The differences were 
highly significant under all stimulants ** = p < 0.01. (B) Precentage of CD177expressing  
neutrophil in two  CD177 negative cord samples. All values are given as mean ±S EM. 
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Figure 3.4  Effect of pharmacological agonists on cell surface expression of CD177
 
by 
unstimulated and stimulated cells (A) Adult neutrophils; (B) Cord blood neutrophils. Note 
that all the stimulants induce significant increase in surface expression of CD177 when 
compared to unstimulated cells in both cord and adult neutrophils ** = p<0.01. (C) 
Comparison of cord and adult neutrophils on the same scale showing higher CD177 
expression on cord neutrophils than adults, ** = p<0.01. The data are presented as mean 
cellular fluorescence ± SEM for ten adult and eight cord samples excluding the two CD177 
negative cord samples.  
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3.2.2     Surface expression of PR3 before and after stimulation  
I analysed membrane PR3 (mPR3) on cord (n=10) and adult (n=10) neutrophil samples, 
before and after stimulation with LPS, fMLP, CytoB, fMLP combined with CytoB, PMA and 
IL-8. Figure 3.5 shows the pattern of mPR3 expression on unstimulated cord neutrophils and 
in response to stimulation with fMLP and fMLP plus CytoB.  In 8 cord samples, bimodal 
mPR3 could be observed before and after stimulation. The last 2 rows in the figure showed 
monomodal pattern of PR3 expression in the two CD177 negative cord samples even after 
stimulation. Although CD177 negative cord neutrophils were able to express mPR3 on cell 
surface possibly via other mechanisms, CD177 seems to be necessary for bimodal PR3 
expression pattern since this was not seen in the negative cord samples.  Adult neutrophils 
express monomodal mPR3 on umstimulted cells but after stimulation especially with fMLP 
combined with CytoB, additional sub-population of neutrophil with low mPR3 expression 
was seen (figure 3.6; 3.7). On the other hand, CD177 expression was bimodal even without 
stimulation with the exception of the two CD177 negative cord samples (figure 3.8 and 3.9). 
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Figure 3.5 .Histogram shows bimodal distribution of mPR3 on cord blood neutrophils of 
unstimulated (control) and neutrophils stimulated with  FMLP alone or  fMLP combined with 
cytoB (f + C).* denotes mPR3 expression of CD177 negative cord samples with monomodal 
expression of mPR3 observed before and after stimulation. 
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Figure 3.6 Effect of fMLP and fMLP with cytoB stimulation on expression of mPR3 in adult 
neutrophils. Neutrophils activated with fMLP alone or fMLP +cytoB induced bimodal 
pattern of mPR3 expression compared with monomodal expression pattern on unstimulated 
cells. Each histogram   represents individual blood samples. 
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Figure 3.7 Overlay histogram showing the expression patterns of mPR3 on unstimulated cell 
(blue), and in the presence of fMLP plus cytoB (red) compared to the isotype control (green) 
on cord and adult neutrophils.* denotes mPR3 expression on the CD177 negative cord 
samples. 
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Figure 3.8 .Histogram shows bimodal distribution of CD177 on cord neutrophils before and 
after stimulation with fMLP alone or combined with cytoB. * denotes CD177 pattern in the 
negative cord samples. 
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Figure 3.9 Histogram shows bimodal distribution of CD177 on adult neutrophils before and 
after stimulation with fMLP alone or with cytoB (f + C). 
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3.2.2.1   Expression of mPR3 on the neutrophils from CD177-negative cord 
samples 
As demonstrated above, the expression of CD177 was not detected on the surface of 
neutrophils from two cord blood samples. Figure 3.10 shows the mPR3 expression on CD177 
negative cord samples compared to the isotype control. The level of mPR3 was higher than 
the isotype control on unstimulated neutrophils in negative cord samples (mean 33.5 units) 
compared to the level of background (mean 3.2 units). Furthermore, after maximal 
stimulation with F+C, CD177-negative cord neutrophils expressed even greater levels of 
mPR3 (mean 53.4 units) compared to the isotype control level (5.2 units). 
Therefore, neutrophils from these two cord samples, despite their negative CD177 status, 
were able to expresses membrane PR3 on their surface before as well as after activation, 
albeit at lower levels than on CD177-positive cells. These results suggest that expression of 
PR3 on the neutrophil surface was mediated by a CD177-independent mechanism or 
alternative low affinity receptor. 
 
Activation of CD177- negative cord neutrophils with LPS, IL-8 and fMLP or cytoB alone did 
not change mPR3 expression compared to unstimulated cells. However, incubation with F+C 
or PMA consistently increased mPR3 on the cell surface of CD177-negative cord neutrophils. 
The expression of PR3 was increased by 3 fold with F+C and by 1.7 fold with PMA.  
However, as only two CD177 negative cord samples were available for analysis, statistical 
analysis of this observation was not possible.  
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Similar levels of mPR3 were observed on the surface of unstimulated CD177-negative cord 
cells and the unstimulated cells from matching adult samples processed in parallel on the 
same day. Activation of cells by fMLP combined with cytoB increased the mPR3 expression 
on adult neutrophils by 30 fold compared to unstimulated neutrophils (MCF 838.9 vs 27.1), 
but mPR3 expression only increased by 3-fold on the CD177-negative cord neutrophils after 
F+C stimulation. Whether this has functional implications (e.g. transmigration or bactericidal 
activity) for CD177 negative neutrophils is nevertheless unknown. 
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A)                                                                              B) 
 
C)                                                                               D) 
                                                                           
 
 
Figure 3.10 Expression of mPR3 on neutrophils from CD177-negative cord samples. (A) 
comparison of PR3 expression between isotype control and CD177 negative cord on 
unstimulated and in presence of fMLP plus cytoB (f+c), note that mean cellular fluorescence 
(MCF) of mPR3 expression increased compared with control (B) Variation of the mPR3 
expression before and after stimulation in the two CD177 negative cord samples (C, D) 
Comparison of membrane PR3 expression on CD177-negative cord neutrophils and matched 
adult neutrophils.    
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3.2.3.2 Cell surface expression of PR3 in response to stimulation on CD177-
positive cells 
The mean fluorescence mPR3 expression for unstimulated cord blood neutrophils (46.6 
±SEM 6.6) was significantly greater than that of unstimulated adult neutrophils (19.4 ± 2.4; p 
= 0.001 by unpaired t-test), which may be related to higher cord CD177 expression. 
Following stimulation with LPS, PMA, IL-8, fMLP, or cytoB and F+C, the mean mPR3 
expression in both adult and cord cells was higher than for unstimulated cells (figure 3.11). 
Cytochalasin B combined with fMLP were consistently the most potent inducer of increased 
mPR3 expression. Following stimulation with F+C,  the mean cellular fluorescence for mPR3 
on cord cells rose significantly to a mean of  972.7  units compared to a mean of 46.6  units 
on unstimulated cord neutrophils p = 0.009. Similarly, mPR3 expression was also 
significantly higher on adult neutrophils treated with F+C (MCF 446.7) than that of 
unstimulated cells which had mean cellular fluorescence of 19.4 units, (p = 0.002). On the 
other hand, stimulation with fMLP alone caused moderate increases in fluorescence intensity 
for mPR3 expression in adult and cord cells with p value <0.05 in both cord and adult.  
Figure 3.13 demonstrates the ratio of MCF between stimulated and unstimulated cells. 
Stimulation of adult neutrophils with fMLP and cytoB resulted in a 25-fold rise in the mPR3 
expression relative to unstimulated cells, while 14.4-fold increase in cord mPR3 was 
observed. For adult neutrophils, stimulation with PMA mPR3 increase of 18.4-fold, and LPS, 
fMLP alone, cytoB alone only increased mPR3 by 2.4-5.7-fold. PMA stimulation of cord 
neutrophils only increased mPR3 by 5.8-fold and other stimulants had a lower effect on cord 
cells. IL-8 consistently had the poorest mPR3 increase of 1.2-fold, which failed to reach 
statistical significance relative to unstimulated cells. 
 
116 
 
In agreement with CD177 expression results, the percentage of mPR3
bright
 cells measured for 
cord neutrophils ranged from 79%-94%, which was consistently higher than the 42%-86% 
observed for adult neutrophils (figure 3.12). However, unlike mPR3, percentages of 
CD177
bright
 cells were not altered by stimulation in each individual.  
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Figure 3.11 Effect of neutrophil activation on membrane expression of PR3 as measured by 
flow cytometry. (A) Cell surface expression of PR3 on cord blood neutrophils compared to 
adult neutrophils. Neutrophils were either unstimulated (un) or incubated for 15 min at 37°C 
with fMLP or fMLP plus cytoB (f+c) significant differences are shown. B) Membrane PR3 
expression on adult neutrophils, (C) membrane PR3 expression on cord neutrophils. Note that 
the fMLP, f+c and PMA induced significant increase in cell surface expression of mPR3 when 
compared with unstimulated cells in both cord and adult blood neutrophils. Data are shown 
as mean ± SEM. * p<0.05, ** p<0.01; n =10. 
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Figure 3.12 Percentage of mPR3 and CD177 expressing on unstimulated neutrophils in cord 
blood compared to unstimulated adult neutrophils, statistical significance is shown in the 
figure. 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
CD177 PR3
%
 b
ri
gh
t 
ce
lls
 
Adult
Cord
p=0.001 
p=0.009 
119 
 
 
 
 
 
 
Figure 3.13 Scatter graph of CD177 and PR3 ratios of mean cellular fluorescence (MCF) 
following stimulations (stim) compared to unstimulated cells (un). (A and B) PR3 ratio in 
adult and cord neutrophils; (C and D) CD177 ratio in adult and cord neutrophils. Note all 
stimulation conditions with the exception of IL-8  resulted in statistically significant increase 
of CD177 and mPR3 expression on the cells surface compared to unstimulated cells in both 
adult and cord neutrophils p<0.05. 
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3.2.3    Neutrophil expression of CD63 and CD66b 
 
Neutrophils primary granule marker CD63 expression was evaluated on the surface of 
neutrophils isolated from both adult and cord blood. CD63 expression on unstimulated cells 
appeared to be slightly higher in adult with mean fluorescence of (43.2± SEM 7.4) compared 
to (31.1± 4.2) in cord unstimulated cells, but the difference was not statistically significant, (p 
= 0.1). Significant surface expression of CD63 is only seen following maximal neutrophil 
stimulation resulting in overt degranulation (figure 3.14). The combination of fMLP and 
cytoB resulted in significantly elevated CD63 expression compared to unstimulated cells 
(mean 144.3; P =0.014) in adult and in cord neutrophils (mean 193; P = 0.009). However, no 
statistically significant difference was found in CD63 expression in response to maximal 
stimulation between adult and cord neutrophils. Stimulation of cord and adult neutrophils 
with LPS, fMLP, cytoB, PMA and IL-8 did not cause any significant increase in the surface 
expression of CD63 compared to unstimulated cells. 
 
Effect of agonists on the expression of secondary granule marker CD66b was also studied on 
adult and cord blood neutrophils. Unstimulated cord and adult neutrophils had higher 
baseline level of surface CD66b expression (MCF, 246 and 203.5 units respectively), in 
contrast to the lower baseline expression of CD63 (31.1; 43.2 units), on both cord and adult 
samples (figure 3.15). In adult neutrophils much greater increase in CD66b expression was 
observed following stimulation with PMA or fMLP combined with cytoB p =0.0006 and p 
=0.0003 respectively compared to unstimulated condition. Activation of adult cells with LPS, 
cyto B and IL-8 induced statistically insignificant increase in CD66b expression compared to 
unstimulated cells; however, increase in CD66b expression after stimulation with fMLP 
achieved statistical significance ( p =0.01). On the other hand, in cord blood neutrophils,  all 
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stimulants caused significant increase in  CD66b expression compared to unstimulated cells 
particularly  fMLP plus cyto B (f+c)  which was the most potent  stimulant for CD66b (p = 
0.006). Furthermore, the levels of CD66b on the surface of adult neutrophils stimulated with 
PMA and f+c appeared to be higher than on cord neutrophils, but failed to reach statistical 
significance. It is also interesting to note the difference between the stimulants as PMA 
showed evidence of degranulation of secondary granules marker (CD66b), but not primary 
granules marker (CD63), while fMLP and cytoB in combination could degranulate both sets 
of granules.  
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Figure 3.14 Effect of neutrophil stimulation on expression of CD63 as measured by flow 
cytometry. CD63 expression was measured as mean cellular fluorescence (MCF) in 
unstimulated cells (un) and in response to LPS, fMLP, fMLP plus CytoB (f+c), PMA and IL-8 
on neutrophils from adult blood (A) and cord blood (B). (C)  Surface expression of CD63 on 
cord blood neutrophils compared to adult, expression shown as mean ± SEM * = p< 0.05; 
**= p <0.01 compared to unstimulated condition (n=10).   
 
0
50
100
150
200
250
300
C
D
6
3
 e
xp
re
ss
io
n
 (
M
C
F)
 
Adult
Cord
U
n
LP
S
fM
LP
cy
to
B
f+
c
P
M
A
IL
-8
0
50
100
150
200 *
A
Adult
C
D
6
3
 e
x
p
re
s
s
io
n
 (
M
C
F
)
U
n
LP
S
fM
LP
cy
to
B
f+
c
P
M
A
IL
-8
0
100
200
300
B
**
C
D
6
3
 e
x
p
re
s
s
io
n
 (
M
C
F
)
Cord
123 
 
 
 
C 
 
 
 
 
 
 
 
 
Figure 3.15 Effect of different stimulants on membrane expression of CD66b. Mean cellular 
fluorescence for APC-conjugated anti-CD66b staining was measured on adult (A) and cord    
neutrophils (B). (C) Comparison of mean expression of CD66b in both adult and cord.   
Mean and SEM shown for ten paired samples.  Significant differences are shown (*= p<0.05; 
** =p<0.01 and ***= p<0.001 relative to unstimulated cells. 
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3.2.4    Neutrophil expression of CD35 and CD43 in response to stimulation 
The data in figure 3.16 demonstrate the mean fluorescence intensity of CD35 expression on 
unstimulated cord and adult neutrophils and in response to LPS, fMLP, CytoB, PMA, fMLP 
in combination with CytoB and IL-8. There was no difference in CD35 expression between 
adult and cord neutrophils in all conditions. In addition, incubation of cord and adult 
neutrophils  with various agonists did not significantly change  CD35 expression compared to 
unstimulated cells with the exception of adult neutrophils response to IL-8 which resulted in 
significant  increase in CD35 expression p= 0.04.  Stimulation of adult neutrophils with 
fMLP + cytoB or PMA, reduced the percentage of neutrophils expressing CD35 significantly 
to 40% (p =0.007) and 47% (p=0.016), respectively compared to unstimulated neutrophils 
81% (figure 3.17).  
 
On the other hand, the percentage of positive cord neutrophils expressing CD35 ranged from 
74 to 79% amongst the unstimulated and stimulated cells (figure 3.17).  Reduction in CD35 
expression only reached significance when the cells were stimulated with (F+C), reducing the 
percentage of CD35 expressing cells to 45% (p =0.042). I also observed a slight reduction in 
the percentage of cord neutrophils expressing CD35 following incubation with PMA but 
statistically this was not significant. However, following stimulation with PMA, the mean 
cellular fluorescence for CD35 in cord neutrophils was reduced significantly from 30.7 in 
unstimulated cells to 18.9 in PMA stimulated cells (p= 0.0095). These stimulants also 
decreased MFI of CD 35 expression in both adult and cord neutrophils. 
All stimulants caused significant reduction (p<0.01) in mean cellular fluorescence (MCF) of 
CD43 expression on adult neutrophils, particularly fMLP  and PMA, which caused highly 
significant decrease in CD43 expression compared to unstimulated cells p < 0.001. The same 
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decreased CD43 expression trend was observed in cord neutrophils.  IL-8 had the least effect 
on CD43 reduction, which was significant for the adult neutrophils (p = 0.02), but not for 
cord neutrophils (mean fluorescence of 40.7 compared to 46.2 for unstimulated cord 
neutrophils) figure 3.18. No significant difference was detected in CD43 surface expression 
between cord and adult neutrophils except when the cells were stimulated with PMA (p = 
0.04). Similar reduction in the percentage of CD43 expressing cells was also observed 
(Figure 3.19), when adult and cord neutrophils were stimulated with the combination of F+C  
but reduction was statistically significant only in  adult neutrophils (p = 0.008). This suggests 
that the enzymes releasing CD35 from the surface are different from those that release CD43, 
as different effects were observed following PMA stimulation. 
CD15, also known as sialyl Lewis
x
, is a leukocyte membrane bound carbohydrate involved in 
adhesion and interaction of E selectin and P selectin on endothelial cells. CD16 (FCγ receptor 
III) mediates the binding of immunoglobulin opsonised particles to phagocytes.  As shown in 
figure 3.20 no significant difference was detected between cord and adult neutrophils 
expression of CD16 and CD15. 
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Figure 3.16 Effect of different stimulants on membrane expression of CD35. Mean cellular 
fluorescence for APC-conjugated anti-CD35 staining was measured on cord (A) and adult 
(B) neutrophils. (C) Comparison of mean expression for both adult and cord.   Mean and 
SEM shown for n=10, significant differences are shown *= p<0.05 and **= p<0.01 
compared to unstimulated cells.  
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Figure 3.17 the percentage of CD35 expressing cells in adult (A) and cord (B) neutrophils, 
above the background staining with isotype matched control.  Mean and SEM are shown for 
ten paired samples, significant differences are shown (p<0.05 = *, p<0.01 = **) compared to 
the percentage of unstimulated cells. 
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Figure 3.18 Effect of different stimulants on membrane expression of CD43. Mean cellular 
fluorescence for PE-conjugated anti-CD43 staining of cord (A) and adult   (B) neutrophils. 
(C) Comparison of mean expression for both adult and cord.   Mean and SEM shown for ten 
paired samples. Significant differences are shown as * p=<0.05, ** =p<0.01 and * 
**=p<0.001. 
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Figure 3.19 Percentage of CD43 positive neutrophils in adult (A) and cord (B), above the 
background staining with isotype matched control.  Mean and SEM are shown for ten paired 
samples, significant differences are shown (** = p<0.01). 
 
 
U
n
LP
S
fM
LP
cy
to
B
f+
c
P
M
A
IL
-8
0
20
40
60
80
100
Adult
A
%
 e
x
p
re
s
s
in
g
 C
D
4
3
U
n
LP
S
fM
LP
cy
to
B
f+
c
P
M
A
IL
-8
0
20
40
60
80
100
Cord
B
%
 e
x
p
re
s
s
in
g
 C
D
4
3
130 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 Mean cellular fluorescence of CD15 and CD16 on unstimulated cord and adult 
neutrophils. No statistically significant deference detected in the expression of two markers 
between cord and adult neutrophils. 
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3.2.5    Intracellular staining for CD177, PR3, SerpinB1 and other proteins 
Parallel to extracellular surface marker expressions, intracellular levels of several proteins 
were also evaluated on unstimulated neutrophils. Only unstimulated cells were examined for 
these baseline level comparisons because of limited cell number availability. The mean 
intracellular fluorescence of PR3 for cord neutrophils was significantly higher than that of 
adult (MCF = 1347.3 units, 862.3 units respectively) p <0.05 by unpaired t test.   Both adult 
and cord PR3 intracellular levels were very high relative to the isotype matched control 
background staining (figure 3.21) and it does not have the bimodal nature observed for 
CD177.   
Examination of intracellular CD177 confirmed the absence of CD177 in the negative two 
cord samples, as they were equivalent to background staining Like the results for surface 
expression, intracellular CD177 levels in cord neutrophils was significantly greater than that 
in adult neutrophils (p<0.001; unpaired t-test). The percentage of both cord and adult cells 
containing intracellular PR3 was 99% (indicating no subpopulations); whereas mean 
percentage of cells containing intracellular CD177 for cord neutrophils was 90% compared to 
69% of adult cells, which always mirrored the patterns observed for surface expression for 
the same samples. This confirms that the surface expression subpopulations for CD177 
expression are responsible for the bimodal PR3 expression on the surface of stimulated cells, 
not the presence of high and low PR3 subsets of neutrophils. 
 
Mean cellular fluorescence of CD66b (a specific marker for the secondary granules) appeared 
to be higher in cords than adult, but failed to reach statistical significance (991.2 units and 
781.2 respectively) figure 3.21 B. In contrast, mean CD63 (a specific marker for the primary 
granules) level appeared to be lower in cord neutrophils relative to adults, but this was not a 
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significant difference. This was of relevance as PR3 is thought to be contained primarily in 
CD63 positive primary granules, but has also been reported to be found in CD66b-positive 
secondary granules.  The intracellular levels of CD35 and CD43 were also investigated as 
surface level reduction was examined for these markers, and other related complement 
regulators (C5a receptor (C5aR) and C3a receptor (C3aR)) were also examined. SerpinB1 has 
previously been shown to be expressed in high levels in neutrophils and may regulate the 
functional activity of PR3, so SerpinB1 levels were also measured. No significant differences 
were detected in MCF levels of C5aR, C3aR and Serpin B1 in unstimulated cord compared 
with adult neutrophils (figure 3.22). However, I did not study the effect of stimulation on the 
expression of these receptors. C5aR and C3aR levels were low, relative to isotype controls, 
while CD35 and CD43 were expressed at much higher levels. 
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Figure 3.21 Intracellular levels of CD177, CD63, CD66b and PR3. (A) Level of PR3 
compared to control in adult and cord neutrophils. (B) Comparison between Adult and cord 
neutrophils  intracellular content of  CD177, CD63, CD66b and PR3 mean cellular 
fluorescence as measured by flow cytometry. (C) Cord/adult ratio of CD177, PR3, CD63 and 
CD66b, n=10. 
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Figure 2.22 (A) Comparison of intracellular levels of complement receptors (C5aR and 
C3aR), CD35, CD43, and anti-proteinase SerpinB1) for unstimulated adult and cord 
neutrophils. (B) Percentage of positive cells expressing proteins above the background 
isotype control staining (n=10). 
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3.2.6    Determination of PR3 by ELISA 
 ELISA method was used to determine PR3 level in the supernatant and cellular fraction of 
adult and cord blood neutrophils in response to different stimuli compared to unstimulated 
controls. Unstimulated intracellular PR3 concentration in cord neutrophils (6.1 pg/cell, SEM 
0.96) was significantly higher than that in adult neutrophils (3.6 pg/cell, SEM 0.46), p = 0.03. 
With the exception of PMA and fMLP combined with cytoB, all other stimulants caused 
minimal release of PR3 into the supernatant and no significant difference was detected in 
released PR3 from cord compared to adult neutrophils (figure 3.24). Total PR3 (combined 
released and intracellular fraction) was significantly higher in cord than in adult neutrophils 
(p < 0.05). Cytochlasin B and fMLP were able to release a mean of 18.9% of the total PR3 
(cells plus supernatant) from adult neutrophils into the supernatant and 15.5% from cord 
neutrophil, p =N/S, whereas PMA stimulation only induced 5.5% of PR3 content from adult 
compared to 6.3% from cord cells. The total PR3 concentration in cord neutrophils was 2-
fold greater than the adult concentration (mean 6255 ng/ml and 3711 ng/ml respectively; p 
=0.03) figure 3.23. PR3 release from CD177 positive cord neutrophils was higher than its 
release from the two CD177 negative cord neutrophil samples. However, CD177 negative 
cord samples were also able to release PR3, figure 3.25.   
 
ELISA and flow cytometry (intracellular measurement of PR3) both consistently 
demonstrated higher PR3 concentration in cord neutrophils compared to adult neutrophils. 
For instance, the adult /cord ratio of PR3 level in ELISA was 0.59, which was comparable to 
the ratio of mean cellular fluorescence intensities for PE-conjugated anti-PR3 staining (0.64).  
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Figure 3.23 Scatterograph of total PR3 concentration present in both supernatant and 
cellular fractions of unstimulated neutrophils showing significantly greater PR3 
concentration in cord compared to adult blood. 
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Figure3.24. Mean PR3 concentrations from cord compared to that from adult neutrophils 
under a various stimulation conditions A) PR3 concentration retained in cellular fraction 
following activation. B) PR3 concentrations released into the supernatant. C) Total PR3 in 
both supernatant and cellular fractions. D) Percentage of total PR3 released into the 
supernatant. Error bars indicate SEM *= P <0.05. 
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Figure 3.25 Mean PR3 concentrations from CD177 negative cord samples compared to that 
from CD177 positive cord neutrophils under a various stimulation conditions A) PR3 
concentration retained in cellular fraction following activation. B) PR3 concentration 
released into the supernatant. 
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3.2.7    Cathepsin G functional activity 
Isolated neutrophils  from cord and adult samples were stimulated with a variety of stimulants 
as described in section 2.5.3. The cellular and supernatant fractions were separated by 
centrifugation and cellular fraction was released by distilled water and Triton X 100 
detergent. Cathepsin G (CatG) activity was measured in both cellular and supernatant 
fractions following exposure to different stimuli, ( n=10). 
 
 Unstimulated adult neutrophils contained significantly more cathepsin G (Cat G) in the 
intracellular compartment than cord neutrophils (mean 45.4  nM  ± SEM 12.1 nM and 18.2 
nM ±  SEM 3.3 nM respectively, p< 0.05). Only a small fraction of Cat G was released from 
both unstimulated adult and cord neutrophil as evidenced by the Cat G activity in adult 10.7% 
and 13.7% for cord neutrophils. Total Cat G activity (combined intracellular and 
spontaneously released values) was significantly greater for unstimulated adult neutrophils 
(mean 53.9 nM ± SEM 13.3) compared to cord (mean 21.3±3.7 nM),  p= 0.042. Similarly, the 
sum total Cat G activity (combined intacellular and released) in response to all stimulants was 
greater for adult neutrophils than cord neutophils (figure 3.26). 
 
Significant differences in retained intracellular Cat G activity  were obtained in the cellular 
fraction post-stimulation between cord and adult neutrophils for all conditions except   IL-8 
where no significant difference was observed in retained intracellular Cat G between adult 
and cord cells. The (F+C)  combination was a much more potent inducer of Cat G release 
than all other stimulants, as no other condition resulted in a significant  release of Cat G 
relative to unstimulated cells. F+C combination were able to release a mean of 56.2% of total 
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Cat G from the adult neutrophils into the supernatant and 49.7% from cord neutrophils, P 
insignificant. The Cat G activity measured in the supernatant was significantly greater from 
adult cells than from cord cells  (mean 31.1 nM vs 10.8 nM;  p < 0.05). The same pattern was 
found when elastase functional assay performed (submitted manuscript by other members of 
the laboratory; data not shown), except that F+C stimulation resulted in more than 60 % 
release of total cellular elastase for both adult and cord neutrophils. No significant differences 
were found in the percentage of Cat G released under any of the stimulation conditions, 
figure 3.26. 
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Figure 3.26 Mean Cat G functional levels from cord compared to adult neutrophils under various 
stimulation conditions. A) Cat G activity retained in cellular fraction following activation. B) Cat G 
activity released into the supernatant. C) Total Cat G activity in both supernatant and cellular 
fractions (calculated from A + B). D) Percentage of total Cat G activity released into the supernatant. 
Only significant differences are marked * p=<0.05, ** =p<0.01 and * **=p<0.001. 
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3.3    Discussion 
3.3.1   CD177 and PR3 
In this study, I analysed the surface expression of CD177 and mPR3 in cord and adult 
isolated neutrophils, and I assessed whether their expression on the plasma membrane of 
neutrophils depends on cell activation state. Based on expression of membrane‐bound 
proteinase 3 (mPR3), two subsets of neutrophils can be identified: neutrophils that hardly 
express proteinase 3 (mPR3
–
 neutrophils) after stimulation, and neutrophils that substantially 
express proteinase 3 (mPR3
+
 neutrophils) after stimulation. Consistent with the results 
reported by others, the expression of mPR3 and CD177 were bimodal (Bauer et al., 2007; 
Brachemi et al., 2007; Von Vietinghoff et al., 2007). However, I found that isolated 
neutrophils from all of adults and some of cord blood samples in the absence of stimuli 
showed uniformly positive expression of mPR3 in agreement with Hu et al., 2009 who 
reported monomodal PR3 in 19/31 adult neutrophils (61%). In addition, I found that after 
incubation of cells with fMLP, PMA and fMLP in combination with cytoB (F+C), the pattern 
of mPR3 expression changed to bimodal, with a low-expression mPR3 and a high-expression 
mPR3 subset.  This finding is also in accordance with Hu and co-workers who found that 12 
of their 19 adult isolated neutrophil samples changed from monomodal to bimodal mPR3 
expression following 15 minutes with TNFα (Hu et al., 2009).  
 In keeping with my results, Bauer et al. showed that CD177 and PR3 are expressed on the 
same subsets of neutrophils and both can be up-regulated in parallel suggesting that CD177 
and mPR3 originate from the same intracellular storage (secondary granule) and shared the 
same mode of trafficking. They concluded that only PR3 present in secondary granules and 
secretory vesicles can be expressed on the membrane (Bauer et al., 2007).  
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It has been shown that percentage of mPR3
+
 and CD177-positive neutrophils display high 
inter-individual variation ranging from 0% to 100% of the total population of neutrophils for 
each person (Halbwachs-Mecarelli et al., 1995; Witko-Sarsat et al., 1999; Rarok et al., 2002; 
Schreiber et al., 2003). This percentage was stable in healthy individuals and did not change 
with G-CSF mobilisation of neutrophils (Goldschmeding et al., 1992; Wolff et al., 2003). 
Results of the present work are in agreement with these studies. I show inter-individual 
variability in cord as well as adult neutrophil CD177 expression and stability of percentage 
expression in each individual even after stimulation with different stimulants. A similar 
pattern of stability of CD177 expression ratio was demonstrated by Stroncek and co-workers 
who found that this ratio remained stable following the expression of CD177 antigen by 
myelocytes (Stroncek et al., 1998).This suggest that myelocyte CD177 expression status 
continues in subsequent myelopoietic stages: metamyelocytes, band and segmented forms 
and that CD177-negative myelocytes eventually produce CD177-negative neutrophils. 
  
 
Genetic control of mPR3 expression is supported by monozygotic twin studies which 
demonstrated that the ratio of mPR3 expressing neutrophils in these twins is highly 
concordant (Schreiber et al., 2003). CD177 gene polymorphism was reported in Wolff et al 
study who found 6 allotypes of this gene, three of them were significantly associated with a 
small CD177 expressing subpopulation, indicating a genetic basis for CD 177 non-expression 
(Wolff et al., 2003). 
 
Variation in membrane expression was noted also in PR3 where a study demonstrated that the 
proportion of freshly isolated neutrophils that express PR3 varies considerably between 
donors from 0-95% but is also extremely stable for each individual over prolonged periods of 
time (Halbwachs-Mercarelli et al., 1995) which is in accordance with our findings.  Although 
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this work is not a longitudinal study, I did repeat the experiments with some individual adults 
2 or 3 times throughout my project and the results were consistent each time.  In this project 
the intracellular levels of PR3 showed some correlation with mPR3 levels in both adult (r = 
0.43) and cord (r = 0.54) although the correlation was not statistically significant and this 
could be due to the limited number of samples. 
 
Herein, I found that the mean percentages of CD177 and PR3 expression in neutrophils were 
higher in cord blood than in adult neutrophils. Stroneck et al showed that the size of positive 
CD177 subpopulation of neutrophils from umbilical cord was 91% which was significantly 
higher than that of neutrophils from both children and adult (56%). This percentage decreased 
by 1 year of age and remained stable thereafter (Stroneck et al., 1998). This suggests that the 
newborn status is to express a predominantly monomodal high and that expression is altered 
in certain subsets through an unknown mechanism.  However, CD177-deficiency is probably 
genetic and expression is never induced in these individuals after birth. 
Many studies have found that stimulation of isolated neutrophils with agonists such as PMA, 
TNFα, IL-8, fMLP, Cytochalasin B, TGF- and GM-CSF up-regulate the expression of PR3 
on CD177-positive neutrophil cell surfaces. (Csernok et al., 1994; Halbwachs-Mecarelli et 
al., 1995; Witko-Sarsat et al., 1999;  Hellmich et al., 2000;  Drewniak et al., 2008). In 
keeping with these studies I observed that some of the unstimulated neutrophils from healthy 
donors express PR3 on their surface and this surface expression is further augmented by 
several stimulants. The relatively greater effects of F+C on mean cell surface expression of 
CD177 and PR3 when compared with the effects of the rest of the agonists likely reflect the 
synergistic effect of this combination on neutrophil degranulation. Bauer et al reported that 
F+C was the most potent stimulant to the extent that mPR3 negative and CD177 negative 
neutrophils  became positive but we could not reproduce such an effect on either mPR3 or on 
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CD177 expression. The group suggested that equal upregulation of CD177 and PR3 indicated 
that PR3 expressed on membrane originate from secretory vesicles and secondary granules 
rather than from primary granules which are less mobilised and did not contain CD177 
(Bauer et al., 2007). Similarly, Abdgawad and colleagues showed that cell surface expression 
of mPR3 is dependent on CD177 and found a strong correlation between the percentage of 
mPR3 positive subpopulations and the percentage of CD177 positive subpopulations. 
 
3.3.2    Effect of cytokines and sepsis on PR3 membrane expression 
Previous study has reported that expression of mPR3 on positive neutrophils is higher in 
septic patients than in healthy individuals (Matsumoto et al., 2006). In sepsis, excessive 
neutrophil stimulation and degranulation resulted in highest mPR3 expression (approximately 
70%) in positive neutrophils. Moreover, cytokines TNFα and IL-8 synergistically increased 
membrane expression of PR3 in neutrophils (Csernok et al., 1994). Membrane expression of 
PR3 was also reported to increase in another study on 46 patient with fatal sepsis where 
leukocytes showed a shift to the left (more band neutrophils) and expression had positive 
correlation with  C Reactive Protein (CRP) ( Von Vietinghoff et al., 2007). This suggests that 
exposure of neutrophil to cytokines and chemo-attractants could mediate the observed 
increases in mPR3 on neutrophil during sepsis. Also, priming of neutrophil  with LPS, TNFα 
and PAF followed by activation with IL-8, resulted in striking synergistic increases in cell 
surface expression of PR3 (Campbell et al., 2000).  Stimulation of neutrophils with TNF-α, 
which brings them to a pre-activated state, may translocate PR3 to the plasma membrane and 
raise the expression level up to two-to three fold of that on resting neutrophils (Reumaux et 
al., 1995).  Elevated levels of CD177 transcription in neutrophils were previously found in 
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patients with bacterial infections, but not in patients with viral hepatitis (Gohring et al., 
2004). 
 Intracellular storage pools of PR3 are reportedly located not only in primary but also in 
secondary granules and secretory vesicles (Witko-Sarsat et al., 1999). Activation of 
neutrophils by TNF is adequate to mobilize secretory vesicles and possibly tertiary granules 
(Bouaoina et al., 2004; Chakrabarti et al., 2006). 
On the other hand, when I measured CD177 expression, unstimulated and stimulated cord 
neutrophils were shown to express significantly higher levels of CD177 on their surface 
compared to adult as shown in figure 3.4. Gender and age difference in expression of CD177 
was also previously described.  For example, CD177 expression was higher in women of 
reproductive age than men and in pregnant women than in healthy non pregnant female 
donors (Caruccio et al., 2003; Taniguchi et al., 2004).  CD177 drops in older women but not 
in older men (Matsuo et al., 2000), which may be related to low oestrogen level in this age 
group and probably indicates that finding elevated level of CD177 in cord neutrophils here 
might be due to the presence of more estrogen in pregnant women which influence their 
infants. However, this suggestion cannot explain the absence of CD177 expression in some 
newborn infants in our study group. Absence of CD177 in these two newborns could be 
inherited, although evaluation of CD177 level in their parents was not done.  This is 
supported with previous reports which demonstrated that absence of CD177 was found in 
approximately 3% of Caucasians, 5% of African Americans and 11% of Japanese (Matsuo et 
al ., 2000, Stroncek et al., 2004). One causes of this deficiency has been reported as an 
mRNA splicing defect (Kiessel et al., 2002).   
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 In the present work I found that the level of mPR3 was notably higher on unstimulated 
neutrophils in CD177-negative cord samples compared to the level of background (isotype 
control). Hu et al., 2009 found 3 healthy donors from 31 volunteers with CD177-negative 
neutrophils which expressed mPR3 after stimulation with TNFα. Therefore, neutrophils from 
these three samples, despite their negative CD177 status, were able to expresses membrane 
PR3 on their surface. These results, in agreement with my findings indicate that expression of 
PR3 on the neutrophil surface can be mediated by other mechanisms independent of CD177 
as a receptor.  
 
Activation of cells by fMLP combined with cytoB considerably increased mPR3 expression 
on adult neutrophils but expression was not altered in CD177 negative cord neutrophils. This 
suggests that the role of CD177 in cell surface expression of mPR3 on unstimulated CD177 
negative cord cells could be compensated by yet unknown mechanisms. In an attempt to 
investigate the underlying mechanism, Campbell et al showed that ionic interactions are 
important in the binding of PR3 to the plasma membrane and PR3 could be eluted from the 
membrane of neutrophil following cellular activation.  PR3 can bind stably to anionic and 
neutral membranes, but binds strongly to negatively-charged bilayers. Moreover, 
hydrophobic residues in PR3 also bind to the membrane with high affinity (Campbell et al., 
2000; Hajjar et al., 2006). In keeping with Hajjar findings, PR3 could be inserted into the 
membrane lipid bilayer via the hydrophobic region (Goldmann et al., 1999). However, other 
workers did not believe that mPR3 binding to neutrophil surface occurs only in a charge-
dependent manner (Owen,  2008) and it was  demonstrated that mPR3 could not be eluted off 
the membrane by drastic PH changes (Witko-Sarsat et al., 1999; Korkmaz et al., 2008). 
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Others suggest that PR3 membrane binding is possibly mediated by proteins other than 
CD177 such as FcγRIIIb (CD16), or β2 integrin (CD11b/CD18) and CD66b (Matsuo et al., 
2000;   David et al., 2003;  David et al., 2005;  Fridlich et al., 2006).  
Membrane bound expression on mPR3 low neutrophils has also been observed in other 
studies (Halbwachs et al., 1995;  Schreiber et al., 2004;  Van Rossum et al., 2007 ). These 
results suggest that CD177 is not an exclusive receptor of mPR3, and the binding sites for 
CD177-independent mPR3 expression are still open for discussion. However, CD177 seems 
to be necessary for bimodal PR3 expression pattern since I found absence of PR3 bimodal 
expression pattern in the two negative CD177 cord samples even after stimulation. 
 
Quantification of intracelluar PR3 was also performed using ELISA in adult and cord 
neutrophils. Unstimulated intracellular PR3 concentration in cord neutrophils (6.1±0.95 
pg/cell) was significantly higher than that in adult neutrophils (3.6±0.46 pg/cell p≤ 0.05). 
ELISA study and flow cytometry analysis both demonstrate higher PR3 concentration in 
neonatal neutrophils than adult neutrophils. The fact that the two very different methods give 
us similar findings adds significant strength to our findings. The ELISA method is a 
summation of all the PR3 either released by all the cells or remaining in the cell pellet 
whereas flow cytometry measures PR3 concentrations in individual cells, before and after 
stimulation. Both methodologies suggest that PR3 concentrations are approximately double 
in cord neutrophils than adult neutrophils. This was the first report of PR3 ELISA in cord 
neutrophils whereas adult levels were in agreement with Witko-Sarsat et al., 1999 and 
Campbell et al., 2000.  
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3.3.3   CD63 and CD66b 
 
CD63, a member of the tetraspanin superfamily, is an activation marker in neutrophils and 
one of the membrane proteins of azurophilic granules, which has been shown in vitro to be 
expressed on the cell surface following neutrophils activation in the presence of fMLP 
following cytochalasin B priming. PMA and fMLP alone are known to induce minimal 
translocation of CD63 (Cham et al., 1994).  CD63 is also found in platelets (Kuijpers et al., 
1991). Lopez et al. found CD63 expression increased on synovial fluid neutrophils of 
rheumatoid arthritis patients (Lopez et al., 1995).  
 
In this work, I did not detect any significant difference in neutrophil CD63 expression 
between cord and adult in unstimulated neutrophils. I have demonstrated that cell surface 
expression of CD63 in response to different stimuli did not change from the baseline of 
unstimulated cells in both adult and cord neutrophils except with F+C. This combination 
brought about greater expression of CD63 in comparison with unstimulated cells in adults 
reflecting their potent effect on neutrophil degranulation, in agreement with earlier reports 
(Dewald and Baggiolini, 1986; Niessen and Verhoeven 1992; Cham et al., 1994). The 
combination of F+C also has great effect on up-regulation of CD63 on cord neutrophils not 
previously reported before this work.  Up-regulation of CD63 in response to F+C was higher 
in cord than in adult neutrophils, but the difference was not statistically significant.   
 
Secondary granules are mobilised easily upon stimulation early during inflammation. They 
appear later in development and are smaller, and more numerous, than azurophilic granules. 
They are de-granulated in vitro by low concentration of PMA or fMLP even in the absence of 
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cyto B (Cham et al., 1994). CD66b is present in membrane of specific granules (Molinedo et 
al., 1999; Molinedo et al., 2010). 
In this project, these agonists had similar effect on CD66b expression on neutrophils, which 
is a marker mainly located in the specific granules. Stimulation of adult cells with fMLP 
alone causes significant increase of CD66b compared with unstimulated neutrophils whereas 
PMA and F+C stimulation induced even more highly significant expression of CD66b in both 
cord and adult neutrophils. Up-regulation of CD66b membrane expression in response to 
both of PMA and F+C was higher in adult than in cord neutrophils, but the difference was not 
statistically significant. These results are in accordance with previous reports and probably 
are explained by the capacity of PMA to elicit release of specific and tertiary granule contents 
and induction of all three major granules secretion by F+C (Molinedo et al., 1991). Our 
findings are in keeping with those of Niessen and Verhoeven 1992 who showed that F+C is a 
potent activator of specific granule degranulation using CD67 rather that CD66b as a specific 
granules marker. Effect of PMA on degranulation of specific granules was reported in many 
studies (Smith and Peters 1982; Dewald and Baggiolini 1986; Niessen and Verhoeven, 1992).  
However, in this study we did not find any differences between cord and adult neutrophils in 
CD66b expression.  
The expression of CD66b in preterm neonates was comparable with that of adults (Payne et 
al., 1993), gestational age has been reported to have no effect on the percentage of CD66b 
positive cells (Weinschenk et al., 1998) and pregnancy has no apparent effect on CD66b 
expression (Sacks et al., 1998; Naccasha et al., 2001). However, pregnant women, who 
delivered prematurely, had a higher intensity of CD66b expression on their neutrophils 
(Gervasi et al., 2001). 
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Neonatal neutrophils may have fewer specific granule numbers and also possibly abnormal 
morphology. Newborn neutrophils have reportedly less lactoferrin content, but release of 
lactoferrin on stimulation is reportedly comparable to adult (Ambruso et al., 1984). 
Mollinedo and co-workers found that cell surface expression of CD11b and CD66b were up-
regulated upon neutrophils activated with PMA, which degranulate specific and tertiary 
granules. Their expression was also up-regulated by fMLP which induces secretion of the 
three major granules in the presence of cytoB.  Moreover, fMLP treatment alone induced up-
regulation of cell surface expression of primary granule marker CD63 but not CD66b 
(Mollinedo et al., 2010). 
 
3.3.4    CD35 and CD43 
CD35 antigen is normally expressed on bands and segmented neutrophils.  It is present in a 
large intracellular pool that could be easily trans-located to the plasma membrane with 
activation (Ahearn and Fearon, 1989), likely secretory vesicles.  
Foetal, preterm neonatal, and term neonatal granules expressed CD35 in an intensity that was 
similar to adult granulocyte (Smith et al., 1990) in agreement with our observation. Similarly, 
Abughali et al. quantified CD35content of neonatal granulocytes and found no difference in 
CD35 level from adults (Abughali et al., 1994). Smith et al. found no significant change in 
CD35 expression between term and adult after fMLP stimulation whereas expression in 
response was significantly less in preterm neutrophil (Smith et al., 1990) 
Contrary to this conclusion, another study found that the expression of CD35 on resting 
neonatal neutrophils was significantly higher than in adult neutrophils but stimulation of 
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neutrophil with fMLP and IL-8 increased CD35 expression more markedly in adults (Lothian 
et al., 1997)  
 We observe that neutrophils from term neonates expressed significantly less CD35 on the 
plasma membrane in response to stimulation than neutrophils from adults. The percentage of 
CD35 expressing neutrophils were significantly down regulated in response to PMA and F+C  
in adult cells whereas only F+C caused significant reduction in the percentage of CD35 
expressing cord neutrophils. In this study, neutrophils from adults expressed significantly 
higher CD35on their surface in response to stimulation with IL-8 than expression in 
unstimulated in agreement with Lothian et al 1997 while it has no significant effect on cord 
neutrophils. 
 
CD43 (Sialophorin/leukosialin), is highly represented on neutrophils and other leukocytes 
(Fukuda and Tsuboi. 1999).  CD43 on neutrophils has both anti-adhesive and pro-adhesive 
functions. CD43 was shown to inhibit E selectin dependent adhesion of circulating 
neutrophils to endothelium while it does not interfere with their integrin-mediated adhesion 
(Mambole et al., 2008; Matsumoto et al., 2008).  
In my study, all stimulants caused significant reduction in CD43 expression on adult 
neutrophils, particularly PMA. The current work is in agreement with Rieu et al. study which 
demonstrated that membrane expression of CD43 was down-regulated  by up 80 % in 
response to cell activation with PMA or F+C while TNFα followed by fMLP stimulation 
resulted in up to  40% decrease of CD43 expression (Rieu et al ., 1992). Other previous 
studies also have shown similar down regulation of CD43 expression by PMA (Halbwachs-
Mecarelli et al., 1996).  
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The same response in term of CD43 expression was observed in cord neutrophils, except 
when stimulated with IL-8 which lead to reduction in CD43 expression, but the down-
regulation was not statistically significant. This finding agreed with Remold-O’Donnell and 
Parent 1994 work who found that PMA, and to much lesser extent, fMLP and IL-8 decreased 
neutrophil expression of CD43. 
 
In addition, Bazi and Strominger 1994 demonstrated that CD43 is enzymatically cleaved from 
the surface of PMA-activated granulocytes. CD43 shedding has been shown to be mediated 
by neutrophil elastase (Cham et al., 1994). Remold-O’Donnell and Parent, 1995 found that 
neutrophils CD43 was cleaved in a dose-dependent manner by low level of neutrophil 
elastase. Cathepsin G can also cleave CD43 although it has lower affinity and 10 times higher 
concentration than elastase is required whereas PR3 could not cleave CD43.  
 
3.3.5    CD16 
CD16 expression on unstimulated cord neutrophils was equivalent to its expression in adult 
neutrophils in this work.  This result is in keeping with Bikou et al report that the expression 
of CD16 in leukocytes and CD35 in myeloid cells in cord blood were comparable to their 
expression in adult neutrophils (Bikou et al., 1997). Moreover CD16 expression was 
reportedly low in elderly particularly in presence of bacterial infection (Butcher et al., 2001).   
 
Takahishi et al found that the mean percentage of CD16 positive neutrophils was 
significantly lower in cord (73.3%) than in adult blood (95.9%). Difference may be related to 
mode of delivery since 5 out of the seven neonates included in their study were born 
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vaginally and only 2 were born by Caesarean section, whereas the 10 cord samples in my 
study were obtained after elective Caesarean section. Different methodology was followed in 
blood collection and purification and collected sample volume was smaller (3 ml of 
heparinised whole blood) (Takahishi et al., 1994). Activation of neutrophil could probably be 
related to delivery mode or manipulation of sample resulting in the lower expression reported 
in this study. Activation of neutrophil is known to induce CD16 shedding from neutrophil 
membrane via proteolytic shedding (Middelhoven et al., 2001). Cord neutrophils from 
vaginally delivered neonates were shown to be primed by labour stress while cord neutrophils 
obtained following Caesarean section were not metabolically primed (Khalfan et al., 1995). 
In this study CD16 expression was measured only in unstimulated neutrophils.  
In addition, total leukocyte and neutrophil counts were higher in cord blood after vaginal 
delivery compared with Caesarean section. However, there were no statistical differences in 
the expression of CD16 or CD35 receptors on neutrophils between the delivery groups in one 
study (Grönlund et al., 1999).   
 
Shedding of membrane receptors may be required to limit cell responsiveness to external 
ligand or to dissociate cells from ligand involved in the transmigration process. However 
shedding may also represent a mechanism for the production of soluble receptors that convey 
signals to other cells in a manner analogous to cytokines (Tedder, 1991). 
Furthermore, I compared the expression of CD15, another specific granule marker that co-
localised with lactoferrin (Buescher et al., 1990). Its expression in cord neutrophils was 
similar to its expression in adult neutrophils in resting condition but I did not study the 
expression in response to stimuli. 
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3.3.6    Cathepsin G and elastase 
Comparative study of functional activity of cathepsin G in cord and adult neutrophils 
described in this chapter has not been previously reported.  However, a few studies have 
compared elastase content in adult and neonatal neutrophils. Some of these studies assessed 
free elastase activity in umbilical cord plasma. They suggested that plasma elastase elevates 
soon after birth probably due to neutrophil activation during delivery and gradually declined 
afterwards (Tsaka and Herkner 1990; Philip et al., 1994; Adeyemi and Abdulle 1998). To 
avoid neutrophil activation during delivery in this thesis, all cord samples were collected 
from neonates born by elective Caesarean section.  
Our findings demonstrate that cord neutrophils contain significantly less cathepsin G and 
elastase than adult neutrophils in agreement with previous work on neutrophil elastase 
activity in our laboratory which showed that cord neutrophils have less elastase activity than 
adult neutrophils.  Due to lack of known substrate that is specific for PR3, I could  not 
investigate the functional activity of PR3. 
However, a similar proportion of protease is released by cord and adult neutrophils in 
response to stimulation. Therefore, in response to stimulus, the total elastase or cat G released 
by cord neutrophils will be proportionately less than the amount released from adult 
neutrophils. This could be an additional contributing factor to cord neutrophils limited 
bactericidal ability and hence to neonates susceptibility to infection.  
Small amount of Cat G is known to leak into extracellular fluid when azurophilic granule 
contents are released from neutrophil in response to physiological stimuli (Owen et al., 
1995).  
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 Stimulation with combination of fMLP and cytoB resulted in release of most of Cat G from 
neutrophils. Elastase activity assay was previously studied in our laboratory. However, in this 
project I repeated elastase activity experiments in parallel to Cat G analysis as both of these 
enzymes are released from the same subset of granules and reproducibility of elastase results 
arguably could be a helpful guide in interpretation of Cat G results. Only unstimulated cells 
or cells receiving maximum stimulation (F+C) were examined as previous work in the 
laboratory showed that these were the only condition to significantly result in release from 
neutrophils. In accordance with previous results, Cat G release was only significantly 
released with F+C. Similar response noticed in the activity of these enzymes to F+C 
stimulation is explained by localisation of both enzymes in the same granule subset, namely 
primary granules. However, some studies suggested that cathepsin G found in the primary 
granules of neutrophils , is also on the surface of neutrophils (Maison et al., 1991; Owen et 
al., 1995; Owen and Campbell  1998).  
 
Owen et al., 1995 found minimal expression of serine proteases (Cat G and elastase) on 
unstimulated neutrophil which was increased remarkably 30-fold in response to PMA 
stimulation. More relevant biologic stimulants had less ability to induce membrane 
expression of these proteases, with fMLP causing a modest two fold increase in their 
expression. LPS had mainly a priming effect as it induced minimal upregulation when used 
alone but when followed by fMLP induced more expression of Cat G and elastase on 
neutrophil surface. They concluded that active neutrophils express persistently active serine 
proteinases on their cell surfaces that are accessible to both natural and synthetic substrates 
(Owen et al., 1995).  
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The important immunological role of neutrophil elastase and Cat G was demonstrated in 
several studies. Mice deficient in elastase and /or Cat G were susceptible to fungal infections 
despite normal neutrophil development and recuritment (Tkalcevic et al., 2000). Neutrophil 
elastase deficient mice have a defect in their ability to clear Gram negative, but not Gram-
positive organisms in some studies (Belauauaj et al., 1998;  Hirche et al., 2008), but recently 
elastase and Cat G were shown to be equally important in eradication of Gram-positive 
bacteria. Evidence from a study on Cat G knock out  and Cat G/elastase double knock out 
mice showed these mice had a reduced ability to clear S pneumoniae serotype 19 pneumonia 
(Hahn et al.,2011). Similarly, Cat G -/- mice were increaseingly susceptible to 
staphylococcus infections (Reeves et al., 2002).  In contrast, one study suggested that Cat G 
deficieny could be compensated by other proteases, as they found that Cat G -/- animals were 
phenotypically normal when challenged with Gram-negative and Gram-positive bacteria 
(Maclover et al., 1999). 
 
High levels of proinflammatory cytockines were found in wound fluid taken from Cat  G 
deficient mice suggesting that Cat G may play a role in inactivating proinflammatory 
molecules at the site of wound injury. The abilty of Cat G to cleave and inactivate cytokines 
IL-1, TNF, and IL-8 could accelerate wound healing and reduce neutrophils influx to the site 
of inflammation.  Therefore, this could also be the reason for delayed wound healing in mice 
deficient in Cat G (Maclover et al., 1999). 
 
Known functions of Cat G are diverse including antimicrobial activity, elastase-like non-
specific degradation of extracellular matrix components such as proteoglycan, collagen, 
laminin, fibronectin and even elastin (Baggiolini et al., 1979) and regulation of inflammatory 
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responses through degradation of complement components and immunoglobulins (Campbell 
et al., 2000). In addition Cat G has been implicated in control of blood pressure by converting 
angiotensinogen and angiotensin I to angiotensin II  ( Tonnesen et al., 1982; Ramahas and 
Pateston 2002). There is intriguing evidence that Cat G plays a direct role in neutrophil 
accumulation at sites of inflammation. Since inhibitors of Cat G diminish neutrophil 
migration in vitro (Lomas et al., 1995). Cat G, as well as elastase, can also cleave CD43, 
whereas proteinase 3 has no CD43 cleaving activity (Remold-όdonnell and Parent, 1995 ). 
Cat G also cleaves CD14, a receptor for LPS, and reduces its cell surface expression (Le-
Barillec et al., 2000).  
 
 3.4 Summary 
In this chapter I have presented flow cytometry data on different markers and enzymes of 
neutrophils obtained from cord and adult blood. Detailed flow cytometry analysis of cord 
blood neutrophils had not been previously published specifically for proteinase 3 and the 
function activity of Cat G. I have demonstrated that neutrophils obtained from cord blood 
express more PR3 and CD177 on the cell surface than neutrophils obtained from adult 
volunteers, but the amounts of surface CD63, CD66b, CD35 and CD43 expression were not 
significantly different. I have additionally shown that cord blood neutrophils contain lower 
Cat G and elastase functional activity than adult neutrophils. A similar percentage of 
neutrophil Cat G is released from cord and adult neutrophils with different pro-inflammatory 
stimulations. 
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Chapter Four 
 
 
Neutrophil proteases in the lungs of infants 
at risk of developing Chronic Lung Disease 
of Prematurity 
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4.1      Introduction 
 
In the preceding chapter, I demonstrated that neutrophils from healthy full term cord blood 
contain more PR3 than adult neutrophils. Neutrophil proteases are implicated in pathogenesis 
of chronic lung disease (CLD) in premature infant but PR3 was not previously studied in this 
context. This chapter will therefore focus on the role of proteinase 3 in the development of 
CLD of premature infants. 
In recent years, we have seen substantial improvement in the treatment and thereby survival 
of infants born prematurely. Consequently, prevalence of long-term complications has 
increased in those infants who are now surviving extreme preterm birth (Horbar et al., 2002). 
Neutrophil proteinases have a pivotal role in the multifactorial and complex pathogenesis of 
CLD.  Imbalance between neutrophil proteinases and their inhibitors is of crucial importance 
to the disturbance of lung development seen in CLD. The best described agent of proteolytic 
lung injury was neutrophil elastase although more recent studies suggest that in the new CLD 
elastase is of reduced importance. Similar to elastase, PR3 have comparable proteolytic 
activity which is considered one of the complex pathogenic factors resulting in lung injury. 
PR3 role in pathophysiology of other lung diseases including cystic fibrosis and emphysema 
has been studied before suggesting its involvement in these diseases.  Hence PR3 was 
implicated in proteinase- mediated airway damage and thereby in pathophysiology of airway 
inflammatory disorders. 
In this chapter I have measured neutrophil PR3 in bronchoalveolar lavage fluid samples 
obtained from infants at risk of developing CLD. The results were compared with other 
proteinases levels in the same samples to see whether a relationship could be found between 
the level of PR3 and MMP-9 or elastase in BAL fluid. 
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4.2 Results 
 
4.2.1 Patient characteristics 
Three groups of mechanically ventilated infants were studied (table 4.1, adapted from Davies 
et al., 2010); premature infants (<32 weeks gestation) who developed CLD (group 1, 20 
newborns), preterm infants who developed and recovered from neonatal respiratory distress 
syndrome (group 2, 17 newborns) and a term control group included 6 babies who were 
ventilated for non-respiratory reasons. Control group neonates were born with gastroschisis 
and underwent primary closure of the abdominal wall defect during the first few hours of life 
and in many cases were ventilated for a number of days following surgery. Infants were 
previously recruited for BAL study by Dr Davies from neonatal unit at the University 
Hospital of Wales and were investigated for elastase activity and MMP-9 levels and their 
inhibitors. 
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Table   4.1 Patient characteristics 
 Chronic Lung 
Disease 
Resolved RDS Term control 
    
Number of Patients  20 17    6 
Number of Samples 80 34 21 
Gestational age 
(weeks)                       (25
+4
-29
+3
) 
27 28
+6 
(27-29
+2
) 
Term 
Birth Weight (grams) 835g 1120g 2550g 
Male: Female 11:9 10:7 3:3 
    
Vaginal :Caesarean  
Delivery 
10:10 6:11 5:1 
Antenatal steroids>24 
hours 
16/20 (80%) 12/17 (71%) 0/6 (0%) 
Patent Ductus  
Arteriosus 
13/20 (65%) 6/17 (35%) 0/6 (0%) 
Surfactant therapy 20/20 (100%) 17/17 (100%) 0/6 (0%) 
Prolonged rupture of  
Membrane(>24 hours) 
4/20 (20%) 1/17 (6%) 0/6 
Length of ventilation  
(days) 
7 day 
(5.5-11 day) 
1 day 
(1-4.5 day) 
3 day 
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4.2.2  Neutrophil PR3 concentration in BAL supernatant 
Sufficient  number of BAL samples were  available to study PR3 concentrations released by 
neutrophils in BAL fluid. Human PR3 belongs to the same serine protease family as elastase 
and Cat G. PR3 is found in primary and secondary granules, and secretory vesicles.  Due to 
the expression of the high affinity receptor (see previous chapter), PR3 can also be expressed 
on the surface of CD177-positive neutrophils from where it can be released into surrounding 
environment upon neutrophil activation (Csernok et al., 1990; Halbwachs-Mecarelli et al., 
1995; Witko-Sarsat et al., 1999).  
 
PR3 ELISA was  performed on BAL fluid of CLD infants, resolved RDS and term controls. 
PR3 was mesurable in all BAL samples, but the peak concentration of PR3 was significantly 
greater in infants who developed CLD, with median of 6049 ng/ml compared to preterm 
infants with resolved RDS or term controls (3440, 740.2 ng/ml respectively) (p = 0.0096, p = 
0.0076, respectively by Mann-Whitney U test) as demonstrated in figure 4.1. There was no 
significant difference in peak PR3 concentration between preterm infants whose RDS 
resolved and term infants. 
 
When longitudinal data for each individual infants was analysed during different ages for 
samples taken, the episodic spikes for increased PR3 concentrations can be appreciated. The 
timing of PR3 spikes was extremely variable, with the initial PR3 spike being after the 
second day of age  as shown in figure 4.2,4.3 and 4.4 for each sesperate groups.  
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Figure 4.1 A scatterplot of the peak PR3 concentration for infants with CLD, resolved RDS 
and term (control) infants, demonstrating significantly higher PR3 peak level in infants 
developing CLD. Median values are marked with a horizontal line and significant differences 
are shown.  
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Figure 4.2 Longitudinal data showing PR3 concentrations for CLD babies, each graph 
represents an individual infant (only babies with more than 3 BAL samples are shown).  
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Figure 4.3 Graphs of longitudinal PR3 concentrations in resolved RDS babies, each graph 
represent an individual infant (only babies with more than 3 BAL samples are represented).  
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Figure 4.4 Graphs showing PR3 concentration in two separate term BAL samples. Each 
graph represents an individual infant (only babies with more than 3 BAL samples are 
represented).  
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4. 2.3 MMP-9, PR3 and Elastase in BAL samples 
The concentration of MMP-9 and elastase activity in the same CLD, RDS and term BAL 
samples has been previously studied in our laboratory by Dr Davies (Davies et al., 2010). 
Herein, I compare the previous results for MMP-9 and elastase activity with PR3 
concentration on the same selected samples for CLD, RDS and term control infants. 
 
The relationships between the peak PR3 concentrations and corresponding peaks in MMP-9 
concentrations, combined with measured elastase activity are shown in figures 4.5, 4.6 and 
4.7 for study arms, CLD, resolved RDS and term control, respectively. These figures 
demonstrate the episodic nature of spikes for both MMP-9 and PR3 concentrations and also 
show the relationship between their peak variability in some samples. In general, it was 
unusual to observe elevation of both PR3 and MMP-9 concentrations or presence of elastase 
activity in the first two days of life. Comparison of proteases  levels showed different 
patterns; occasionally PR3 closely mirrored the levels of MMP-9 (CLD patients number 8, 
17, 19, 22 , 34 and RDS patient 11) while other times the PR3 levels appeared to change 
independently of MMP-9 levels (CLD patients 10, 39, 46, RDS patients 25 and term infants 
35 and 37). 
What is clear is that despite being considered a predominantly azurophilic granule protease, 
PR3 levels were totally independent of elastase levels.  Furthermore, the amount of PR3 in 
the BAL samples far exceeded the levels of any other protease examined for these patients. 
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Figure 4. 5. Graphs of PR3/MMP9 concentrations over first days of life 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Graphs show longitudinal data PR3 (blue line) and MMP-9 (red line) 
concentrations for CLD babies. Each graph represents the same baby over specific period. 
Vertical arrows represent samples in which elastase activity was detectable.  
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Figure 4.6 Graphs showing relationship between PR3 concentration (blue line) and MMP-9 
concentration (red line) for individual RDS babies. No elastase activity was detectable in any 
patient in this group. 
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Figure 4.7 Graphs show longitudinal data PR3 (blue line) and MMP-9 (red line) 
concentrations for term (control) infants. No elastase activity was detectable in any patient in 
this group. 
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4.2.4 Peak concentration of PR3, MMP-9 and Elastase 
Figure 4.8 (A) demonstrates the peak concentrations of PR3 and MMP-9 in the BAL fluid 
samples from the same CLD infants. The peak levels of PR3 concentrations were 
significantly higher than the corresponding peak MMP-9 concentration on the same CLD 
newborns (median PR3, 196.2 μM; MMP-9 4.16 μM, p = 0.001). As shown in figure 4.8 (A), 
Elastase activity was low and only detectable in a small number of BAL CLD samples (in at 
least one BAL fluid samples collected from10/20 CLD newborns). 
 
In addition, significant difference was also observed between the peaks of both proteases in 
BAL samples from resolved RDS babies as demonstrated in figure 4.9 (A) (median PR3 
147.7 μM;  MMP-9 of 1.4 μM,  p <0.0001). No elastase activity was reported by Davies et al 
for any of the samples that I was able to co-investigate in this same sub-set of RDS BAL fluid 
samples examined here , but overall, elastase activity was demonstrated at some point in only 
2/17 resolved RDS newborns in the original sample series.  
Elastase activity was not demonstrated in serial BAL fluid samples obtained from term 
control group  whereas significant difference was detectable between peak PR3  and  MMP-9 
level,  figure 4.10 (A)  (median PR3 44.8 μM  vs  MMP-9 of 1.2 μM,  p =0.02). 
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4.2.5 Correlation between proteases levels 
Irrespective of the longitudinal relationship of the sample collection, each sample was 
analysed for a correlation between PR3 and MMP-9 levels to determine if there was a 
relationship between the levels. A significant correlation was found in CLD samples between 
PR3 and MMP-9 (figure 4.8B) with a Spearman correlation co-efficient of 0.65, p<0.0001. 
A similar positive correlation was also shown between PR3 and MMP-9 concentrations taken 
from infants with resolved RDS (r =0.42, p =0.01) (figure 4.9 B). As shown in figure 4.10 B, 
no correlation was found between the two proteases in the term control samples (r =0.3, p = 
0.1). 
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Figure 4.8 figures demonstrate the relationship between PR3, MMP-9 and Elastase. A) 
Scatter plot of peak concentrations of PR3, MMP-9 and elastase in CLD infants, horizontal 
lines indicate median value and significant difference is shown. B) The figure shows the 
correlation between log MMP-9 and log PR3 in CLD BAL fluid. 
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Figure 4.9 figures demonstrate the relationship between PR3, MMP-9 and Elastase. A) 
Scatterplot of peak concentrations of PR3, MMP-9 and elastase in RDS infants, horizontal 
lines indicate median value and significant difference is shown. B) The figure shows the 
correlation between log MMP-9 and log PR3 in RDS BAL fluid samples. 
 
 
P
R
3
M
M
P-
9
E
la
st
as
e
0
100
200
300
400
500 p< 0.0001
A
C
o
n
c
e
n
tr
a
ti
o
n
 (

 M
)
2 4 8
1
2
4
8
r=0.42
p=0.01
B
Log PR3(nM)
L
o
g
 M
M
P
-9
 (
n
M
)
178 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 figures demonstrate the relationship between PR3, MMP-9 and Elastase. A) 
Scatterplot of peak concentrations of PR3, MMP-9 and elastase in term infants, horizontal 
lines indicate median value and significant difference is shown. B) The figure demonstrates 
the relationship between log MMP-9 and log PR3 in term BAL fluid (ns=not significant). 
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 4.3     Discussion 
This study is a continuation to previously published work from our laboratory which 
investigated the relationship between proteases and their inhibitors in ventilated neonates and 
provided detailed analysis of the protease-inhibitor balance in infants at risk of developing 
CLD (Davies et al., 2010). 
The study group included 36 newborns all of them have gestational age less than 32 weeks. 
The median gestational age of infants who develop CLD was 27 weeks compared to 28
+6
 
weeks for infants whose RDS resolved.  The study included six full term infant as controls. 
All preterm born neonates included in the study were intubated for RDS received exogenous 
surfactant therapy and most of them had antenatal corticosteroid given 24 hours before 
delivery. Ventilation setting was adjusted to deliver low pressure, low volume ventilation 
according to the neonatal unit protocol and all infants born with respiratory distress received 
postnatal antibiotic until blood cultural were shown to be negative. On the other hand, term 
infants were ventilated post-operatively after surgical repair for gastroschisis and were 
selected for control group rather than term newborns ventilated for respiratory infection or 
birth asphyxia in order to avoid the confounding effect of infection or hypoxia on 
physiological lung function. No specific lung abnormality is linked to gastroschisis and at 
birth the lung should be healthy. 
Many studies that have examined lung lavage samples for protease analysis on infants have 
used tracheal aspirate fluid (TAF); however, this largely reflects upper airway secretions. By 
using bronchoalveolar lavage fluid this study analyses proteolytic changes from the lower 
airways, which is particularly important in new CLD where large oversimplified alveoli are 
seen. 
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No previous study has examined the concentration of PR3 in neonatal lung lavage and its role 
in the development of CLD has not been studied before. In this chapter I have measured PR3 
concentration in CLD, resolved RDS and term control infants although I could not run PR3 
ELISA in all full set of the previous study samples because some of them have been fully 
used for previous investigations by other students. The detection of PR3 level in almost all 
samples in the three study groups is different from episodic pattern of elastase activity results 
reported from the same sample set (Davies et al., 2010). 
Davies et al measured elastase activity in CLD, resolved RDS and in control term. Neutrophil 
elastase activity was detected only in 18% of total CLD BAL fluid samples (23/129), 
compared to 7% of the total BAL fluid samples from RDS groups (3/46) whereas no elastase 
activity was detected in the 23 samples obtained from control term infants. Furthermore, 
elastase activity was episodic in nature and was present only in some of the samples from 
each infant. The timing of the activity spikes was also extremely variable, with the initial 
spike of elastase activity seen at a median of 7 days after birth. They demonstrated that the 
rise of elastase activity was positively correlated with the increase in BAL fluid neutrophils 
counts. Alpha 1- anti-trypsin- elastase (AAT-E) complex was detected in 90% of CLD 
samples compared with 47% of RDS group. This may explain high PR3 concentration in 
BAL in the CLD and RDS groups  in my study  since α 1 anti-trypsin (AAT) is an inhibitor 
of elastase as well as PR3 but the affinity of elastase to bind α 1 anti-trypsin is higher than its 
affinity to PR3 (Korkmaz et al., 2005). 
MMP-9 protein peak concentrations were significantly higher in CLD group than in RDS 
infants. The same episodic pattern for elastase activity was demonstrated in MMP-9 
concentration and its rising pattern started after the second day. 
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The results of this chapter demonstrated that infants developing CLD have a significantly 
greater peak of PR3 concentration than infants with resolved RDS and term control. 
Longitudinal PR3 concentration in BAL samples of majority of the newborns closely 
parallels the pattern of MMP-9 concentration levels in the same infants i.e. the episodic 
release of these two proteases coincides in many of the BAL samples. No significant 
difference in PR3 concentration was detectable between RDS and term neonates.  
In this study I provide evidence that neutrophil PR3 is present in significant levels in 
bronchial lavage aspirates and its presence seemingly reflect a role in pathogenesis of CLD in 
neonates.  
PR3 is one of the three main neutrophil serine proteases found in neutrophil azurophilic 
granules along with cathepsin G and elastase. They share some functions, for example, their 
ability to catalyse the cleavage of proteins into smaller peptides or amino acids. Kao et al., 
1988 demonstrated that, similar to elastase, PR3 could induce experimental emphysema, 
when instilled in hamsters probably due to its ability to degrade elastin and matrix structural 
proteins. Serine proteases can also contribute to prolongation of inflammation through their 
activation and inactivation of zymogens, protease inhibitors, cytokines, growth factors and 
cell surface receptors (Owen and Campbell 1999; Witko-Sarsat et al., 2000; Wiedo et al., 
2005; Pham, 2008).  
Enzymatic activity of released proteases in lung is tightly regulated by anti-protease 
inhibitors that include AAT and elafin. A disturbance in the balance between serine proteases 
and these inhibitors is thought to play a role in neutrophil dominated lung inflammation. 
Protease-inhibitor imbalance is due to excessive neutrophil degranulation and subsequent 
release of proteases. The relation between elastase and its inhibitors, AAT and serpin was 
studied before on these samples and AAT-elastase complex was detected in 90% of CLD 
182 
 
samples compared to 47% of the RDS group. Davis et al., 2010 also found that the peak 
percentage of AAT present as complex is greater in the CLD group suggesting that even 
though elastase activity may be controlled it is still ongoing and would support the hypothesis 
that at the pericellular level elastase released lung injury could be occurring. Elastase is 
inhibited more readily with AAT due to this inhibitor higher affinity to bind elastase than 
PR3 which may explain the high level of PR3 concentration in BAL, relative to elastase. It is 
not clear whether PR3 was free or bound to inhibitors, since I did not study the relationship 
between PR3 and any of its inhibitors because of inadequate volume of the samples. However 
the relationship between PR3, elastase and elafin has been studied before and it was 
demonstrated that the efficiency of PR3 inhibition by elafin is much lower than that by other 
inhibitors of PR3 and elafin concentration is lower than AAT in the lung. Moreover, AAT 
behaves as an irreversible inhibitor of PR3, whereas the PR3-elafin complex is transient and 
dissociable, such that it could progressively be transferred to ATT (Ying and Simon 2001).  
One important observation is that, secretory leukoprotease inhibitor (SLPI) a small protein in 
the lungs can inhibit elastase and Cat G, but not PR3 (Rao et al., 1993). SLPI is present in 
epithelial lining fluid of respiratory tract at molar concentrations almost half of that of 
elastase but two thirds of SLPI recovered is non-functional. It plays an insignificant role in 
protecting the normal respiratory epithelium against elastase except in upper airways where 
SLPI accounts for 80 to 90 % of elastase inhibitory activity (Vogelmeier et al., 1991). 
Interestingly PR3 can selectively degrade oxidised and native SLPI (Rao et al., 1993). 
 
PR3 has some biochemical features that are not shared by elastase; in particular its plasma 
membrane localisation (Halbwach-Mecarelli et al., 1995).The hydrophobicity of PR3 and its 
subsequent membrane association may play a role in the resistance to proteolysis in bronchial 
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lavage fluid. Moreover, other leukocytes in addition to neutrophils, particularly monocytes 
may release PR3 adding another source to the high concentrations of PR3 especially in CLD 
and RDS groups (Witko-Sarsat et al., 1999). 
 
Only one study highlighted the role of PR3 in lung inflammation, but this study was in cystic 
fibrosis patients of an older age group. Witko-Sarsat and colleagues, measured elastase and 
PR3 in sputum of CF patients using ELISA and demonstrated that PR3 levels were higher 
than elastase concentration in CF whereas PR3 concentration was found to be lower than 
elastase in non CF bronchiolitis. PR3 contained in CF sputum is enzymatically active and the 
evidence of PR3 activity is supported by demonstrating resistance to inhibition by SLPI. On 
the other hand, lysates from purified blood neutrophils isolated from control or from CF 
patients contained approximately five times less PR3 than elastase.  
Cord blood neutrophils in my study revealed more PR3 in neonates than in adult neutrophils 
although Witko-Sarsat et al. reported that neutrophil lysates or purified azurophil granules 
contained five times more elastase. This suggests that PR3 released not only from primary 
granules but also from vesicles as well as from specific granules which are easily mobilised.  
 
The role of matrix metalloproteinases in the development of CLD remains unclear, MMP-9 is 
found in the gelatinase granules from where it is release at a lower stimulation threshold than 
elastase from primary granules upon neutrophil activation (Lominadze et al., 2005). Several 
studies investigated MMP-9 and it is role in CLD, but they give conflicting results. Most 
studies have demonstrated no difference in MMP-9 concentrations between infants who 
developed CLD and infants who have RDS (Cederqvist et al., 2001; Danan et al., 2002; 
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Ekekezie et al., 2004; Sweet et al., 2004). Dik et al. reported that MMP-9 concentrations 
were actually reduced in CLD infants compared to infants whose RDS resolved (Dik et al., 
2006). Tambunting et al. studied the role of MMP-9 in the development of CLD in baboon 
model and demonstrated that the CLD animals had high concentrations of MMP-9 compared 
to controls (Tambunting et al., 2005). In this project I found that PR3 concentrations in BAL 
fluid from CLD group had a strong and highly significant correlation with the concentrations 
of MMP-9 measured on the same samples (r 0.65 and p = <0.0001).  
In general, levels were found to start from relatively baseline, then to have sudden episodic 
spikes at variable time points after birth, but frequently occurred late following prolonged 
period of intubation. The episodic spikes for the various factors tended to be coincident and I 
hypothesised that infection was the most likely explanation. Infection has been linked 
previously with the development of CLD (Davies et al., 2006) and may be also an important 
factor in the release of neutrophil proteases. 
Proteinase 3 may lead to lung injury with other proteases including MMP-9 and elastase. 
Better understanding of the complex interaction between proteases and their inhibitors would 
facilitate effective prevention of proteolytic lung injury. Given the importance of infection in 
causing the episodic proteases spikes, appropriate approach to reduce CLD would be 
treatment of chest infection, good infection control and surveillance. 
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4.4 Summary 
In this chapter I have found that the peak level of PR3 in BAL fluid obtained from CLD 
infants was significantly higher than that in infants who had RDS and term control babies. 
PR3 concentration showed episodic spikes and displayed high variability between 
individuals. Similar findings had been demonstrated for MMP-9 concentrations. Significant 
correlation was demonstrated between longitudinal data of MMP-9 and PR3 levels in CLD 
infants and also in infants who had resolved RDS, which is in contrast to the expected 
relationship between elastase and PR3 being contained in the same granule subset (primary). 
In conclusion, my data suggest that PR3 could play a major role in proteinase-mediated 
airway damage and in the pathogenesis of lung diseases in neonates. 
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Chapter Five 
 
 
Terminal complement components 
concentration and complement functional 
activity in cord and adult sera 
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5.1     Introduction 
In the previous two chapters, the focus was on the neutrophil as a one of the cellular 
component of the innate immune system. This results chapter will therefore focus on the 
quantitative and functional aspects of complement system as an example of humoral arm of 
innate immunity that have  important role in eradication of pathogens. 
The complement system is a key player in innate immunity and its role in combating invasive 
pathogens is more prominent in newborns owing to their immature adaptive immunity. 
Hereditary deficiency of terminal complement components has been described in many 
ethnicities and studies have shown that affected individuals are prone to infections, 
particularly from Neisseria meningitides (Figueroa and Densen 1991; Pettigrew et al., 2009). 
Moreover, the virulence of many Gram-negative and -positive bacteria was attributed to their 
ability to evade complement utilising different strategies (Pausa et al., 2003; Silverman et al., 
2005; Rooijakker and Van Strijp 2007; Zipfel et al., 2007; Schneider et al., 2009). Newborn 
serum has low opsonic activity and C9 deficiency which limits the capacity to form MAC 
and hence may predispose to severe invasive infections (Høgåsen et al., 2000). 
 
Complement studies in neonates have focused on quantitative assays and also on functional 
abilities of term and preterm newborn serum, mainly measured as erythrocyte haemolytic 
activity and bacteriocidal effect on epidemiologically important Gram positive and negative 
pathogens. Invasive Ureaplasma infections primarily occur in preterm neonates with an 
immature immune system or in immune compromised patients such as those who are 
hypogammaglobulinaemic or receiving immunosuppressive therapy. This suggests an 
essential role for a healthy immune system to fight off Ureaplasma infection. However, 
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nothing is known about the interaction between newborn complement system and 
Ureaplasma parvum.  
Methods used for quantitative assay of complement components include 
immunoelectrophoresis, electroimmunediffusion, radial immunodiffusion, and 
immunonephlometry, but sensitivity and specificity of these methods are lower than ELISA 
(Høgåsen et al., 2000). Complement measurement varies with method and with genetic 
differences between populations (Sonntag et al., 1998b). Variation in precision and relative 
accuracy between these methods has been described but is not fully explained.  For instance, 
the areas of precipitation in radial immunediffusion are ill- defined in occasions (Adinolfi and 
Beck 1975). Results may also depend on anti-serum specificity and source (Buffone and 
Lewis 1977).  
The aim of this work was to optimise sandwich ELISA methods using the most sensitive 
antibodies from commercial and non-commercial sources to accurately measure terminal 
complement components in cord and adult serum. Amino acid hydrolysis was used to 
accurately quantify highly purified C6, C7, C8 and C9. I also compared the haemolytic 
activity of cord and adult serum and ability to kill serovars of U parvum before and after 
correcting low complement C6-C9 concentrations in cord serum. 
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5.2     Results 
 
5.2.1   Comparison of different monoclonal capture antibodies for purified 
C6 and native serum C6  
In order to optimise our C6 ELISA, Hycult, Quidel and non-commercial monoclonal 
antibodies from Prof. B. Paul Morgan’s (BPM) laboratory, Cardiff University were each 
diluted in coating buffer and used as capture antibodies to coat Nunc Maxisorb 96 well plates.  
Hycult antibody binding was more efficient in terms of capturing purified Quidel C6 as well 
as C6 in human serum than Quidel anti-C6 antibody. The non-commercial BPM has the 
lowest ability among antibodies to capture C6, particularly in serum (Figure 5.1 A and B). 
Subsequently, experiments were carried out to identify the best working concentration of the 
most sensitive anti-C6 (Hycult) antibody (Figure 5.1 C). The ELISA plate was coated with 
different concentration of Hycult antibody and 4μg/ml was chosen as the optimal working 
concentration of the most sensitive antibody to measure C6 level in cord and adult serum as 
well as in pooled adult sera. 
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Figure 5.1 ELISA detection using different monoclonal antibodies (mAbs) to capture 
C6.Tested capture antibodies were Hycult Biotechnology, Quidel and non- commercial BPM. 
A) Capture purified C6; B) capture native C6 in serum and C) determination of the optimum 
working concentration of most sensitive (Hycult) antibody for coating of wells. 
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5.2.2   Complement component C7 ELISA 
 Choosing the suitable capture antibody for C7 was an essential point during our assay 
development, therefore the suitability of different antibodies for capturing C7 was tested.  
The sensitivity of Hycult anti-C7 antibody to capture purified C7 and native C7 was more 
than the sensitivity obtained with anti-C7 Quidel antibody. Non-commercial BPM anti-C7 
antibody was the least sensitive antibody (figure 5.2 A and B). Polymorphism has been 
reported in C7 which is a central protein of terminal components cascades, and “N” and “M” 
alleles have been reported (Würzner et al., 1995). Hycult anti-C7 antibody WU 4-15 is a 
monoclonal antibody that recognizes only the M allele for C7 molecules. 
In this study WU-4-15 antibody was used initially for detection of C7 from cord and adult 
serum sample. I observed that WU-4-15 could detect C7 in all cord and adult sera except one 
adult serum where no C7 was detected. Since this individual had full lytic complement 
function, further investigation of this antibody’s specificity revealed that it did not detect 
other C7 alleles as shown in figure 5.3. This made WU-4-15 inappropriate for further use and 
the experiments shifted to the less optimal Quidel anti-C7 antibody. To enhance the signal for 
Quidel  anti-C7 antibody, it was determined that capturing the monoclonal antibody on plates 
coated with 4 μg/ml of rat anti-mouse IgG1 monoclonal antibody enhanced its ability to 
capture C7 and improved measurement (figure 5.2 C). Therefore Quidel anti-C7 antibody 
was used to measure the levels of C7 in cord and adult sera. Figure 5.3 B shows that no 
significant correlation was found between the C7 concentrations in adult serum obtained by 
Hycult and Quidel antibody (r = 0.4; p = 0.15), which suggests that the Quidel anti-C7 
antibody does not share a bias for a single C7 allele. 
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Figure 5.2 comparison of different monoclonal antibodies (mAbs) ability to capture 
C7.Tested capture antibodies were Hycult Biotechnology, Quidel and non- commercial BPM. 
A) Ability of tested antibodies to capture purified C7 (B) ability to capture native C7 in serum 
and (C) Effect of adding rat anti-mouse IgG antibody on the sensitivity of Quidel monoclonal 
antibody. 
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Figure 5.3 Level of C7 in adult serum, (A) C7 concentrations in adult sera using two different 
monoclonal antibodies Hycult and Quidel. Arrow points to adult VxF5 serum which probably 
has C7 N allel not detectable by Hycult antibody. It has also the lowest value when measured 
by Quidel antibody. (B)  Correlation between Quidel and Hycult C7 concentrations in adult 
sera. 
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5.2.3   Optimizing of the capture C8 ELISA 
As a first step in the development of C8 ELISA, two monoclonal antibodies were used as 
capture antibodies for purified C8 and serum C8. Figure 5.4 shows that non-commercial 
BPM anti-C8 antibody was the most efficient of the antibodies in capturing C8 for ELISA.  
Optimisation of the best working concentration was performed in serum samples and two 
micrograms/ml was the optimal working concentration for BPM anti-C8 to capture purified 
and serum C8.  
 
The ability of the selected antibodies on the basis of their sensitivity in capturing their 
corresponding complement components in purified and native form were also tested to assess 
their ability to capture C6, C7 and C8 within exogenous C5b-9 complex. Figure 5.5 shows 
that selected mAbs were also capable to capture the corresponding components even when 
the components are already assembled in the terminal complex form. 
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Figure 5.4 Ability of Quidel and non-commercial BPM monoclonal antibodies to detect C8 
by ELISA. (A) Ability of tested antibodies to capture purified C8. (B) Ability to capture native 
C8 in human serum. 
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Figure 5.5 ELISA detection using monoclonal antibodies (mAbs) to capture their 
corresponding components C6, C7 and C8 within C5b-9 complex. A doubling dilution of 
mAbs was used to coat the wells at 4μg/ml for Hycult C6, 2μg/ml for Quidel C7 and 2μg/ml 
for non-commercial anti-C8 (BPM).  
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5.2.4   Optimising ELISA for C9 
The ability of five preparations of monoclonal antibodies to recognise Quidel purified C9, 
native serum C9 as well as C9 in C5b-9 complex was compared. Antibodies were used to 
coat Nunc Maxisorb 96-well plates at a concentration 2-4μg/ml. One polyclonal anti-C9 
antibody was used to detect bound C9 (diluted 1/1000) which was subsequently visualised by 
Jackson Laboratories’ HRPO-conjugated minimum cross-reactivity Donkey anti-goat 
antibody and OPD. Antibody A223 performed the worst as a capture antibody for purified 
and native C9 as well as for C9 within the complex, figure 5.6 and 5.7. The affinity of aE11 
antibody was similarly weak in capturing purified C9 and C9 in serum but was able to detect 
C9 within C5b-9 complex. In addition, immobilising A223 and aE11 antibodies with rat anti-
mouse IgG1 monoclonal antibody did not enhance the ability of these antibodies to capture 
purified C9 and C9 within the serum, as had been achieved for the anti-C7 above. Antibodies 
WU13-15 and non-commercial B7 were the best capture antibodies for purified C9 and C9 
within the complex. Adding rat anti-mouse IgG antibody did not enhance the sensitivity of 
these antibodies to capture purified C9. On the other hand, anti-mouse IgG enhanced the 
ability of X197 to capture purified C9. B7 and X197 antibodies were the best capture 
antibodies for native C9 in serum followed by WU 13-15.  Non-commercial B7 was uniquely 
the most efficient capture ELISA antibody for C9 in all examined conditions, therefore the 
best working concentration for B7 was sought and 2μg/ml was found to be the optimal 
concentrations for measuring C9 levels in cord and adults samples.  It is important to note 
that WU-13-15 and aE11 are sold as neo-epitope C9 antibodies and that they are not 
supposed to recognise native C9.  To this end the ability of WU-13-15 to capture purified 
(and therefore potentially altered) C9 was much greater than the ability to detect serum C9, 
whereas aE11 was only effective at recognising C9 in the context of sC5b-9 complexes, 
figure 5.6 and 5.7. 
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Figure 5.6  ELISA detection using monoclonal antibodies (mAbs) to capture C9.Tested 
capture antibodies were Quidel-anti-C9 (cat.A223), Hycult Biotechnology anti-C9 (clone 
WU13-15,  X179 and aE11)  and locally available anti-C9 (clone B7). (A) Ability of these 
mAbs to recognise Quidel purified C9. (B and C) Effect of adding rat anti-mouse IgG 
monoclonal antibody on the ability of these (mAbs) to detect purified C9. 
 
0 50 100 150 200 250
0.0
0.5
1.0
1.5
2.0
2.5
B7
X197
A223
WU13-15
aE11
A
ng/ml pure C9
A
b
s
o
rb
a
n
c
e
 (
4
9
0
 n
m
)
0 50 100 150 200 250
0
1
2
3
4
A223
WU13-15
aE11
C
C9 concentration (ng/ml)
A
b
s
o
rb
a
n
c
e
 (
4
9
0
 n
m
)
0 50 100 150 200 250
0.0
0.5
1.0
1.5
2.0
2.5
B7
X179
WU 13-15
A223
B
C9 concentration (ng/ml)
A
b
s
o
rb
a
n
c
e
 (
4
9
0
 n
m
)
199 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 compares of different monoclonal antibodies (mAbs) for capturing C9. (A) Ability 
of mAbs to capture native C9 in serum. (B) Their ability to capture C9 within C5b-9 complex. 
(C) Determination of the optimum concentration of the most sensitive C9 capturing antibody 
B7, doubling dilution of mAbs was used to coat the wells starting at 1μg/ml to 4μg/ml for 
non- commercial monoclonal antibody (B7). 
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5.2.5   Levels of Terminal components in cord and adult serum 
All complement component levels measured, except C7 were lower in cord serum compared 
to adult levels (figure 5.8). Complement levels were expressed as mean with lower and upper 
95% confidence intervals (CI). Adult C7 levels were 42.29  mg/L  (36.67-47.92 mg/L), 
comparable to neonatal C7 levels of 43.03 mg/L (37.24 -48.81mg/L), while neonatal C6 
(12.84mg/L, CI 9.88-15.79 mg/L) and C8 (14.11 mg/L, 95% CI 11.22-16.99 mg/L) levels 
were 25-34% of adult C6 (37.49, CI 27.1 - 47.4 mg/L) and C8 (55.17 mg/L, 45.32-65.01 
mg/L) levels (p<0.001). Neonatal C9 levels were very low (6.4% of adult level) (2.98 mg/L, 
CI 1.63 – 4.32 mg/L) compared to adult levels (45.89 mg/L CI 36.48- 55.29 mg/L; p<0.01). 
Complement concentration values were corrected with amino acid hydrolysis correction 
factors of the provided standards (determined at Quidel) which were 0.89, 0.69, 1.705 and 
0.95 for C6, C7, C8 and C9 respectively. Optimised ELISA methods was also applied on 
international pooled adult serum to obtain reference adult levels of C6-C9.When compared 
with cord serum samples the results showed the same statistically significant differences 
figure 5.9.  The reference adult values for C6, C7, C8 and C9 expressed as mean ( ± 95% CI ) 
were 30.89 mg/L (CI 17-44.7 mg/L), 45.67 mg/L (CI 41.7-49.6), 46.36mg/L (CI 45.1-47.5) 
and 35.45 mg/L (CI 33.1-37.8) respectively. Cord/pooled serum percentages were 41.55%, 
94.34%, 30.43% and 8.37% for C6, C7, C8 and C9 respectively. 
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Figure 5.8 Scatter plot showing levels of terminal complement components in cord and adult 
sera,  C6 (A), C7 (B), C8 (C) and C9 (D). Mean levels differences were highly significant, (p 
<0.0001) for C6, C8 and C9 whereas no statistically significant difference was found for C7 
level in cord and adult serum. Horizontal lines represent the mean.     
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Figure 5.9 Levels of terminal complement components in cord and international pooled adult 
sera. Levels shown as mean ± SEM. (***) denotes highly significant difference, p <0.0001. 
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5.2.6 Haemolytic activity of cord serum and the effect of C9 
supplementation  
Haemolytic activity in cord sera was found to be markedly lower than adult levels. 
Achievement of 50% haemolysis level required an average serum dilution of 1/22 for adult 
compared to 1/12 for cord (p <0.05). However, when cord sera were supplemented with 
purified C9, the most deficient terminal component, to a concentration of 50 mg/L. The 
resulting neonatal CH50 values were equivalent to adult values despite low C6 and C8 levels 
in cord sera (Figure 5.10). 
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Figure 5.10 Haemolytic activities of cord and adult sera. Inverse dilution of cord and adult 
sera to achieve 50% haemolysis of antibody-sensitised sheep erythrocytes are shown. Limited 
CH50 in cord sera were restored by adding purified C9 (final concentration 50 mg/L). 
Significant differences are shown in the figure, ANOVA test, n=20). 
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5.2.7   Analysis of the complement killing assay of Ureaplasma parvum 
The killing assay described in material and methods chapter, section 2.3.5 enabled the 
determination of magnitude of Ureaplasma killing by six adult sera and 14 cord sera. 
Occasionally, wells were observed in which colour change was absent although subsequent 
wells further down concentration were positive (figure 5.11). To keep consistency in 
determining 1 CCU ( the final well in which colour change occurs), negative wells were 
counted as positive if a single negative well was subsequently followed by two or more 
positive wells. In addition, to rule out any bias in spontaneous negative wells within the 
titration, all killing assay experiments were repeated in duplicate on independent days. As 
degree of killing was calculated from the relative bacterial growth following exposure to 
matched sera with complement intact (NHS) or following heat-inactivation (HI) controls, 
poor growth following exposure to HI control could result in an artificially low killing. 
Therefore, only experiments where bacteria exposed to HI serum that grew to at least 10
3 
CCU were considered valid. 
5.2.8   Cord and adult sera variation in SV1, 3, 6 and 14 killing by 
complement pathways 
The ability of 50% cord serum to kill representative strains of each U parvum serovar is 
shown in figure 5.12. When all activation pathways were available, 2/14 cord sera reduced 
the CCU of DFK-1 (SV1) by greater than 1000-fold, 6 /14 reduced CCU by 10 to 100-fold, 
while no killing (<10-fold killing) was observed for 6/14 (figure 5.12 A). Twelve out of 14 
cord sera reduced HPA5 (SV3) CCU by greater than 1000-fold, (1/14/) reduced CCU by less 
than 1000-fold and the final cord (1/14) reduced CCU by 100 fold (figure 5.12 B). 
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Figure 5.11 Complement killing assay to determine the bactericidal activity of cord and adult 
sera. The four representative serovars of U. Parvum were DKF-1 (SV1), HPA5 (SV3), HPA2 
(SV6) and HPA32 (SV14). (A) The killing capacity of 50% normal cord serum (NCS). (B) 
Killing of all serovars by normal human serum (NHS).  Pink wells represent growth of 
Ureaplasma whereas yellow wells represent absence of growth. Killing was determined by 
calculating the fold decrease in CCU from NHS relative to the heat-inactivated normal 
human serum (HI-NHS) control.( yellow colour  wells indicate  no killing while pink colour 
indicates killing). 
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A single serum decreased HPA2 (SV6) CCU by greater than 10-fold, and the remaining 13 
sera decreased numbers by less than 10 –fold (i.e. not significant killing; figure 5.12 C). No 
killing of HPA32 (SV14) was seen for any of the cord sera, figure 5.12 D. Therefore, no 
significant killing of SV6 or SV14 could be mediated by cord sera. 
In comparison, bactericidal effect of adult sera (figure 5.13) showed greater degree of killing 
where a single adult serum reduced HPA5 (SV3) CCU by greater than 1000 fold, while the 
five remaining adult sera decreased the CCU by greater than 10,000 fold. All adult sera were 
able to reduce DKF1 (SV1) CCU by greater than 10-fold relative to heat-inactivated controls; 
the greatest bactericidal activity was observed up to 10,000 fold killing.  A single adult serum 
decreased HPA2 (SV6) CCU by greater than 10 fold whereas the remaining five sera reduced 
numbers by less than 10 fold. All six adult sera failed to kill HPA32 (SV14) as evidenced by 
less than 10 fold reduction in CCU.  This indicates that adult sera were equally as poor at 
killing SV6 and SV14 as were cord sera. 
In Summary, complement-mediated Ureaplasmacidal effect of adult sera was greater in SV1 
than cord sera whereas both sets have almost equal bactericidal ability to eradicate SV3. 
Servars 6 and 14 were resistant to killing by cord as well as adult serum. Figure 5.14 shows 
the mean Ureaplasmacidal capacity of cord and adult sera against all serovars, when results 
are combined for comparison. 
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Figure 5.12 -The Killing capacity of cord sera against the four serovars of U. Parvum. (A) 
SV1 isolate DKF1, (B) SV3 isolate HPA5, (C) SV6 isolate HPA2 and (D) SV14 isolate 
HPA32.  Each number in the x axis indicates individual cord serum.  
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Figure 5.13 The Killing capacity of adult sera against four serovars of U. Parvum. (A) SV1 
isolate DKF1, (B) SV3 isolate HPA5, (C) SV6 isolate HPA2 and (D) SV14 isolate HPA 32. 
Each number in the x axis indicates individual adult serum. 
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Figure 5.14 The Killing capacity of cord compared to adult sera against the four serovars of 
U. Parvum. (A) SV1 isolate DKF1, (B) SV3 isolate HPA5, (C) SV6 isolate HPA2 and (D) 
SV14 isolate HPA 32. 
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5.2.9   Titration of serum for killing capacity 
 
I determined the capacity of different serum concentration (titrated serum) for complement-
mediated U parvum killing assay. To see if complement component concentration played a 
role in the degree of ureaplasmacidal activity at different serum dilutions, a series of killing 
experiments for six adult and seven  cord sera were performed at 2-fold dilutions from 50% 
to 6.25% (figure 5.15).  The fold-killing of different concentrations of adult and cord sera for 
SV1 and SV3 are shown.  The bactericidal effect of cord and adult sera on SV1 was directly 
proportional to the concentration of serum used.  A 10-fold decrease in SV1 killing was seen 
for adult sera when concentration decreased from 50% to 25% and no significant killing was 
observed at 12.5% or lower. In line with lower complement component concentration,   
killing of SV1 by 50% cord serum was similar to the bactericidal effect of adult serum   25% 
concentration. No significant killing was observed at 25% or lower cord concentration (figure 
5.15A). The level of adult and cord  serum killing of SV3 was almost the same at 50% or 
25% serum concentration but killing capacity dropped equally  by about 10-fold at 12.5% and 
then became insignificant at 6.25% in adult serum while  at this concentration cord serum 
was still able to kill SV3. In conclusion, unlike SV1 killing, cord sera killing of SV3 were 
equivalent to adult killing, until diluted to 6.25% when it was higher than adult sera (figure 5. 
15 B). 
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Figure 5.15 The ability of varying concentrations of adult and cord sera to kill (A) SV1 and 
(B) SV3. Red bars represent killing of adult sera and blue bars represent the killing of cord 
sera. Numbering of x-axis represents concentration of sera. 
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5.2.10 The supplementation of complement component C9 alone or 
combined with C6 and C8 did not change the bactericidal capacity of 
neonatal serum against U parvum   
The bactericidal ability of neat 50% cord sera against SV1 and SV3 was not enhanced with 
serum supplementation with 5μg/ml of Quidel purified C9 (Figure 5.16). Since complement 
component C9 and to a lesser extent, C8 and C6 were the most deficient terminal components 
in neonatal serum; 50 μg/ml of each component was added to the selected cord serum. 
Serovar killing in response to incubation with cord sera was compared in parallel to the same 
sera supplemented with C6, 8 and 9. Figures 5.17 and 5.18 show that supplementation of cord 
serum with C6, C8 and C9 did not change its bactericidal effect on SV1, SV6 and SV14. 
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Figure 5.16 Effect of Supplemental C9 on the bactericidal activity of cord sera against (A) 
SV1, (B) SV3. Each number in the x axis indicates individual cord serum. Green bars 
represent serum supplemented with C9; Brown bars denote serum without C9 supplement.  
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Figure 5.17 Effect of adding purified C6, C8 and C9 on the ability of cord sera to kill the four 
different serovars of U Parvum. Complement C6, C8 and C9 supplement did not enhance the 
Ureaplasmacidal capacity of cord serum. Green bars represent serum supplemented with C6, 
8 and 9; Brown bars denote serum without supplement of C6-9. 
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Figure 5.18   Complement killing of cord serum supplemented with C9 or combination of C6, 
C8 and C9. (A) Effect of adding C9 on the capacity of cord serum (NCS) to kill SV1 and SV3. 
(B and C) Ureaplasmocidal effect of cord sera supplemented with C6, C8 and C9 on the four 
representative serovars of U Parvum (B) DKF-1 (SV1), HPA5 (SV3), (C) HPA2 (SV6) and 
HPA32 (SV14). Killing was determined by calculating the fold decrease in CCU from NCS 
relative to the heat-inactivated normal cord serum (HI-NCS) control. (Yellow colour wells 
indicate no killing and pink colour indicates killing) 
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5.2.11   Detection of anti- Ureaplasma IgG responses within serum by 
Western blots 
In order to detect the presence of any anti- Ureaplasma antibody in cord serum, Western blot 
analysis was performed using the 14 cord sera samples to detect reactivity against the four 
serovars representatives of U. parvum (figure 5.19). The blots from cord 1 and 2 show the 
two seronegative sera in this study. These membranes were subsequently probed with 
seropositive serum to rule out the possibility of false negative results. Blots from cord 3 and 4 
had similar banding patterns of each respective serovars. DKF-1 lanes produced a dark band 
of just greater than 60 KDa; this band was conserved across all serovars blotted with these 
sera but with greater intensities. A second less intense band of just greater than 70KDa was 
also observed in most of the blotted sera for DKF1, showing the same pattern previously 
observed in adult serum by Beeton et al 2012. These bands do not correlate with a greater 
degree of SV1 killing. Serum from cord sample 14 revealed a conserved band from all 
serovars between 43 and 65 KDa, similar band was observed in sample 3, 4, 7 and 11. 
 
An additional clear band about 41 kDa for HPA5 was also observed for most cord sera except 
in negative cord samples 1 and 2 along with cord 13 which showed the lowest killing 
capacity of SV3. Similarly, another band was seen for all serovars of about 84 KDa in most 
cord sera. HPA2 had a unique band with a slightly higher than 72KDa for cord 3 and 4. Cord 
7, 12 and 14 produce a number of bands to each isolates with varying intensity. A final 
intense band of high molecular weight (around 130KDa) was seen in the lane containing 
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HPA32 of cord 3, 4, 6, 7, 8, 9 and 11sera. Due to using whole-cell lysates the bands present 
on the Western blot represented both internal (non-complement activating) and external 
(complement activating) antigens and individual band reactivity or intensity may not 
necessarily relate to magnitude of killing by serum.  
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Figure 5.19 Immunoblots of SV1 isolate DKF-1, SV3 isolate HPA5, SV6 isolate HPA2 and SV14 
isolate HPA32 probed with cord serum. Each blot image denotes individual cord serum. 
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5.3   Discussion 
 
5.3.1   Terminal complement components levels (C6, C7, C8 and C9) 
The concentrations of terminal complement components have been reported by a number of 
studies and they found that newborn serum contains low levels of these components 
compared to adults (Davis et al., 1979; Johnston et al., 1979; Drew and Arroyave, 1980 
Stonntag et al., 1998b). The same findings were observed in our study where serum of 
normal full term newborns was low for components (C6, C8 and C9) of terminal complement 
system pathway compared to adult levels. One exception was C7 which was identical to adult 
level. Compared to adult levels, the average term neonatal levels of C6 was 12.8 mg/L 
(34.2% of adult level), C7 was 43 mg/L (101%), C8 was 14.1 mg/L (25.5%) and C9 was 2.9 
mg/L (6.4%). In addition, the concentrations of these components were compared with 
international pooled adult standards and the percentages were 41.5, 94.3%, 30.4% and 8.3% 
for C6, C7, C8 and C9 respectively. Previous studies of terminal complement components 
levels in full term infants compared to adults ranged between 44-58 % for C6 levels, whereas 
its level in preterm neonates was 35-39 % and similarly low C8 level was demonstrated in 
term and preterm neonates with levels of 36-38% and 29% respectively.  Reported C7 was 
95-120% in term neonates in keeping with our results while adequate C7 level was 
demonstrated even in preterms as well at 73-75% (Adinolfi et al., 1981; Lassiter et al., 1992; 
Wolach et al., 1997).   
One of our adult samples in this work had no detectable C7 when tested with Hycult mAb. 
This is consistent with the known polymorphism of C7 which was first detected based on 
charge difference by isoelectric focusing. C7 M/N polymorphism was another allotyping 
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based on reactivity to allospecific mAb. WU 4-15 recognizes all C7 molecules in 
homozygous C7
*
 M individuals and 50% of C7 in heterozygotes but the reaction is very weak 
in C7
* 
N homozygous individuals which is the allotype of this individuals. C7
* 
M 
homozygous alleles is present in 99% of Caucasians (Würzner et al., 1992).  Whereas the 
serum in our study that failed to react with WU 4-15 came from an individual from Tibet. 
 
 Levels of C9 were consistently low in previous studies but values varied considerably 
possibly due to different methodology. Higher percentage of C9 in cord relative to adult 
serum (50-55%) was reported by only one group of researchers using single radial 
immunodiffusion (RID) (Wolach et al., 1994; Wolach et al., 1997). Other groups reported 
cord C9 levels of 10-20% of adult level (Davies et al., 1979; Adinolfi et al., 1981; Høgåsen et 
al., 2000). Moreover,  more recent study reported a median level that is 10.8% of adult levels 
and interestingly 13% of 72 newborns had C9 levels less than 2% of adult values (range of 
0.6- 35.2 %) . Profound C9 deficiency in this study was correlated with gestational age and 
with ability of cord serum to form MAC (Høgåsenet al., 2000). Ueda et al. (1980) studied C9 
in 2 groups of full term newborn on basis of their weight for gestational age. Both groups 
appropriate for gestational age (AGA) and small for gestational age (SGA) had C9 levels of 
2.8 mg/ L which was 12% of maternal level. Maternal reference values are known to be 
higher than non- pregnant adults and in one study maternal C9 level was approximately 
double the amount of C9 in non-pregnant adult serum (Adinolfi et al., 1981). 
Another difference between our present data and most of the previous reports in addition to 
method was the way of measurement and how levels were presented.  Most previous reports 
expressed complement components levels solely as percentage rather than expressing the 
result in actual units like mg/ml. 
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Here in, amino acid hydrolysis was additionally used to accurately quantify affinity purified 
C6, C7, C8 and C9. The results of the present study are in accord with previous work 
demonstrating that terminal complement levels are 40-80% lower in infant than in the older 
child and adults (Ballow et al., 1974; Feinstein and Kaplan 1975; Adamkin et al., 1978).  
 
5.3.2   Synthesis of terminal complements components  
Complement in newborn are synthesised by the foetus since complement components are not 
transferred across the placenta (Ueda et al., 1980). The liver is the major site of synthesis of 
complement components (Ramadori et al., 1984) and C9 is known to be one of the acute 
phase proteins (Adinolfi and Lehner 1988). Evidence was also obtained from research on 
hepatoma cell lines which was able to synthesise terminal components C5, C6, C7 and C8 
(Morris et al., 1982). Other tissues and cell types could produce C6 to C9 in vitro and extra 
hepatic synthesis of complement was reviewed by Morgan and Gasque (1997). Human 
umbilical vein endothelial cells have been shown capable of in vitro synthesis of all terminal 
complements C6-9 (Johnson and Hetland 1991; Langeggen et al., 2000., Langeggen et al., 
2001). Similarly, peritoneal macrophages could synthesise complements C5 to C9 (Hetland 
and Bungum 1988).   
Neutrophils were demonstrated to store large amounts of C6 and C7 that could be released 
upon stimulation. This store was not due to uptake from the serum nor synthesised in 
neutrophils but probably pre-synthesised during myelopoeisis (Høgåsen et al., 1995). 
Pulmonary synthesis of C5-9 was demonstrated by incorporation of radiolabelled amino acids 
in complement synthesised by type II pneumocytes and fibroblast cell lines derived from 
lung. Synthesised complement C5-C9 were visualised by autoradiography of double 
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immunodiffusion plates (Rothman et al., 1989). Platelets could also secrete C9 and C8 and to 
lesser extent C5, C6 and C7 when stimulated in vitro (Houle et al., 1989). 
C7 level in cord is uniquely higher than levels of other terminal components. In addition, it is 
not an acute phase protein and therefore hepatic rule in C7 synthesis was re-evaluated. In vivo 
studies following orthotopic liver transplant supported the view that liver is the primary site 
of C6 and C8 synthesis, but not C7 (Hobart et al., 1977; Alper et al.,  1980; Würzner et al., 
1994). C7 was also detected in 2 siblings after renal transplant. Both of them had 
homozygous mutation in C7 gene leading to C7 deficiency, but transplant restored 
haemolytic activity and C7 was maintained at plasma level of 7-9% of normal values. C7 
synthesis is believed to be in endothelial cells in the kidney (Rameix-Welti et al., 2007).   
 
5.3.3   CH50 
CH50 is considered the best single measurement of the functional integrity of the cascade of 
complement. Haemolytic activity is a useful indicator of complement component deficiencies 
since homozygous complement deficient individuals usually have abnormal CH50. In 
general, complement activity must be decreased by more than half to affect CH50 (Pettigrew 
et al., 2009).   
The results of the present study show that haemolytic activity CH50 in cord sera was 
markedly lower than CH50 in adult sera. Fifty per cent haemolysis level was obtained with an 
average adult serum dilution of 1/22 compared to 1/12 for cord serum (p <0.05) with  CH50 
cord/adult ratio of 0.54 in keeping with previous studies where CH50 ratio compared to adult 
levels which was about 60% as shown in Table 5-1 with a range between 43% to 90% 
(Sawyer et al., 1971; Johnston et al., 1979;  Strunk et al., 1979; Shapiro et al., 1981; 
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Notarangello et al., 1984; Ferriani et al., 1990;  Sonntag et al., 1998b). Sawyer et al were the 
only team to report a level as high as 90% but there study included only 6 newborn and 4 of 
them had haemolytic disease of newborn which probably affected the result. The ratio 
dropped to 60% when compared to maternal CH50 (Sawyer et al., 1971). Another group of 
studies reported lower CH50 in newborn when compared with that of their mothers (range 
was 24-60%) due to higher CH50% in mothers than in non-pregnant adults (Kohler, 1968; 
Fireman et al., 1969; Adinolfi, 1970; Sawyer et al., 1971, Pedraz et al., 1980). High maternal 
CH50 could be related to higher levels of complement components, especially C9 which was 
reported to be double the level of non- pregnant adults (Adinolfi et al., 1981). 
 
In the present work, quantitative analysis of terminal complement components showed that 
C9 was the most deficient component in cord sera (6.4% of adult level). When cord serum 
was supplemented with purified C9, CH50 results were restored to adult values despite the 
lower C6 and C8 levels (34.2 and 25.5 % respectively).  
Haemolysis is due to production, deposition, and subsequent action of activated C5-C9 
complex on the target cells.  Since terminal complement components C6, C8 and C9 were 
demonstrated to be low in cord sera, it would be reasonable to expect that the observed defect 
in haemolytic activity of cord sera reflects their inadequate levels. In agreement with this, 
Adamkin et al., 1978 found that cord serum CH50 was more than 2SD below the mean CH50 
of adult serum. Addition of purified C5 to C9 to cord serum to obtain final levels equivalent 
to these components level in normal adult serum only partially restored CH50. Maximal 
CH50% of cord sera was achieved by adding factor B and properdin along with components 
C3-C9. A study in newborn rats showed similarly low C9 levels and reduced haemolytic 
activity that was partially restored when exogenous human C9 was supplemented in vivo to 
newborn rats or added in vitro to their serum. Haemolytic activity matures gradually to 80% 
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in 3 weeks old rats. Moreover, haemolytic activity was better in unsupplemented sera taken 
from 1 week old rats than in sera from 2 days old supplemented with human C9 which may 
be explained by species specific affinity of native C5b-8 complex to bind more avidly to rat 
C9 than to exogenous human C9 (Lassiter et al., 1997). In addition, adding purified porcine 
C7 restored haemolytic activity of C7 depleted human serum in a dose dependent manner 
which denotes a high degree of functional and structural similarities of C7 in these species 
(Agah et al., 2000).    
Fujita et al. (1992) in a case report of a 7 year old Japanese boy diagnosed with hereditary C9 
deficiency showed that serum haemolytic activity of this boy was 30% of the normal CH50 
level. In other reports of patients with hereditary deficiency of complement components, low 
haemolytic activity was restored when the deficient components were added to the serum. 
Würzner et al 1992 found that previously undetectable CH50 level in C6 deficient patient 
was restored when purified C6 supplement or normal human serum was added. 
 
 
In a study from Korea, CH50 of C9 deficient individuals was approximately 30-40% of NHS 
(Kang et al., 2005). In the absence of C9, MAC consisting of C5b through C8 haemolyses 
erythrocytes, although its efficiency is lower than that of the C5b-9 MAC (Kang et al., 2005).   
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Table 5.1 Percentage of CH50 activity in term newborn relative to maternal CH50 ( ) and 
healthy adult volunteer serum 
Study Number of newborn 
studied 
CH50 percentage  
Kohler, 1968 23 (60)  
Fireman et al., 1969 24 (53)  
Sawyer et al., 1971 6-11 (60), 90  (Compared with 
(Maternal) and adult 
serum. 
Notarangelo et al., 
1984 
12 56  
Johnston et al., 1979 27   
Pedraz et al., 1980 58 (29)  
Drew and Arroyave  
1980 
11 52  
Strunk et al., 1979 30 81  
Shapiro et al., 1981 11 (AGA) 66  
 17 (SGA) 65  
Wolach et al., 1997 34 69  
Sonntag et al., 1998 125 43 median  
Present work 20 54  
 
 
 
5.3.4   Analysis of the complement killing assay 
Humoral and cellular innate immunity are the first line of body defence against invading 
pathogens. The role of innate immunity is more crucial in newborn infants whose adaptive 
immune response is not functioning to its full capacity. The established predisposition of 
neonates to infection promotes extensive research on infants’ response to pathogens. My  
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work assessed the complement mediated cytolytic activity of cord sera compared to adult sera 
against Ureaplasma parvum which was brought to attention lately as an important perinatal 
pathogen and potential suspect in pathogenesis of CLD.      
Ureaplasma which is a commensal organism in the urogenital tract in many asymptomatic 
people have been reported to be the most commonly isolated organism from mothers 
especially in preterm labour (Cassel et al., 1986, Yoon et al., 1998). Abele-Horn et al. 
showed that from 170 mothers positive for Ureaplasma colonisation 10% experienced 
chorioamnionitis compared to none of the Ureaplasma negative group.  Moreover, 35% of 
the Ureaplasma positive group had premature rupture of the membranes compared to 12% in 
the control group and 41% delivered prematurely compared to only 10% (Abele-Horn et al., 
1997). Intrauterine infections and the ensuing inflammatory response results in the production 
of prostaglandins leading to uterine contractions, cervical dilations and membrane rupture 
and preterm delivery (Waites, 2005). A number of conditions in neonates have been 
associated with Ureaplasma infection following transmission from the mothers which include 
meningitis, systemic infection, pneumonia and CLD. 
Bactericidal effect of newborn serum on Ureaplasma parvum serovars was studied in this 
chapter in the context of quantitative and functional investigation of neonatal complement 
system.  
The killing assay described in this study was successfully used in our laboratory to identify 
the bactericidal activity of 12 sera from healthy adult volunteer against different strain of U 
parvum (Beeton et al., 2012). Here in, I used the same method to identify the bactericidal 
activity of 14 cord sera against the four serovars of U parvum compared to bactericidal effect 
of adult sera. The results in this study showed that all cord sera could kill Ureaplasma 
serovar (SV3) equivalently to adult serum even when samples from both groups do not have 
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specific anti-Ureaplasma IgG antibody when tested by immunoblotting. Two cord sera (14 
%) killed SV1 by > 1000 fold compared to 5/12 adult (41 %).  None of the cord sera could 
kill SV6 or SV14 in contrast to adult sera where 5/12 samples killed SV6 (41 %) and 4/12 
killed SV 14 (33 %). Complement components C6, 8 and 9 were lower in cord than in adult 
sera as shown in section 5.2.5. However, adding these purified components to compensate for 
their deficiency in cord sera did not restore its bactericidal activity against SV6 or SV14 
killing despite the presence of multiple anti-Ureaplasma IgG bands in the cord serum. Of 
note, adult samples capable of killing SV6 or 14 seem to be bactericidal for all serovars.  
 Serovars 1 and 6 were the most prevalent serovar isolated from a group of pregnant women 
who delivered prematurely (Fernández Molina et al., 2003; Knox et al., 2003; Yi et al., 
2005). SV6 was the most common serovar identified in semen samples after a standard 
washing procedure used during assisted reproduction hence SV 6 is more adherent to host 
cells than other Ureaplasma serovars ((Knox et al., 2003). This finding is not completely 
understood but it could be potentially related to serovar pathogenicity and virulence.  
 
Beeton et al., 2012 demonstrated that classical pathway is the predominant complement 
pathway involved in killing of all serovars. In addition, they speculated that killing of SV1, 
SV6 and SV14 was dependent upon the presence of IgG subclasses1, and 3 whereas killing of 
SV3 was C1q-dependent, but independent of any detectable anti-ureaplasma 
immunoglobulin.  
Benstein et al., 2004 previously reported the ability of MBL from multiple species to bind 
SV3; however, they did not investigate complement activation or bactericidal activity. 
Minimal role of alternative and lectin pathways in U parvum serovar killing is supported by 
the negligible killing noted in the absence of Ca
2+ 
and MBL, respectively.  Furthermore, all 
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killing was abrogated by the addition of a function blocking anti-C1q monoclonal antibody, 
substantiating the classical pathway as responsible even for SV3 killing (Beeton et al., 2012). 
MBL levels have been reported significantly lower in preterm neonates but no difference was 
demonstrated between its level in full term neonates and adults (Lau et al., 1995). However, 
ureaplasmacidal effect was recently attributed to surfactant protein A, one of the collectins, 
which by opsonisation enhances ureaplasmacidal effect of macrophages (Okogbule-Wonodi 
et al., 2011). Moreover, the role of SP-A is illustrated by a study of SP-A knock- out mice 
with experimental U parvum pneumonia where delayed clearance of the infection as well as 
exaggerated inflammatory response was shown (Famuyide et al., 2009). SP-A binds equally 
to U parvum SV1, SV6 and U urealyticum serovars. We did not measure the level of SP-A in 
our study but it is known that SP-A is increased progressively with gestational age (Kaneko 
et al., 2001). However, SP-A does not activate complement and opsonisation for cellular 
ureaplasmacidal activity would not influence our cell-free killing assay. Other pathogen 
recognising receptors such as TLRs are engaged in recognising Ureaplasma and induction of 
inflammatory mediators release by macrophage and neutrophils. SV3 activates NF-K
B
 
through TLR2 in cooperation with TLR1 and TLR6 (Shimizu et al., 2008). 
Bacteriolysis probably plays an important role in intrauterine confinement of infection thus 
prevention of blood stream invasion by bacteria that are usually sensitive to the complement -
mediated bactericidal activity in serum, such as  serum killing capacity shown for E coli 
(Lassiter et al., 1992).  
 
In normal serum, cytolysis may occur when complement proteins are assembled on the 
bacterial surface to form the membrane attack complex (C5-9). The process of bacteriolysis 
may be initiated after activation of the classical pathway or alternative pathway of the 
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complement. During activation of the classical pathway, C3b covalently binds to the bacterial 
surface, resulting in the formation of the C4b-2a-3b complex, which has the capacity to 
cleave C5 to C5a and C5b. Membrane bound C5b may then bind C6 and C7 to form a 
trimolecular complex, which may insert into the outer membrane surface of the bacteria 
(Hammer et al., 1975). C8 then binds to C5b-6-7 to cause leakage of ions (Kolb et al., 
1972).The subsequent binding and polymerisation of several molecules of C9, a factor 
required for the efficient complement- mediated cytolysis, resulting in the formation of a 
large more stable membrane attack complex (Kolb et al., 1972; Joiner et al., 1985). Many 
studies found that the insertion of MAC into the cell membrane may result in sufficient injury 
to cause death of the bacteria (Joiner et al., 1985; Mackay and Danker 1990).  
  
It is reported that there is an absolute requirement for all five components (C5b, 6, 7, 8 and 
C9) of this lytic complex for killing of a number of gram negative bacteria (Schreiber et al., 
1979). Studies reported that poly C9 may be required to trigger a process of bacterial inner 
membrane dissociation (Kroll et al., 1983, Taylor and Kroll, 1984). 
In adults with genetic deficiency of the proteins that constitute the MAC, investigators 
reported predisposition to recurrent Gram negative sepsis caused by some species like 
Neisseria (Würzner et al., 1992).  The concentrations of C8 and C9 in the serum of human 
neonates have been reported to be 10-20 % of the concentration measured in serum from 
adult (Ballow et al., 1974) and the result of this chapter agreed with previous reports. The 
limited ability of neonate serum to eradicate bacteria may be due to insufficient 
concentrations of one or more of heat- stable complement proteins of the classical or the 
membrane attack pathway (C5-C9). However, supplementation of deficient components of 
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cord serum complement C6, C8 and C9 did not alter its Ureaplasmacidal capacity against the 
tested serovars. 
 This work on bactericidal capacity of cord serum resembles Lassiter’s work on cord serum 
bactericidal effect against an important Gram negative neonatal pathogen, E coli. In vitro 
studies on cord serum showed that supplement of deficient C9 restored the killing capacity 
against E coli (Lassiter et al., 1997).  The group did an experimental study on a rat model in 
which supplemental C9 enhanced the capacity of neonatal rats to kill pathogenic E coli. 
Survival of infected rats was positively correlated to the concentration of C9 and with 
bactericidal activity of the serum. Intra-peritoneal injection of C9 diminished the intensity of 
infection and enhanced survival of infected rats but protection was limited because of short 
half- life of exogenous C9 (Lassiter et al., 1997). However, in the present work I did not find 
any change in the degree of Ureaplasma killing capacity of cord serum supplemented with 
C9.  Joiner et al. (1985) found that the precise immunological mechanism responsible for the 
diminished capacity of neonatal serum to kill U parvum is not clear yet.  
Moreover, in a preliminary step, I added freshly purified cord neutrophils to Ureaplasma 
serovar culture to assess ureaplasmacidal effect of neutrophils on all serovars but no killing 
was observed. In a previous study, neutrophils isolated from healthy adults were able to 
phagocytose Ureaplasma in absence of antibody opsonisation. However, engulfed 
ureaplasma remained viable after phagocytosis which could be of pathogenetic importance. 
Adding complement enhanced the release of chemiluminescence and the role of complement 
is also supported by activation of C1q by Ureaplasma.  
Killing of Ureaplasma serovars is modified not only by host factors but also by serovar 
variation in resistance to host immune response and on its inherent virulence factors. IgA 
protease, urease, phospholipase A and C are suggested Ureaplasma virulence factors (Glass 
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et al., 2000). Resistance to host defence and pathogenesis of chronic Ureaplasma parvum 
infection was also linked to difference in serovar ability to form protective biofilm (García-
Castillo et al., 2008). 
5.3.5   Serological status of the cord sera  
To determine the serological status of the cord sera, Western Blots containing whole-cell 
lysates of Ureaplasma antigen were probed with 14 cord sera (Figure 5.19). Twelve samples 
out of the 14 examined sera showed some degree of reactivity, whereas, two were fully 
seronegative for anti- Ureaplasma IgG antibodies. To ensure the negative results were not 
falsely negative, the blots were subsequently probed with seropositive serum where expected 
banding was seen, therefore ruling out poor transfer. These seronegative sera failed to kill 
SV1, SV6 and SV14 but could kill SV3. A variety of different and conserved banding 
patterns of varying intensities was elicited by seropositive cord sera when blots were probed. 
High levels of killing were associated with the presence of multiple bands of higher binding 
intensity in cord samples 5, 6, 9 and14. An exception to this role was the absence of reaction 
to SV14 isolate HPA32 when exposed to cord 6, 7, 9 and 11 although high molecular weight 
band around 130KDa was seen. An interesting observation was the banding patterns 
produced by most cord sera against SV1 isolated DKF-1which was similar to that of adult 
sera described by Beeton et al 2012 who detected bands of 60 and 70 KDa. In a number of 
cases, such as with cord 14, bands were present but the degree of killing was minimal. This 
may represent an antibody response which was raised against internal antigens which would 
not be exposed in intact viable cells but manifested after cell lysis. Of course activation of 
complement can only occur following binding of the antibody to antigens present upon the 
surface of bacteria, and as western blot dose not distinguish between surface and internal 
antigens this could account for this finding.  
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5.4    Summary 
This chapter has described an ELISA assay to measure the levels of terminal complement 
components and the function activity of the complement system in cord serum compared to 
adult. The key findings were that newborn serum contains low levels of C6, C8 and C9 with 
the exception of C7 which was identical to adult level. The haemolytic activity in cord sera 
was lower than CH50 in adult sera but adding C9 to cord sera restored its CH50 to adult 
level. Additionally this chapter has described an assay to quantify the bactericidal effects of 
cord and adult serum upon clinically important serovars of Ureaplasma parvum. The 
bactericidal capacity of neonatal serum compared to adult serum was impaired especially 
against SV1. SV3 was the most serum sensitive serovar whereas killing of the resistant 
serovars SV6 and 14 could not be induced by addition of the deficient components C6, C8 
and C9. 
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Chapter Six 
 
 
General Discussion 
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6.1     Overview 
 
In this thesis I have sought to compare some aspects of the cellular (neutrophils) and non-
cellular (complement) parts of innate immune system in newborns and adults. My research 
concentrated on the levels and functional activities of the triad of neutrophil proteases (PR3, 
Elastase and Cat G) released by primary granules, including exocytosis on certain neutrophil 
granule specific markers. I have sought to examine the differences in neutrophil surface 
expression of membrane proteinase 3 (mPR3), CD177, CD63, CD66b, CD35 and CD43 in 
cord and adult neutrophils. I have paid particular attention to the role of different stimulants 
in up-regulating the expression of these markers. Furthermore, intracellular levels of PR3, 
CD177, CD63, CD66b, CD43, CD35, SerpinB1, C5aR and C3aR were also examined in the 
resting neutrophils. Different neutrophil stimulants were used to determine whether any 
observed difference in release or surface expression of these neutrophil granule contents was 
due to variation in mobilisation, or related to inherent difference in total cellular amounts for 
adult and cord neutrophils. I have focused in detail on the functional and quantitative levels 
of terminal components C6, C7, C8 and C9 in neonates compared to adults. In addition, I 
have examined the role of complement activation pathways for the killing of U parvum in an 
in vitro system. 
6.2     Cord blood neutrophil 
Little is known about neutrophil function in neonates in relation to adult. Therefore, I studied 
the effect of maturity on human neutrophils degranulation among full term healthy neonates 
and adults. CD177 is a specific neutrophil antigen believed to be a high affinity receptor for 
mPR3 expression on neutrophil surface. CD177 is upregulated during bacterial infection and 
sepsis and plays a role in different diseases such as immune mediated neutropenia, 
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transfusion related acute lung injury and polycythemia rubra vera (PRV). Until recently little 
was known about the function of this receptor on neutrophil. I asked the question whether 
CD177 expression and other neutrophil markers were affected by maturity. Initially, I have 
confirmed the finding of previous studies that the adult neutrophil expression of CD177 was 
bimodal and CD177 expression showed inter-individual variation with the stability of the 
percentage of the positive CD177 expressing cells per individual even after the cells were 
activated with different stimuli (Halbwachs-Mercarelli et al., 1995; Witko-Sarsat et al., 1999; 
Schreiber et al., 2003; Wolff et al., 2003). I have demonstrated that CD177 expression was 
significantly higher in cord neutrophils compared to adult neutrophils and this observation 
has been reported only in one study before by Stroncek et al. (1998). PR3 is a main 
autoantigen in anti-neutrophil cytoplasmic antibody-associated vasculits and its surface 
presentation on neutrophils has pathogenic importance. PR3 expression on the surface of cord 
blood neutrophils has not been published before. The neutrophils with positive expression of 
both PR3 and CD177 varied considerably between individuals ranging from 0% to 100% but 
the mean percentages of CD177 and PR3 expression were higher in cord blood than in adult 
neutrophils. I have demonstrated that the expression of PR3 was very low and monomodal in 
resting neutrophils in all adult samples and also in some of cord samples. This pattern of 
expression changed to bimodal in response to different stimuli in agreement with a previous 
report (Hu et al., 2009), although their neutrophil stimulation methods were different and Hu 
et al. only examined adult cells. Herein, I detected mPR3 on the surface of neutrophils of two 
negative CD177 cord samples which suggests that CD177 was not the sole receptor for 
mPR3. However, expression of mPR3 in negative CD177 cord samples does not contradict 
the current understanding that CD177 remains the high affinity receptor for mPR3 
expression. The mechanism leading to expression of PR3 on the surface of CD177-deficient 
neutrophils is not fully understood yet. In retrospect, I could have studied CD177 expression 
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on the neutrophils taken from the parents of the CD177 negative cord samples to see if it was 
inherited. Of note, despite expression of mPR3 on neutrophils from negative CD177 cord 
samples, it was monomodal even after stimulation. CD177 seems to be essential for bimodal 
expression of mPR3 on neutrophil surface. Further study of more CD177 negative samples is 
necessary to confirm this observation.  
I demonstrated that CD177 and m PR3 expression was rapidly induced on the cell surface of 
neutrophils following exposure of both cord and adult samples to various stimulants. PR3 
was found in primary granules, secondary granules as well as secretory vesicles and plasma 
membrane (Csernok et al., 1990; Halbwachs-Mecarelli et al., 1995; Witko-Sarsat et al., 
1999), while CD177 was reported to be found in secondary granules and its expression was 
more or less of same intensity on myelocytes, metamyelocytes and segmented neutrophils, 
but was not found in promyelocytes. Transcription of the gene encoding the CD177 antigen is 
probably switched off at some myelopoietic stage in CD177 negative samples for those 
individuals that become bimodal as adults. However, those individuals that lack CD177 on all 
cells may have other mechanisms underlying the failure to express. Furthermore, the nature 
of CD177 and PR3 interaction are still unknown and importance of their role in host 
immunity is not fully understood. CD177 deficient populations have been described without 
any apparent underlying pathology. 
In this study I confirmed the previous observation that term neonatal neutrophils expressed 
CD35 with an intensity that was similar to adult neutrophils. Shedding in response to 
stimulation was more pronounced in cord neutrophils. I observed that neutrophils from term 
neonates expressed significantly less CD35 on the plasma membrane in response to 
stimulation than neutrophils from adults. However, the percentage of CD35 expressing 
neutrophils was significantly lower in response to PMA and fMLP + cytochalasin B in adult 
cells, which could be related to the protease deficit found in neonatal neutrophils (MMP-9, 
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MMP-8 and elastase; unpublished results). However, only stimulation with F+C caused 
significant reduction in the percentage of CD35 expressing cord neutrophils, suggesting 
different methods of shedding may occur between these neutrophil groups. 
All stimulants caused significant reduction in CD43 expression on adult neutrophils, 
particularly PMA. The same effect on CD43 expression was observed in cord blood 
neutrophils. The explanation for this could be that CD43 was enzymatically cleaved from the 
surface of activated neutrophils or the shedding could be mediated by neutrophil proteases.  
In the present work, no significant difference in neutrophil CD63, CD66b, CD15 and CD16 
expression was detected between cord blood and adult neutrophils.  
Estimation of intracellular and surface expression of mPR3, CD177 and other markers was 
performed using flow cytometry; PR3 results were validated with more quantitative ELISA 
methods for lysed neutrophil PR3 and released supernatant PR3. Unstimulated cord 
neutrophils contained a higher PR3 content than adult cells, for both methodologies 
validating the significance of these result. Both methods showed that maximum PR3 release 
followed stimulation with fMLP + cytochalasin B even in CD177 negative cord samples. 
  
6.2.1     Neutrophil proteases 
Since significant function of neutrophil proteases is detected at the surface of activated 
neutrophils, measuring and quantifying membrane bound activities is of major interest for 
understanding their role during inflammation. I identified lower Cat G and elastase activity in 
neonatal neutrophils compared to adult neutrophils. However, similar proportion of each 
protease could be degranulated from the neutrophils following various pro-inflammatory 
stimuli for neonatal cells. This implies that lower intracellular stores translate into lower 
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releasable proteolytic capacity for neonates relative to adults. Neonates have a less mature 
immune system than adults that renders them more vulnerable to infection. Reduced protease 
content of neutrophils could be another factor that makes neonates less able to kill bacteria. 
Since my study examined Cat G and elastase content of a set number of neutrophils by 
functional assay of individual neutrophils, it was not possible to know whether the 
neutrophils themselves were smaller in cord blood neutrophils and contained the same 
density of granules as adults; nor if the neutrophils were the same size but contain smaller 
amount of proteases. In retrospect I could have put isolated neutrophils through a Coulter 
counter, a device that detects changes in electrical conductance cross a small aperture as fluid 
containing cells flow through it. This device measures cellular volume and would have 
enabled us to examine differences between adult and cord blood neutrophils. 
Of note, Cat G functional activity was performed immediately after neutrophil separation. In 
4 adult-cord blood neutrophil dyads, Cat G functional activity results were reproducible when 
the experiment was repeated next day (12 hours after the first experiment), indicating that 
storing cells and supernatants in these types of studies could have been batched for 
investigation without loss of activity.   
All of cord blood samples in this work were obtained from full term newborn. Other studies 
have shown that differences in neutrophil function are greater in immature preterm neonatal 
cells, but as the ethics available for this study included only term newborns, cord samples 
from preterm neonates were not studied. 
6.3    Chronic lung disease  
Majority of spontaneous preterm delivery is associated with perinatal infection and premature 
neonates are particularly vulnerable to infection. A recent comprehensive meta-analysis that 
included 59 studies and 15,295 infants reported on association between chorioamnionitis and 
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development of CLD although it showed a significant publication bias leading to 
exaggeration of the magnitude of the association (Hartling et al., 2012). 
 Perinatal infection is implicated in the complex pathogenesis of CLD. Microbial infection of 
the lung in preterm ventilated infants leads to influx of inflammatory cells and release of pro-
inflammatory cytokines. The role of Ureaplasma species in CLD pathogenesis was studied 
first in animal models. Response has varied from one study to another, possibly due to 
differing virulence of studied Ureaplasma serovars and host species differences. Moreover, 
humans are the specific host for U parvum and U urealyticum hence less prominent reaction 
in animal model is not surprising (Viscardi, 2012). 
Neutrophil proteases and other proteolytic enzymes (MMP-8, MMP-9) degrade tissue matrix 
and the prolonged inflammation may impair the repair process in the critical window during 
lung development resulting in the characteristic abnormal lung growth found in new CLD.  
MMP-8 or neutrophil collagenase which has a major role in the proteolysis of collagen-I was 
elevated in BAL fluid from babies who eventually developed CLD (Sweet el al., 2004). 
Collagen-I is an important structural protein that provides the tensile strength in extracellular 
matrix (Davidson, 1990).    
The action of these enzymes is regulated by different inhibitors and balance between 
proteases and their inhibitors is essential to prevent lung tissue damage. Neutrophil proteases 
have been linked to CLD in preterm newborn infants and the precursor acute RDS has been 
shown to be neutrophil-dominant pathology (Arnon et al., 1993). It is likely the persistence of 
neutrophils and their impact on enhancement and perpetuation of the ongoing inflammatory 
process allows for the development of the lung injury that characterises CLD (Kotecha et al., 
2003).  
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I examined PR3 levels in BAL fluids from premature neonates, previously examined for 
MMP-9 and elastase levels (Davies et al., 2010). PR3 levels in serial BAL samples taken 
from this cohort were assessed using ELISA, although the complete set of samples was not 
available for analysis because they had been used up for the previous study by our laboratory. 
The data from this cohort study has shown that the peak in total PR3 levels was higher in 
infants who develop CLD compared to those babies with resolved RDS and higher than the 
ventilated term control group. No significant difference was detected between PR3 in term 
babies and resolved RDS patient samples. PR3 elevation in BAL fluid from preterm 
newborns who went on to develop CLD was episodic and coincided with peaks in elastase 
and MMP-9 levels in the same samples. This common episodic pattern was not fully 
explained but could be triggered by infection.   
 
Previously more emphasis was put on the role of elastase in CLD but the contribution of PR3 
seems to be underestimated in CLD. Elastase and PR3 are present in the same neutrophil 
granules so they should be released together when neutrophils are activated. In addition, PR3 
was the most abundant of the neutrophil proteases with each  adult neutrophil estimated to 
store 3pg of PR3, compared to 1.1 pg of elastase  and 0.85 pg of CatG, respectively 
(Campbell et al., 2000). Furthermore, PR3 may be harder to regulate: affinity of AAT is 
much higher for elastase than for PR3 (Rao et al., 1991; Korkmaz et al., 2005) and it was 
predicted that 89% of AAT would bind elastase whereas only 11% would bind PR3 (Rao et 
al., 1991). In addition, PR3 is not inhibited by SLPI or antichymotrypsin while it is only 
minimally inhibited and transiently bound by elafin (Rao et al., 1991; Ying and Simon., 
2001). In contrast to membrane bound elastase, mPR3 was resistant to inhibition by AAT 
(Korkmaz et al., 2005). The net result is that released PR3 which can degrade a wide range of 
lung matrix protein remains unopposed in the lung. 
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Ureaplasma colonised neonates were more likely to develop CLD than Ureaplasma negative 
patients in a cohort of 230 preterm newborns (< 32 weeks) ventilated for 2-32 days (Viscardi, 
2012). Updated strategies proposed to prevent CLD revolve around reducing the damage 
caused by proteases and on treating the inciting infection or colonisation. Protease inhibitors 
have been the focus of studies examining prevention of neutrophil protease harmful effects 
on developing lung. Multiple protease inhibitors may be a useful therapeutic intervention; 
however, further work is required to find inhibitors of choice with greater inhibitory effect 
and less susceptiblity to proteolytic degradation. Extensive work was done on neutrophil 
elastase interaction with inhibitors and the search was extended in the last years to find 
appropriate synthetic inhibitors that can inhibit the main proteases and improve the method of 
administration for optimal efficacy (Matsuzaki et al., 2005; Okayama et al., 2006). 
 
Antibiotic treatment has also been of interest for prevention of pathogenesis of CLD. Earlier 
studies on erythromycin did not show any positive effect on prevention (Bührer et al., 2001; 
Baier et al., 2003). A newer generation of macrolide, azithromycin, which purportedly has 
anti-inflammatory properties, was shown to be capable of inhibiting production of pro-
inflammatory cytokines by neutrophils and monocytes from tracheal aspirates of premature 
neonates (Aghai et al., 2007). Azithromycin, in a pilot randomised placebo-controlled double 
blind study, also reduced the use of steroids and duration of hospital stay and ventilation in 
the treated neonates. These effects were due to its anti-inflammatory effect and ability to alter 
the innate immune response to infection since Ureaplasma infected or colonised infants were 
excluded for some reason (Ballard et al., 2007). A more recent study by the same group has 
shown some benefit in the Ureaplasma colonised or infected subgroup of very low birth 
weight infant when treated with azithromycin where the odds ratio for CLD or death 
decreased to 0.026, 95% CI 0.001-0.618 (Ballard et al., 2011). A similar recent study on 
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Ureaplasma culture positive preterm newborns (birth weight 750-1250 g) concluded that 
clarithromycin (another related macrolide) prevented the development of CLD (Ozdemir et 
al., 2011). However, macrolide resistance has been noted in some Ureaplasma strains 
(particularly in the US and China), which should be regarded when considering prophylactic 
role of antibiotics as indiscriminate use of antibiotic could promote emergence of resistant 
bacteria. Moreover, other potential concerns are raised with macrolide antibiotics including 
hepatotoxicity and hearing impairment (Brown et al., 1997).    
 
6.4    Complement system and Ureaplasma 
Ureaplasma has recently been shown to be killed by adult human serum (Beeton et al., 
2012).  Therefore, an in vitro experiment was prepared to assess the role of membrane attack 
complex (MAC) mediated killing of the complement system using cord serum. The 
ureaplasmacidal capacity mediated by complement activity of cord serum was compared to 
adult serum against Ureaplasma parvum.  Terminal complement components responsible for 
(C6-C9) forming the membrane attack complex (MAC) on the target cells, leading to 
pathogen cell lysis were compared. In chapter 5, I demonstrated that cord sera are deficient in 
C6, C8 and C9. A significant finding was that all cord sera could still kill Ureaplasma 
parvum serovar (SV3) equivalently to adult serum, irrespective of whether the serum 
contained specific anti-Ureaplasma IgG antibody when tested by immunoblotting. However, 
none of the cord sera could kill SV6 or SV14, unlike some adult sera. Some degree of killing 
was observed in SV1 although it was lower than the degree of killing noticed in adult serum. 
Beeton et al., 2012 demonstrated that classical pathway was the predominant complement 
pathway involved in killing of all serovars. In addition, they speculated that killing of SV1, 
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SV6 and SV14 was dependent upon the presence of IgG subclasses 1 and 2 whereas killing of 
SV3 was dependent, in half of their samples on IgG3.  
 In normal serum, cytolysis may occur when complement proteins are assembled on the 
bacterial surface to form the membrane attack complex (C5-9). In this study I have confirmed 
previously published findings which showed that the concentrations of terminal complement 
components in newborn serum were significantly lower than adult level, with only one 
exception, C7, which was identical to the adult level. Although my results followed the trend 
of previous published work, I used more accurate methodology to obtain reference values 
compared with the  older semi-quantitative methods previously used which are no longer 
used for clinical or research purposes (Davis et al., 1979; Johnston et al., 1979; Drew and 
Arroyave, 1980;  Sonntag et al., 1998b).  
 
To optimise the sensitivity and specificity of my measurements, I tested panels of monoclonal 
antibodies for each component to be measured from commercial and non-commercial 
sources. Where necessary, sensitivity and range of assay were enhanced by immobilising 
monoclonal antibodies with rat anti-mouse IgG1 monoclonal antibody. In addition amino acid 
hydrolysis was used to accurately quantify affinity purified C6, C7, C8 and C9. The refined 
method was used in adult samples to evaluate the level of these components. Subsequently, 
analytical work was extended to test the terminal components levels in international pooled 
adult serum in order to provide a readily available revised reference levels for C6-C9.   
 
 Since the killing capacity of cord serum against Ureaplasma was lower than adult serum as 
shown in chapter 5, we postulated that this observation was related to the lower level of 
terminal complement components found in cord serum, compared to adult serum, particularly 
C9. However, adding purified C9 or adding a combination of C6, C8 and C9 to compensate 
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for their deficiency in cord sera did not restore its bactericidal activity against SV6 or SV14 
killing, despite the presence of multiple anti-Ureaplasma IgG bands in the cord serum. Of 
note, adult serum samples capable of killing SV6 or 14 seem to be bactericidal for all 
serovars.   
 In a previous study, neutrophils isolated from healthy adults were able to phagocytose 
Ureaplasma in absence of antibody opsonisation. However, engulfed ureaplasma remained 
viable after phagocytosis which could be of pathogenetic importance (Taylor-Robinson et al., 
1986).  In a preliminary step, I added freshly purified cord neutrophils to Ureaplasma culture 
to assess ureaplasmacidal effect of neutrophils on all serovars but no killing was observed. 
Neutrophil killing of Ureaplasma needs to be addressed in future work using markers that 
can be detected by flow cytometry or similar methodology to detect the dynamics of 
neutrophil Ureaplasma phagocytosis and killing capacity.  
 
Haemolytic activity is a useful indicator of complement component deficiency since 
homozygous complement deficient individuals usually have absent haemolytic functional 
activity (CH50). In general, complement component concentration must be decreased by 
more than half to affect CH50 (Pettigrew et al., 2009). In this study I have confirmed the 
finding of previous work that cord serum has significantly lower complement haemolytic 
activity CH50 than adult serum (Shapiro et al., 1981; Notarangello et al., 1984; Ferriani et 
al., 1990; Sonntag et al., 1998b). 
In agreement with previous reports (Davies et al., 1979; Adinolfi et al., 1981; Hoggasen et 
al., 2000) C9 was the most deficient component in cord sera (6.4% of adult level). 
Supplementation of cord serum with C9 alone was adequate to restore CH50 to adult values 
despite the lower C6 and C8 levels (34.2% and 25.5 % of adult values respectively).  
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The observed deficiency in neonatal complement function and the lower levels of multiple 
terminal complement components which decreased ability to form MAC required for 
effective bacteriolysis is likely to increase the risk of serious neonatal infection. Evidence of 
enhanced complement activation suggests a role in adverse pathological consequences in 
certain neonatal conditions; however, the exact mechanisms underlying activation are still 
undetermined. Further work on the neonatal complement system especially in premature 
infants is necessary for better management and therapy of these high risk infants.  
 
6.5    Future Research 
 This thesis has raised a number of questions that need further investigation. Although PR3 is 
known to have the potential to promote inflammation and injure tissues, the biologic forms 
and the function of PR3 in neutrophils from healthy term and adults donors have received 
little attention. In this work I have shown that the expression of CD177 and PR3 was higher 
in term infants than adult. It would be interesting if further investigation included cell surface 
expression of PR3 and CD177 on neutrophils from premature infants.  
Furthermore, neonates appear to be fairly uniform in CD177 expression at birth, relative to 
bimodal expression in adults; it would be useful to follow developing children to observe 
when the differentially expressing subsets emerge and the nature of the gene regulation that is 
responsible for this phenomenon. Functional studies should also focus on physiological role 
of CD177 expression on neutrophils and its interaction with PR3, relative to their 
antimicrobial function and ability to leave the vasculature in response to inflammation as 
well. Expression of CD177 in neutrophil haematopoietic stages could also be examined and 
linked with expression of PR3 in the developing lineage. 
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All our in vitro studies of neutrophil and complement were performed using cord blood from 
term infants collected following elective Caesarean section. I would like to assess the impact 
of decreasing gestational age on the ability of degranulation of neutrophils particularly the 
PR3 and CD177. In addition, study the ability of complement system in those preterm infants 
to kill ureaplasma. Further research on neutrophil proteases elastase, Cat G and PR3 studied 
herein would benefit from set groups in which neonates are divided according to gestational 
age, including extremely preterm infants between 23-28 weeks gestation in the presence of 
healthy adult group. This is of particular interest as the major site of haematopoesis changes 
from the liver to the bone marrow through this time period and could have a dramatic effect 
on the function and composition of neutrophils through these times 
 
Working with preterm cord blood will be more challenging than term infants because 
significantly preterm infants are not often delivered by elective Caesarean section unless 
necessitated by foetal compromise or maternal ill health, so samples might not be easily 
obtained from this group. In addition,  extremely preterm or severely compromised foetus 
frequently has a very small, thin umbilical cord which will yield only a very small blood 
sample therefore neutrophil separation might be difficult with the current methodology that 
need larger sample volumes. 
 
Measurement of the exclusive functional activity of PR3 will require optimising a specific 
substrate for PR3 which is so far not available (PR3 substrates are readily cleaved by 
elastase). The results in this thesis showed that the expression of PR3 and its level in term 
infants was higher than that in adults. Study of the functional activity of this proteinase would 
be beneficial to see whether the high concentration reflects high functional activity or not 
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compared with adults. Serine protease triad content and activity should be studied also in 
preterm cord blood neutrophils. 
 
Other categories of proteases and their inhibitors would also be of interest in the context of 
CLD include matrix metalloproteinases such as MMP-8 as well as cysteine proteases such as 
Cathepsin B, H, K, L and S which has not been studied in detail for premature and full term 
neonates  compared to adults. Better understanding of the complex interaction between 
proteases and their inhibitors would facilitate effective prevention of proteolytic lung injury. 
 
The role of PR3 in the pathogenesis of CLD in preterm infant has not been studied before and 
this would be an area of interest for further investigation. This could be investigated further 
using animal models where bacteria could be instilled into the lung to cause infection or by 
delivering protease directly to preterm animals lungs for brief period but otherwise giving 
optimal care including surfactant and antibiotic therapy and then to see if new CLD changes 
occur in the lung. The sheep model has been particularly well developed. However, only 
mice can be used in gene targeting to create PR3 knock-out animals to allow more definitive 
characterisation of the in vivo role of this enzyme in pathogenesis of CLD. 
 
 
 Having defined reference values of terminal complement components for term infants and 
normal healthy adults, the next step should be to evaluate the levels of these components in 
preterm neonates of different gestational age groups to allow accurate comparisons between 
studies and analysis using current most accurate methodology. However, preterm neonates 
can often have an underlying microbial trigger that could lead to activation and consumption 
of complement, which will have to be adequately controlled for in these studies.   
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As part of the terminal complement pathway, C5b should have been included in the 
investigation for the full complete terminal components profile in term and preterm newborns 
vs. adult serum.   
 
This report on the Ureaplasmacidal capacity of cord sera against U parvum could be 
expanded more using term and preterm cord serum Ureaplasmacidal capacity on additional 
strains of clinical importance of these serovars which were not investigated here. Further 
work should also test Ureaplasmacidal capacity of cord sera on serovars of the other 
important species, U. urealyticum to determine any variation in their susceptibility to 
complement mediated killing.  
 
In addition, further study on the mechanisms underlying variation in susceptibility to 
complement mediated killing should be undertaken. Possible mechanisms already exploited 
by many other pathogens, such as serum resistance through binding serum complement 
regulators to evade complement mediated killing, should be investigated. It would be of 
interest to explore the possibility of complement evasion by serovars, SV6 and SV 14 of 
Ureaplasma serovars to escape the ureaplasmacidal action of serum. 
 
6.6    Final summary 
In this thesis I sought to understand the effect of maturity on human neutrophils and 
complement function among neonate and adults. Neutrophils from term cord blood express 
more PR3 and CD177 on the cell surface than neutrophils from adult, but the amounts of 
surface CD66b, CD63,CD15, CD16,  CD35 and CD43 expression were not significantly 
different even after stimulation.  
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I have shown that cord blood neutrophils deficient CD177are able to effectively express PR3 
on their surface suggesting that CD177 was not the sole receptor for mPR3. Significant 
differences was demonstrated in the intracellular expression of both CD177 and PR3 in cord 
blood neutrophils compared to adult neutrophils, whereas, no obvious variations were 
detected in the expression of SerpinB1, C3aR, C5aR, CD66b, CD63, CD35 and CD43.  
Neutrophils from cord blood contained less elastase and Cat G than neutrophils isolated from 
adult blood but a similar proportion of protease was released following proinflammatory 
stimulation. 
Longitudinal analysis of BAL fluid samples from infants at risk of developing CLD 
demonstrated that PR3 concentration was significantly greater in infants who develop CLD 
compared to infants with resolved RDS. I have found significant relationships between 
episodic spikes of PR3 and MMP-9 in BAL fluid in both preterm infants at risk of developing 
CLD and in resolved RDS patients.  
 
In the complement chapter, term neonates were found to have lower CH50 and lower levels 
of terminal complement component (except for C7) concentrations when compared to adult 
values. 
 Variation in sensitivity  of U. parvum to bactericidal action of adult and cord serum showing 
that SV3 was the most sensitive serovars in both cord and adult serum while SV6 and 14 
were resistant. The killing in adult serum was obviously more than cord serum in SV1. 
Substituting deficient complement component with purified proteins did not restore the 
bactericidal capacity of cord serum against SV6 and SV14 but supplementation of cord serum 
with purified C9 restored the CH50 to adult values.  
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INFORMATION SHEET Version 4 (17
th
 February 2010) – HEALTHY ADULT 
CONTROL 
 
Principle Investigators: Professor Sailesh Kotecha, Consultant Neonatologist 
Contact Details: Neonatal Unit, 029 20 74 3374 
 
Study Title 
 Developmental regulation of neonatal neutrophils and monocytes function. 
 
Invitation 
You are being invited to take part in a research study.  Before you decide it is important for 
you to understand why the research is being done and what it will involve.  Please take time 
to read the following information carefully and discuss it with others if you wish.  Ask us if 
there is anything that is not clear or if you would like more information.  Take time to decide 
whether or not you wish to take part. 
 
Part 1 of this leaflet tells you the purpose of this study and what will happen if you decide to 
take part. 
Part 2 gives you more detailed information about the study. 
 
Thank you for reading this leaflet. 
 
Part 1 
 
1.1. What is the purpose of the study? 
We are trying to understand why some premature babies develop the disease called chronic 
lung disease of prematurity or CLD. Lung inflammation (redness and soreness) is common in 
babies who develop CLD. However, some of our work has shown that an under-developed 
immune system may be one reason why premature babies develop CLD. We wish to examine 
blood cells (which cause lung inflammation in babies who develop CLD) from babies born 
on time or prematurely to determine if their cell function is under-developed when compared 
to similar cells from healthy adults.  
 
1.2. Why have I been chosen? 
We wish to obtain blood samples from three groups: 
a) Babies born on time who are being delivered by an elective caesarean section 
b) Babies who are born prematurely (i.e. less than 32 weeks gestation) 
c) Healthy adult donors 
 
Because you are a healthy adult, we would like to obtain 20 – 30 mls (one tablespoonful is 10 
ml) to use as controls for our experiments and compare the results with those from babies 
born on time or prematurely.  
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1.3. Do I have to take part?  
It is up to you to decide whether or not you want to take part. If you do decide that you would 
like to take part, you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part, you are still free to withdraw at any time and without 
giving a reason.  
 
1.4. What will happen if I take part? 
We would like to obtain blood (20 – 30 ml) from your arm to use for our studies.  
 
1.5. What are the risks of taking part? 
Blood samples are routinely taken by our team. It usually results in a sharp pin prick on 
insertion of the needle.  
 
1.6. What are the benefits of taking part? 
We cannot promise that the study will help you but the information we get from this study 
may help us to improve the treatment of premature babies in the future. 
 
1.7. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The detailed information on this is given in Part 2. 
 
1.8. Will my taking part be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled 
in confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making a decision. 
 
Part 2 
 
2.1. What will happen if I don’t want to carry on with the study? 
If you decide to withdraw from the study, we would like to use the data collected up to your 
withdrawal. Any stored blood samples that can be identified as yours will be destroyed if you 
wish. 
 
2.2. What if there is a problem? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have grounds 
for a legal action against Cardiff University but you may have to pay for it.  Regardless of 
this, if you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should still be available to you. 
 
2.3. What will happen to the results of the study? 
We will publish the results in reputable medical journals and present the data at scientific and 
medical meetings. Your name and details will NOT be revealed at any stage. Please let us 
know if you would like a copy of the report.  
 
2.4. What will happen to the samples collected? 
 From the blood samples we will separate the blood cells and the fluid (plasma). We will 
determine if there are differences in the function of the blood cells, including their survival, 
production of products which promote inflammation or tissue injury and their ability to kill 
germs.  
 
Sometimes we may have some of the blood sample left over after our initial tests. We would 
like to ask you if we may use any remaining sample for future studies. We would have to re-
apply to the ethics committee to use the sample for any new studies. If you are happy for us 
to use the sample in the future, you will be asked to sign a separate consent form. If you do 
not agree to future use of the sample then we shall destroy any remaining sample at the end of 
this study. 
 
2.5. Will my taking part be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential. All data collected will be processed on a secure, password-protected 
computer at Cardiff University. Any information about you which leaves the hospital will 
have your name removed so that you cannot be recognised from it. We will assign a number 
to each subject and use this to label the samples obtained for the study.  
 
2.6. Who is paying for the study? 
The studies are being funded by the Wellcome Trust and Arriva Pharmaceuticals.  
 
2.7. Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your and your baby’s safety, rights, wellbeing and dignity. This 
study has been reviewed and given a favourable opinion by the South East Wales Research 
Ethics Committee. 
 
2.8. Who can I contact for further information? 
You may contact Professor Sailesh Kotecha by telephoning 029 20 74 4187 or by email 
(KotechaS@Cardiff.ac.uk) to: Professor Sailesh Kotecha, Neonatal Unit, Heath Hospital, 
Heath Park, Cardiff CF14 4XN.  
 
Thank you for taking time to read this information leaflet. Please do not hesitate to ask 
Professor Sailesh Kotecha or Dr Salima Abdulla if you would like to discuss anything 
further.  
 
Dr Salima Abdulla       Professor Sailesh Kotecha 
Clinical Research Fellow    Consultant in Neonatal Medicine 
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 CONSENT FORM – HEALTHY ADULT CONTROLS 
 
Developmental regulation of neonatal neutrophils and monocytes 
function. 
Name of Researcher:   Professor Sailesh Kotecha, Consultant Neonatologist, 
Neonatal Unit, Heath Hospital, Cardiff CF14 4XN 
                      
 Please initial 
box 
1. I confirm that I have read and understand the information sheet dated 17
th
 February 2010 
  (version 4) for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw  
  
at any time. 
 
3.  I consent to my blood being used       
  
________________________ ________________ ____________________ 
Name Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher Date Signature 
  
 
1 for patient, 1 for researcher 
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Poster - International Organisation for Mycoplasmology (IOM) July 2012 -Toulouse – 
France 
 
Despite developmental complement deficiency, neonatal serum is bactericidal for 
Ureaplasma serovar 3, but complement component supplementation and addition of 
pooled IgG fails to induce killing of serovars 6 and 14. 
 
Salima Abdulla, Sailesh Kotecha, O. Brad Spiller 
Cardiff University, School of Medicine, Institute of Molecular and Experimental Medicine, 
Cardiff, CF14 4XN, U.K. 
 
Compelemnt is a cornerstone of innate immunity, as well as modulating and enhancing 
humoral and cellular immunity. However, normal term neonatal serum is disadvantaged by a 
developmental insufficiency of lytic complement components, which is worsened by premature 
birth. Furthermore, normal neonatal serum contains only IgG transferred from the mother and 
low innate IgM levels. Ureaplasma spp. remains one of the most common infectious agents 
associated with premature labour and preterm newborns have higher rates of pulmonary 
Ureaplasma infection. We have previously characterised Ureaplasma parvum killing by adult 
serum: uraplasmacidal activity for Ureaplasam serovars (SV) 1, 6 and 14 required specific 
anti-ureaplasmal IgG and classical complement pathway activation, while SV3-killing was 
complement-independent, but IgG-independent. Here we extend these studies to neonatal 
serum.Complement function assay, Ureaplasma killing and new ELISA methods were used to 
compare serum from 20 adults and 20 uncomplicated term caesarean-delivered newborn 
umbilical cord serum. The ability of neonatal and adult serum to kill Ureaplasma SV3 were 
equivalent despite neonatal serum C6 and C8 levels being 25-30% and C9 levels only 6.6% of 
adult levels. Further, 7 of 14 neonatal sera could kill SV1, but none could kill SV6 or SV14. 
Reconstitution of the low complement components to adult concentrations corrected the 
functional neonatal serum deficit as measured by clinical assay, but did not increase the killing 
for SV1, 6 or 14. All but 2 of the neonatal sera contained anti-Ureaplasma antibodies reactive 
with all by immunoblot and addition of commercial purified pooled IgG with complement 
components to neonatal sera did not increase Ureaplasma parvum killing. However, 
complement mediated killing for SV3 could be removed by depletion of IgM with a specific 
immune-affinity column, suggesting that low levels of innate IgM in neonatal serum are 
sufficient to mediate ureaplasmacidal complement activation. 
 
  Poster - Postgraduate research day November 2011 
PR3 expression and release by cord and adult neutrophils and its level in 
bronchoalveolar fluid. 
Salima Abdulla, Sailesh Kotecha, Philip L  Davies, O. Brad Spiller 
Department of Child Health, Cardiff University, School of Medicine. 
 
Background Proteinase 3 (PR3) is serine protease, ubiquitous in neutrophil granules and 
present on plasma membranes of CD177-positive neutrophils. PR3 in the inflamed lung may 
play a key role in host defence and airway remodelling. 
Method Neutrophils isolated from ten paired cord and adult blood samples were stimulated 
with fMLP, Cytochalasin B (CytoB), lipopolysaccharide (LPS), IL-8 and phorbol ester 
(PMA). Flow cytometry was used to evaluate PR3 expression on unstimulated neutrophils 
and also in response to stimulants. PR3 ELISA assay was performed on supernatants and 
cellular fractions. PR3 level was also measured in bronchoalveolar lavage (BAL) samples 
obtained from ventilated preterm infants (<32 weeks gestation) and term controls.  
Result unstimulated adult and cord neutrophils showed monomodal positive expression of 
membrane-bound PR3 (mPR3) whereas stimulation with fMLP, PMA and fMLP in 
combination with CytoB resulted in a biomodal pattern of mPR3 expression. Mean 
unstimulated cord neutrophil mPR3 expression (78.021±27.7) was significantly higher than 
that of unstimulated adult neutrophils (16.91±3.2; p = 0.0367). Following stimulation the 
mean mPR3 expression in both adult and cord cells was higher than on unstimulated cells. 
Cord neutrophils contain 6.25 ± 0.95 pg/cell of PR3 while adult neutrophil level was 3.71± 
0.49 pg/cell. The proportion of PR3 released by cord and adult neutrophils was similar. Peak 
concentration of PR3  was significantly higher in BAL from infants who  developed  CLD  
(median 6.05 μg/ml) compared  to preterm infants whose RDS resolved (3.44 μg/ml) and 
term control (0.74 μg/ml) (P 0.0096, 0.0076 respectively). 
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Despite relative C9-deficiency, neonatal serum is bactericidal for Ureaplasma serovar 3, but 
addition of C6-C9 and specific IgG fails to induce killing of serovars 6 and 14. 
Abdulla,S,,  Hakobyan, S.,  Kotecha, S.,  Brad  O, Spiller   
Cardiff University, School of Medicine, Cardiff, UK,                                                
Background: Ureaplasma remains one of the most common causes of premature labour and 
pulmonary Ureaplasma infection in preterm neonates. We previously demonstrated IgG1 and 
C1q dependent killing of Ureaplasma serovars (SV) 1, 6 and 14 for adult serum, but SV3 
C1q-dependent killing was IgG-independent. Normal term neonatal serum has only maternal 
IgG, low non-specific IgM levels and a relative deficiency of C6, C8 and C9. 
 Results: Neonatal C6 and C8 levels were 25-30% of adult serum concentration and C9 
levels were 6.6% of adult levels, however, ability of neonatal and adult serum to kill 
Ureaplasma SV3 were equivalent. Thirty percent of neonatal serum could kill SV1 and none 
could kill SV6 or SV14. Reconstitution of C6-C9 to adult levels corrected the CH50 deficit, 
but did not increase the killing for any of the serovars, despite measurable anti-Ureaplasma 
antibody presence in neonatal serum or addition of exogenous antibody. Killing results for 
SV3 suggest that low levels of immature IgM in neonatal serum are sufficient to mediate 
bactericidal activity. 
 Conclusion: Bactericidal deficit of neonatal serum has been described, and C9 relative 
deficiency is suspected to be a cause. Here we find Ureaplasma SV3 is unusually sensitive to 
neonatal serum, while killing of SV6 and 14 could not be induced by addition of purified C6, 
C8 and C9 with or without addition of anti-Ureaplasma antibodies. C1q-dependent killing of 
Ureaplasma SV3 is IgM-dependent, even in neonatal serum, and the target for IgM is likely 
carbohydrate that is serovar-specific 
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Optimising measurement of terminal complement components in adult and newborn serum 
by ELISA by refining capture antibodies and purified standards. 
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1
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2
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1
.,  Brad Spiller
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,O 
1- Cardiff University, School of Medicine, Cardiff, UK,   2- Quidel Corporation, Santa Clara, 
CA, USA 
Background: Accurate measurement of terminal complement components has been limited 
by using subjective methodology and use of poorly characterised standards.  
Methods: State-of-the-art ELISAs were created for measuring C6, C7, C8, and C9, choosing 
the most sensitive monoclonal antibody from commercial and non-commercial sources. 
Where necessary, sensitivity and range of assay were enhanced by immobilising monoclonal 
antibodies with rat anti-mouse IgG1 monoclonal antibody. Amino acid hydrolysis was used 
to accurately quantify affinity purified C6, C7, C8 and C9. Confidence intervals for 
complement concentration were determined in 20 normal adults and 25 cord sera from 
uncomplicated caesarean-delivered term newborns.  
Results: Adult C7 levels were 37.77 ± 2.89 mg/L, comparable to neonatal C6 levels of 38.83 
± 3.15 mg/L, while neonatal C6 (9.4 ± 1.00 mg/L) and C8 (12.5 ± 1.15 mg/L) levels were 25-
30% of adult C6 (30.52 ± 1.55 mg/L) and C8 (50.7 ± 3.50 mg/L) levels (p<0.001). Neonatal 
C9 levels were very low (2.47 ± 0.60) compared to adult levels (37.31 ± 4.80 mg/L; p<0.01) 
and supplementation with purified C9 alone corrected the poor CH50 values for neonatal 
serum. All antibodies were able to detect their relative components in purified soluble C5b-9 
complex to varying degrees; however, some anti-“neoepitope”C9 antibodies recognise 
purified C9 that was not denatured and retained function. 
Conclusion: Optimised sandwich ELISA methods with definitively quantified ultrapure 
standards allows the determination of true confidence intervals for complement component 
concentration. These methods will be applied to the international standard serum pool to 
provide a readily available standard source. 
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Comparative Bactericidal deficit of neonatal and adult serum complement against 
Ureaplasma parvum 
Salima A. Abdulla, Michael L. Beeton, Sailesh Kotecha, and O. Brad Spiller 
Cardiff University, School of Medicine, Department of Child Health, Cardiff, CF14 4XN 
Introduction: The complement system is essential for opsonisation and killing of 
pathogens. Infection remains a major cause of morbidity and mortality in newborns and 
their susceptibility is partly attributed to functional and quantitative deficits in innate 
immunity including the complement system. Little is known about the bacteriocidal role of 
complement in neonates against Ureaplasma (a major cause of premature birth and chronic 
lung disease).  
Methods: The bactericidal capacity of adult compared to cord sera against 4 serovars of 
Ureaplasma parvum was determined.  Ureaplasma survival (in colour changing units) was 
measured following incubation for one hour at 37 C with a 6.5- 50% titration of adult and 
cord sera as well as a heat inactivated matched control. ELISA assays were developed to 
measure C6-C9 terminal lytic complement components, and were supplemented where 
determined to be lower than adult levels. Degree of killing was determined by comparing 
fold decrease of Ureaplasma survival following incubation with heat inactivated versus 
normal sera.  
Results: All cord sera could kill SV3 equivalently to adult serum. Six cord sera out of 15 
(compared to 7/12 adult sera) killed SV1 and none of the cord sera could kill SV6 or SV14 
(compared to 5/12 and 4/12 adult serum). Normal neonatal C6 levels were 37.7%, C8 levels 
were 33% and C9 levels were 8.7% of adult values; however, supplementation of cord sera 
to adult levels did not restore SV6 or SV14 killing. Immunoreactivity to SV6 and SV14 was 
as prevalent in cord sera as in adults by Western blot.  
Conclusion: Cord sera had strong bactericidal activity for SV3, less killing effect upon SV1 
and no bactericidal effect on both SV6 and SV14. Correcting complement components C6, 
C8 and C9 levels (or adding exogenous IgG) had no effect on bactericidal activity of cord 
sera. 
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Optimising measurement of terminal complement components in adult and newborn 
serum by ELISA by refining capture antibodies and purified standards. 
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Background: Accurate measurement of terminal complement components has been limited 
by using subjective methodology and use of poorly characterised standards.  
Methods: State-of-the-art ELISAs were created for measuring C6, C7, C8, and C9, choosing 
the most sensitive monoclonal antibody from commercial and non-commercial sources. 
Where necessary, sensitivity and range of assay were enhanced by immobilising monoclonal 
antibodies with rat anti-mouse IgG1 monoclonal antibody. Amino acid hydrolysis was used 
to accurately quantify affinity purified C6, C7, C8 and C9. Confidence intervals for 
complement concentration were determined in 20 normal adults and 25 cord sera from 
uncomplicated caesarean-delivered term newborns.  
Results: Adult C7 levels were 37.77 ± 2.89 mg/L, comparable to neonatal C6 levels of 38.83 
± 3.15 mg/L, while neonatal C6 (9.4 ± 1.00 mg/L) and C8 (12.5 ± 1.15 mg/L) levels were 25-
30% of adult C6 (30.52 ± 1.55 mg/L) and C8 (50.7 ± 3.50 mg/L) levels (p<0.001). Neonatal 
C9 levels were very low (2.47 ± 0.60) compared to adult levels (37.31 ± 4.80 mg/L; p<0.01) 
and supplementation with purified C9 alone corrected the poor CH50 values for neonatal 
serum. All antibodies were able to detect their relative components in purified soluble C5b-9 
complex to varying degrees; however, some anti-“neoepitope”C9 antibodies recognise 
purified C9 that was not denatured and retained function. 
Conclusion: Optimised sandwich ELISA methods with definitively quantified ultrapure 
standards allows the determination of true confidence intervals for complement component 
concentration. These methods will be applied to the international standard serum pool to 
provide a readily available standard source. 
 
 
 
